

Alma Mater Studiorum – Università di Bologna

DOTTORATO DI RICERCA IN

Scienze Veterinarie

Ciclo \_XXXI\_

Settore Concorsuale: \_07/H3\_

Settore Scientifico Disciplinare: \_VET/05\_

TITOLO TESI

**Insights on molecular characterization and on methods of detection  
of Infectious Bursal Disease virus and Avian Mycoplasmas**

**Presentata da:** dott.ssa Viviana Felice\_

**Coordinatore Dottorato**

Prof. Arcangelo Gentile

**Supervisore**

Prof.ssa Elena Catelli

**Esame finale anno 2019**

## INDEX

<b>INTRODUCTION</b> .....	1
<b>CHAPTER I: Infectious bursal disease</b> .....	3
1.1 Aetiology .....	4
1.1.1 Taxonomy.....	4
1.1.2 Virus structure .....	4
1.1.3 Viral replication.....	7
1.1.4 Strain classification.....	7
1.1.5 Susceptibility to physical and chemical agents .....	10
1.2 Epidemiology and pathogenesis .....	11
1.2.1 Incidence, prevalence and distribution .....	11
1.2.2 Natural hosts and transmission.....	11
1.2.3 Pathogenesis .....	12
1.2.4 Interaction of IBDV with immunitary system .....	12
1.2.5 Immunosuppression.....	13
1.3 Clinical signs and lesions .....	14
1.3.1 Clinical signs .....	14
1.3.2 Gross and microscopic lesions.....	14
1.4 Diagnosis .....	17
1.4.1 Isolation and identification of IBDV .....	17
1.4.2 Detection of specific Abs .....	18
1.5 Prevention.....	19
1.5.1 Traditional live vaccines.....	19
1.5.2 Inactivated vaccine .....	19
1.5.3 New-generation vaccines.....	20
<b>CHAPTER II. <i>Mycoplasma gallisepticum</i> and <i>mycoplasma synoviae</i></b> .....	22
2.1 Aetiology .....	23
2.1.1 Taxonomy.....	23
2.1.2 Morphology and growth requirements .....	23
2.1.3 Biochemical properties .....	24
2.1.4 Structure and interactions with the host.....	24
2.1.5 Susceptibility to chemical and physical agents .....	24
2.2 Epidemiology and pathogenesis .....	26
2.2.1 MG and MS distribution.....	26

2.2.2	Natural hosts and transmission.....	27
2.2.3	Virulence factors and interaction with the immune system.....	28
2.3	Clinical signs and lesions .....	29
2.3.1	Clinical signs .....	29
2.3.2	Gross and microscopic lesions.....	30
2.4	Diagnosis .....	32
2.4.1	Isolation and identification of MG and MS.....	32
2.4.2	Detection of specific Abs .....	34
2.5	Prevention and control.....	35
2.5.1	Management procedures.....	35
2.5.2	Vaccination.....	35
2.5.3	Medication.....	36
2.6	Sitography.....	37
2.7	References .....	38
CHAPTER III: PUBLISHED PAPER Genome sequence analysis of a distinctive Italian Infectious Bursal Disease virus.....		58
CHAPTER IV: Influences of swab types and storage temperatures on isolation and molecular detection of Mycoplasma gallisepticum and Mycoplasma synoviae .....		86
CHAPTER V: Gene targeted sequencing analysis of Mycoplasma gallisepticum strains in commercial poultry flocks from Middle East and South Asia.....		95
CHAPTER VI: Molecular detection and characterization of Mycoplasma gallisepticum and Mycoplasma synoviae strains in backyard poultry flocks in Italy.....		108

## Abstract

Among the diseases that threaten the health of poultry, immunosuppressive and respiratory infections play a major role.

The first part of this thesis focuses on the phylogenetic analysis of an emerging genotype of the Infectious Bursal Disease virus (IBDV), denominated ITA. Sequence alignments revealed that the virus shared residues with either very virulent IBDVs or low-virulence strains, confirming its distinctive genetic characteristics. Moreover, no evidences of recombination and reassortant phenomena were found in the ITA genotype.

Substantial economic losses are caused in poultry by *Mycoplasma gallisepticum* (MG) and *Mycoplasma synoviae* (MS) infections. In Chapter IV, the influences of swab type and storage temperatures on the detection of MG and MS, by both culturing and conventional or qPCR, were evaluated. The results suggest that swabs with a plastic shaft should be preferred for MG/MS detection via culture and PCR. While a lower storage temperature at 4°C was optimal for culture recovery, room temperature was adequate for molecular detection.

In chapter V, molecular characterisation of MG strains from Middle East and South Asia was attempted by gene-targeted sequencing (GTS) of the MG surface-protein genes MGA\_0319, *mgc2*, *gapA* and *pvpA*.

In Chapter VI, molecular characterisation of MG and/or MS strains from Italian backyard flocks was attempted. The MS strains were typed by sequencing of the *vhhA* gene and mostly assigned to types C, D and F. An MS sequence showed peculiar characteristics, thereby not allowing assignment to known MS types. Different subclusters of MG were found by GTS analysis. The circulation of different mycoplasma strains in Italian backyard flocks constitutes a severe risk for commercial poultry production.

## INTRODUCTION

The Food and Agriculture Organization of the United Nations (FAO) has estimated that in 2016, the global poultry meat and egg production amounted to 120 and 81 million tons, respectively (<http://www.fao.org/poultry-production-products/production/en/>). In Italy, 1,354,000 tons of poultry meat were produced in 2017 (<https://www.unaitalia.com/mercato/annata-avicola/>). Commercial farms dominate the poultry industry, although backyard poultry raising is widespread in several geographic areas, including Italy.

Among the diseases that threaten poultry health, immunosuppressive and respiratory infections, caused by either viruses or bacteria, play a major role.

Of these, infectious bursal disease (IBD) is a worldwide, highly contagious disease of chickens caused by an *Avibirnavirus* called IBDV. The target organ of the virus is the bursa of Fabricius, where the developing B-lymphocytes are affected, resulting in impairment of the humoral immunity of the birds. As a result, the birds show increased susceptibility to secondary infections and a suboptimal response to vaccinations. In Italy, the first report of IBD dates back to 1965 (Rinaldi et al., 1965); afterwards, the disease has become endemic in Italy, and live vaccination was introduced (Asdrubali and Franciosini, 1993). In a recent study, an emerging IBDV genotype, the ITA, was detected in IBD-live-vaccinated broilers without clinical signs of IBD and with a history of poor growth performance. In this context, the first part of this thesis focuses on the genome sequence and phylogenetic analysis of a field isolate of the ITA genotype (strain IBDV/Italy/1829/2011) to determine its origin through a complete molecular characterisation.

*Mycoplasma gallisepticum* (MG) and *Mycoplasma synoviae* (MS) represent the most important avian *Mycoplasma* species in the poultry industry, causing considerable economic losses on a global level (Mohammed et al., 1987). In general, MG causes chronic respiratory disease in chickens and sinusitis in turkeys (Kleven, 1998), while MS mostly occurs as a subclinical upper respiratory infection, which can progress to respiratory disease when combined with others respiratory agents; it can also be responsible for synovitis (Lockaby et al., 1999). The control of MG and MS has generally been based on the eradication of the organisms from breeding flocks and the maintaining of a *Mycoplasma*-free status both in breeding birds and their progeny by implementation of strict biosecurity measures. The early detection of infections is extremely important and obtained by culture or molecular methods (Ferguson-Noel et al., 2012). Several factors influence the successful of isolation and/or detection of MG or MS, such as the temperature and/or the time of storing of oropharyngeal swabs and the types of swabs used. In Chapter IV, the comparison of two types of swabs (wooden *versus* plastic shafts)

and the influences of different storage temperatures on the detection of both MG and MS by culture, conventional and quantitative PCRs is discussed.

When the maintenance of the free *status* from MG and/or MS is not feasible, vaccination is applied. *Mycoplasma gallisepticum* and/or *Mycoplasma synoviae* field strains could be detected from vaccinated chickens, and differentiation between field- and vaccine-derived strains is essential, as well as the molecular characterisation of strains for epidemiological purposes.

Chapter V deals with the molecular characterisation of MG strains circulating in commercial poultry farms of Middle East and South Asia, using the Gene Targeted Sequencing (GTS) method, which consists of the amplification of four MG surface-protein genes (MGA\_0319, *mgc2*, *gapA* and *pvpA* gene fragments) (Ferguson-Noel et al., 2005).

While continuous monitoring, good management practices and biosecurity measures are strictly applied in poultry integrated companies, poor or absent disease control strategies characterise backyard poultry production.

While information is available on MG and MS strains circulating in Italian industrial farms, knowledge on the epidemiology and the molecular characteristics of MG and MS in backyard poultry farms is scarce.

Therefore, Chapter VI is focused on MG and MS strains detected in 11 backyard poultry flocks in different Italian regions, characterised by the GTS method (MG) or by PCR targeting of a fragment of the *vlhA* gene (MS). The type and subtype were assigned to each MS strain analysed based on the number of nucleotides included in proline-rich repeats (PRR) and the mutations in the RIII region, as reported by Benčina et al. (2001).

**CHAPTER I**  
**INFECTIOUS BURSAL DISEASE**

## 1.1 Aetiology

### 1.1.1 Taxonomy

Infectious bursal disease (IBD), also known as “Gumboro disease,” is a worldwide, highly contagious poultry disease caused by the IBD virus (IBDV), which belongs to the *Avibirnavirus* genus within the Birnaviridae family (Van den Berg, 2000). The Birnaviridae family is a distinct double-stranded RNA (dsRNA) family of viruses that infect animal species from birds to mollusks, fish, as well as insects. Currently, the family is grouped into four main genera according to its hosts: the genus *Aquabirnavirus*, causing Infectious Pancreatic Necrosis of fish, molluscs and crustaceans; *Avibirnavirus*, whose type species is IBDV of birds; *Entomobirnavirus*, which infects insects, and *Blosnavirus*, whose type species is the blotch snakehead virus (<https://talk.ictvonline.org/taxonomy/>; Eterradossi and Saif, 2013).

### 1.1.2 Virus structure

The IBDV is a single-shelled, nonenveloped virion with icosahedral symmetry and a diameter varying from 55-65 nm. The capsid symmetry is skew, with a triangulation number of  $T = 13$  and a typical laevo icosahedral geometry (Ozel and Gelderblom, 1985; Coulibaly et al., 2005). The genome is composed of two segments of double-stranded RNA (A and B). Segment B (2.8 kb) encodes for the viral protein (VP) VP1, which is an RNA-dependent RNA polymerase (RdRp) (Von Einem et al., 2004), while segment A (3.17 kb) contains two partially overlapping open reading frames (ORFs) that encode the major components of the virus. One encodes for a polyprotein NH<sub>3</sub>-VP2-VP4-VP3-COOH and the other for the non-structural VP5 protein (Birghan et al., 2000; Lejal et al., 2000). The polyprotein is self-cleaved by the viral protease VP4 to yield a precursor VP2 (pVP2), VP3 and VP4 (Lejal et al., 2000). The pVP2 product is further processed to mature VP2, which is the major capsid protein, during viral replication and the capsid assembly (Irigoyen et al., 2009). Of these, VP2 and VP3 form the outer and inner capsids of the virus, respectively (Böttcher et al., 1997) (Figs. 1 and 2). The VP1 is composed of amino acids (aa) 1-845 and is present in virions both as a free polypeptide and as a genome-linked protein that is covalently linked to the 5' ends of the genomic RNA segments (Müller and Nitschke, 1987). The tridimensional structure of the IBDV RdRp shows that the polypeptide chain can be divided into three functional regions: the N-terminal (aa 1–167), which is responsible for protein priming, the central polymerase domain (aa 168–658), which contains all structural motifs of RdRp, and the C-terminus (aa 659–878), preventing back-primed RNA synthesis during protein priming (Garriga et al., 2007). The VP1 is responsible for the replication of the viral genome and the synthesis of mRNAs (Le Nouën et al., 2012).



The VP2 (aa 1-512) is the major structural protein, constituting 51% of the virion (Dobos et al., 1979). Inside the amino acid sequence of VP2, a hypervariable region is located between aa 206 and 350. This sequence includes two major hydrophilic peaks, A and B, at positions 212–224 and 314–324, respectively, and two minor hydrophilic peaks, C and D, at positions 249–254 and 279–289, respectively. Most of the aa changes observed among IBDV strains, which are associated with antigenic and virulence variations, are clustered in these regions (Nagarajan and Kibenge, 1997). The VP2 contains three distinct domains, namely base (B), shell (S) and projection (P) domains (Coulibaly et al., 2005).

Several studies have focused on the VP2 protein. It is the major structural protein that induces the neutralisation of antibodies (Abs) and is responsible for the antigenic variation due to the previously mentioned hypervariable region (Qin and Zheng, 2017; Qi et al., 2013; Jackwood and Sommer-Wagner, 2011). It shows a serine-rich heptapeptide region at position 326 to 332, associated with virulence of IBDV strains (Nagarajan and Kibenge, 1997). Brandt et al. (2001), using an *in vivo* trial, have reported that the aa Gln253, Asp279 and Ala284 in VP2 are involved in virulence, cell tropism and pathogenic phenotyping of virulent IBDV.

The VP3 (aa 756-1012) is the second major structural protein of IBDV, constituting 40% of the virion (Dobos et al., 1979). Among the five proteins of IBDV, VP3 is the most multifunctional protein: it interacts with VP2, VP1, dsRNA and itself (Tacken et al., 2003; Onã et al., 2004; Mertens et al., 2015) and acts as a scaffold protein. It binds both to viral genomic dsRNA and VP1 to assemble into ribonucleoprotein complexes (Mertens et al., 2015), in which VP3 significantly stimulates RdRp activity (Ferrero et al., 2015). Moreover, VP3 is an antiapoptotic protein (Busnaiego et al., 2012) and prevents the induction of beta interferon (IFN- $\beta$ ) (Ye et al., 2014).

The VP4 (aa 513-755) is a viral protease able to cleave *in trans* and is responsible for the interdomain proteolytic autoprocessing of the pVP2-VP4-VP3 polyprotein into the pVP2 precursor, VP4 and VP3 (Böttcher et al., 1997; Birghan et al., 2000).

Recently, other functions of the VP4 protein have been found; it is a biomarker for discriminating between pathogenic and non-pathogenic IBDV (Wang et al., 2009) and inhibits the expression of type I interferon (Li et al., 2013).

The nonstructural VP5 (145–149 aa) is a cytolytic protein which accumulates within the cell membrane of infected cells and promotes the egress of the viral progeny (Yao et al., 2001). It is non-essential for virus replication *in vitro* (Mundt et al., 1997) or *in vivo* (Yao et al., 1998), prevents apoptosis of the infected host cell in the early stages (Liu and Vakharia, 2006) and promotes apoptosis in later stages (Lombardo et al., 2000). More recently, studies using 3D models have reported that

VP5 has a structure similar to the leucine-rich repeat family of proteins and to the Toll-like receptor 3 of the host (Ganguly and Rastogi, 2018).




Figure 1. Schematic representation of IBDV viral structure: the capsid is composed of 260 trimers of VP2 that form spikes, projecting if from the capsid. VP3 forms a ribonucleoprotein complex with the genomic RNA. ([https://viralzone.expasy.org/162?outline=all\\_by\\_species](https://viralzone.expasy.org/162?outline=all_by_species)).




Figure 2. Schematic representation of the genome of IBDV and the encoded proteins (King et al., 2012).

### 1.1.3 Viral replication

The IBDV infection begins with the attachment of viral particles or VP2 to the cellular receptors of host cells, namely surface immunoglobulin M (sIgM) (Sharma et al., 2000, Chi et al., 2018). The Ile-Asp-Ala sequence within the P domain of VP2 was identified as the functional ligand motif to  $\alpha 4\beta 1$  integrin. In addition,  $\alpha 4\beta 1$  heterodimer is abundant in immature lymphocytes, confirming the tropism of IBDV for young chickens. The IBDV- $\alpha 4\beta 1$  link activates the mechanism cascade for endocytotic internalisation of IBDV (Qin and Zheng, 2017).

The internalisation of the IBDV particles occurs by a clathrin-independent endocytosis mechanism, based on several cellular factors. The low concentration of calcium ions in the endosoma activates the loss of the compact structure of the virus particle and promotes the release of the peptide pep46 (a capsid-associated peptide generated from the C-terminus of pVP2) from the viral capsid, destabilising the endosomal membrane and forming pores with a diameter of < 10 nm, resulting in the release of viral particles from the endosome into the cytoplasm (Galloux et al., 2007).

The transcription of the dsRNA genome by viral polymerase occurs inside the virion, so that dsRNA is never exposed to the cytoplasm. The RdRp produces two mRNA molecules from each of the dsRNA genome segments. The mRNAs can be detected in infected cells at 3–4 h post infection (King et al., 2012). The model proposed for assembly of IBDV particles involves most of the viral proteins: the VP1 interacts with the viral RNA (Dobos, 1995), and the VP3 interacts with itself, pVP2, VP1 and the viral genome (Lombardo et al., 1999).

The virus particles accumulate within the cytoplasm of infected cells, and the VP5 forms pores in the membrane of infected cells, contributing to virus release (Lombardo et al., 2000), which could be favoured by the fact that VP5 prevents apoptosis of infected cells during early stages of infection (Qin and Zheng, 2017). However, the detailed mechanism of virus release is largely unknown.

### 1.1.4 Strain classification

The IBDV strain can be characterised relating on its antigenicity, pathogenicity or molecular characteristics.

*Antigenicity.* The IBDV can be divided into two major antigenic groups known as serotype 1 and serotype 2, but only serotype 1 viruses cause disease in chicken. Two well-documented antigenic types, classic and variant strains, have been described based on studies on the antigenicity of the serotype 1. A third group, the very virulent IBDV (vvIBDV), has been described based on pathogenicity (Van den Berg et al., 1991). The antigenic phenotype of IBDV is determined by specific aa located at the apex of loops (P<sub>B</sub>C, P<sub>D</sub>E, P<sub>F</sub>G, P<sub>H</sub>I) of the VP2 (Coulibaly et al., 2010). The first antigenic type is the so-called “classic” or “standard” strain (Rosenberger et al., 1975). The variant viruses have been described later in the USA and are antigenically different from the classical strains

(Jackwood and Saif, 1987). The third group of viruses, vvIBDV, have been reported in 1991 (van den Berg et al., 1991). Although they appear to be antigenically different from the classic and variant strains, the name “very virulent” is based on pathogenicity and not on antigenicity (van den Berg et al., 2004).

*Pathogenicity.* Based on experimental trials in specific pathogen-free (SPF) chickens, three pathotypes of IBDV have been reported: classic, variant and vvIBDV strains. Variant caused poor or absent clinical signs and mortality, but severe macroscopic and/or microscopic lesion in the Bursa of Fabricius; classic strains induced 10-50% of mortality, with clinical signs and associated lesions; vvIBDV showed pathogenicity similar to classic strains, but mortality may reach 100% (OIE, 2016). For the *molecular characterisation* of IBDV, RT-PCR and restriction endonucleases analysis have been used (Lin et al., 1993). These approaches are known as *restriction endonuclease (RE)* or *restriction fragment length polymorphism (RFLP)* analysis of RT-PCR products (OIE, 2016).

A further molecular characterisation of IBDV strains can be achieved using full genome sequencing and phylogenetic analysis. Because the reassortant IBDV strains were reported, sequencing of both genome segments is needed (Jackwood et al., 2011). Reassortment phenomena occur when cells are co-infected by two distinct IBDV strains (Qi et al., 2016); reassortants with segments from serotype 1 and serotype 2 IBDV or segment A from an attenuated and segment B from vvIBDVs have also been reported (Jackwood et al., 2011a; Jackwood et al., 2016; Lee et al., 2017). Not all viruses identified as vvIBDV by sequencing are highly pathogenic because they could be reassortant strains; also, variant IBDV strains do not form a homogeneous group.

In this sense, the current classification schemes of IBDV are confusing or incomplete. A new genotyping system which can easily be applied in all laboratories has recently been proposed by Michel and Jackwood (2017). Because most of the aa mutations, influencing the current classification methods, are found in the hypervariable (*hv*) region of VP2, the new classification is based on phylogenetic analysis of a 560-bp (nt 702-1261) fragment of the hvVP2. Seven genogroups (named G1-G7), containing several subgroups (identified by lower-case letter), have been found. Genogroup 1 strains are globally distributed, while Genogroup 2 mostly occurs in North America and Genogroup 3 in other continents. Many strains are classified into genogroups G4-G7 and have mutations likely to contribute to the modification of antigenicity (Michel and Jackwood, 2017) (Figs. 3 and 4). For reassorted vvIBDV, VP1 should be included in the genogroup classification (Jackwood et al., 2018). A new nomenclature for the IBDV virus has also been proposed: serotype/isolation host/country of origin/common name/year of isolation and genogroup (Jackwood et al., 2018).

Genogroup	Previous classification	Reference strains (GenBank accession Number)
1	Classical	228E (AF457104) D78 (AF499929) F52-70 (AY321953) Lukert (AY918948) STC (D00499)
2	Antigenic variant	AL-2 (JF736011) DeIE (AF133904) T1 (AF281238)
3	vvIBDV	Henan (KT884486) HK46 (AF092943) OKYM (AF092943) UK661 (NC_004178)
4	dIBDV	dIBDV/UY/2014/2202 (KT336459) MG4 (JN982252) TY2 (LC136880)
5	Variant/classical recombinant	Mexico04M101 (DQ916210)
6	ITA	ITA-02 (JN852986)
7	Australian	V877-W (HM071991)

Figure 3. Classification of IBDV isolates by the genogroup method (Michel and Jackwood, 2017).




Figure 4. Phylogenetic analysis of the 105 nucleotide sequences of hvVP2 of IBDV. Reference strains are identified by name and GenBank accession number. The phylogeographic genogroups are reported (Michel and Jackwood, 2017).

### **1.1.5 Susceptibility to physical and chemical agents**

The IBDV is a stable virus. It maintains infectivity in the flocks for 122 days after clean-up and disinfection and up to 52 days in feed and water (Müller et al., 2012). It can potentially be spread between farms through airborne transmission (Zhao et al., 2013). The trade of chicken meat is a critical point for the spreading of IBDV (OIE, 2000). In addition, the cooking of chicken meat previously inoculated with IBDV, reaching an internal temperature of 71-74°C, did not inactivate the virus (Etteradossi and Saif, 2013). In another study, the use of a UV lamp inactivated 72.35% of airborne IBDV (Zhao et al., 2014).

The virus can be inactivated by phenol-chloroform (Jackwood, 1996). It survived at 70°C for 30 minutes, and exposure to 0.5% chloramine for 10 minutes and 0.5% formalin for 6 hours destroyed the virus (Landgraf et al., 1967); an iodine complex had deleterious effects on the virus at 23°C for 2 minutes (Etteradossi and Saif, 2013).

## 1.2 Epidemiology and pathogenesis

### 1.2.1 Incidence, prevalence and distribution

The incidence of IBDV infections in major poultry-producing areas is high, and theoretically, all flocks are exposed to natural infection (Etteradossi and Saif, 2013).

In 1957, the first classical IBDV outbreak was described; antigenic variants emerged in the USA in 1985 (Etteradossi and Saif, 2013). In 2008, vvIBDV were detected in the USA (Alkie and Rautenschlein, 2016). Classical IBD viruses occur worldwide, with the probable exception for New Zealand (<https://www.cabi.org/isc/datasheet/80665>), and VvIBDV strains have been isolated in Asia, Central Europe, Russia, the Middle East and South America.

### 1.2.2 Natural hosts and transmission

The IBDV is highly host-specific. While turkeys (*Meleagris gallopavo*) and Peking ducks (*Anas peking*) may be asymptomatic carriers of serotype 1 strains (Ingrao et al., 2013; Qin and Zheng, 2017), only chickens (*Gallus gallus*) develop IBD after infection by serotype 1 viruses (Etteradossi and Saif, 2013). Experimental inoculation of IBDV serotype 1 in quails, partridges, pheasants and guinea fowls did not result in any clinical signs (Ingrao et al., 2013).

As the severity of the disease is directly related to the number of susceptible cells present in the BF, the age of greatest susceptibility to clinical disease is 3-6 weeks, when the BF is at its maximum development (Van den Berg, 2000). Particularly, chickens younger than 3 weeks do not show clinical signs, but develop severe immunosuppression, while in older chickens, clinical disease occurs (Ingrao et al., 2013). In any case, immunosuppression is the major common outcome. The age susceptibility is broader with vvIBDV strain infections (Van den Berg, 2000).

Different susceptibilities have been reported based on breeds or genetics of the chickens: layer-breed and layer-type chickens show higher mortality rates compared to broiler-type chickens (Nielsen et al., 1998). Moreover, the genetic background influences the disease outcome; in the early phase of the disease, there are more severe lesions and higher mortality rates in layer-type compared to broiler-type chickens (Arcibasi et al., 2010). In addition, layer-type chickens of all genetic backgrounds showed significantly higher IBDV antigen loads in the BF compared to broiler-type birds (Tippenhauer et al., 2012).

The IBDV is highly contagious and persistent in the environment. Only horizontal transmission by the faecal-oral route is known for IBDV; the virus is shed in the faeces for up to 2 weeks post infection (Etteradossi and Saif, 2013). Wild birds or rodents might act as mechanical vectors, such as the lesser mealworm (*Alphitobius diaperinus*), up to 8 weeks after an outbreak (Etteradossi and Saif, 2013). In a recent study, IBDV was recovered from exhausted air of a room hosting birds experimentally

infected with IBDV; it was concluded that the airborne virus is a potential risk of virus spreading to the environment (Zhao et al., 2013). Other animals, such as wild birds (Ogawa et al., 1998), mosquitoes (Howie and Thorsen, 1981) or rodents, might also play a role as mechanical vectors of the virus (Edgar and Cho, 1976).

### **1.2.3 Pathogenesis**

After oral infection, the virus replicates in gut-associated macrophages and lymphoid cells and enters the portal circulation, leading to primary viraemia. After 4 hours (h) post-infection (p.i.), the virus is detectable in the gut-associated macrophages and lymphoid cells of the caecum. After 5 h, it is detectable in the liver, from which it travels to the bursa of the Fabricius via the blood stream, where it replicates (11 h p.i.) (Van den Berg, 2000; Ingraio et al., 2013; Alkie and Rautenschlein, 2016). By 13 h p.i., most bursal follicles are positive for virus detection, and virus replication leads to diffuse lymphoid cell destruction in the medullary and the cortical areas of the follicles (Sharma et al., 2000). The IBDV has a predilection for actively proliferating immature lymphocytes of lymphoid organs (Saif, 1998). By 16 h p.i., a second viraemia occurs, resulting in the spread of the virus to other organs, where secondary replication occurs (Van den Berg, 2000).

### **1.2.4 Interaction of IBDV with immunitary system**

The innate immune response is the first line of defence against pathogens. This response is mediated by pattern recognition receptors (PRRs), which detect pathogen-associated molecular patterns (PAMPs). In chickens, 10 different Toll-like receptors (TLRs) have been identified (St. Paul et al., 2013). Several TLRs recognise viral PAMPs: TLR3 detects dsRNA derived from viral replication, while TLR7 detects single-stranded RNA (ssRNA). Moreover, the viral replication triggers upregulation of TLR21 transcripts. However, differential regulations of TLR3 and TLR7 have been reported during mucosal IBDV infection (St. Paul et al., 2013; Alkie and Rautenschlein, 2016).

An IBDV infection involves the host immunitary cells by destroying IgM-bearing B lymphocytes, attracting T cells and activating macrophages, resulting in the activation and/or suppression of cytokines and chemokines.

The depletion of bursal follicles is due to necrosis and apoptosis. Apoptosis involves several IBDV-infected cells in bursal, thymic and splenic cells. In addition, the lack of the virus in some bursal and thymic cells death by apoptosis, suggests that IBDV probably induces apoptosis of both infected and uninfected bystander cells (Sharma et al., 1993), confirming the role of immunological mediators in the process. Recently, Cubas-Gaona et al. (2018) have reported that the genomic dsRNA is a major viral factor that contributes to the triggering of apoptosis.



In this process, T cells are not susceptible to IBDV infection, although they modulate IBDV pathogenesis, limiting viral replication in BF up to 5 days p.i. and promoting bursal damage and the delay of bursal recovery through the release of molecules (Rautenschlein et al., 2002). In response to IBDV infection, an influx of T lymphocytes CD4<sup>+</sup> (T helper) and CD8<sup>+</sup> (cytotoxic) cells into the BF occurs (Ingrao et al., 2013). Particularly, in the presence of IBDV infection, Guo et al (2012) have reported that IRF1 and IRF4 were up-regulated and down-regulated, respectively. However, IRF1 induces APCs to secrete IL-12, which promotes the differentiation of T helper cells to Th1 cells, while IRF4 promotes the differentiation of T helper cell to Th2 cells (Lohoff and Mak, 2005). The Th1 response triggers a cell-mediated immune response reducing Ab production, which might contribute to IBDV-associated immunosuppression (Guo et al., 2012). The cytotoxic T cells are involved in the clearance of virus-infected cells (Ingrao et al., 2013). To date, the role of Natural Killer (NK) cells in IBDV pathogenesis is not yet understood (Alkie and Rautenschlein, 2016). An exacerbated cytokine immune response and B cell depletion due to apoptosis are the main factors that contribute to the severity of the disease. Recent studies have shown that very virulent IBDV cause high rates of mortality, possibly through the induction of an exacerbated innate immune response resulting in a “cytokine storm” (Lowenthal et al., 2013).

### **1.2.5 Immunosuppression**

Immunosuppression has been defined as a “state of temporary or permanent dysfunction of the immune response resulting from damage to the immune system and leading to increased susceptibility to disease agents” (Dohms and Saif, 1984).

All compartments of the immunitary system are affected by IBDV infection (innate immunity, humoral immunity and *cell-mediated immunity*). After exposure to IBDV, the intestinal macrophages are infected with IBDV and undergo apoptosis and lysis, contributing to reduced innate immunity. Moreover, IBDV causes a lytic infection of IgM<sup>+</sup> B lymphocytes, primarily in BF, but also in secondary lymphoid organs, leading to a reduction in circulating IgM<sup>+</sup> B cells (Sharma et al., 2000). Activated T cells will overproduce IFN- $\gamma$ , which, in turn, will stimulate macrophages for the production of pro-chemokines and cytokines such as IL6. This exacerbated cytokine production conditions the symptoms and outcome of the IBDV infection. Afterwards, up-regulation in T cell activation is followed by a feedback down-regulation in convalescent chickens, leading to T cell immunosuppression (Rauw et al., 2007; Ingrao et al., 2013).

In addition to injury from “direct” interaction between IBDV with several compartments of the immunitary system, there are secondary alterations due to ineffective immune responses to vaccination for several agents (Eterradossi and Saif, 2013).

## 1.3 Clinical signs and lesions

### 1.3.1 Clinical signs

Based on the virulence of the strain, age or breed of the chickens, the disease may take a clinical or subclinical course. The incubation period of IBD is short; clinical signs appear within 2–3 days after exposure to the virus and generally last for 5–7 days (Sharma et al., 2000). The most severe clinical signs are seen in chicks of 3–6 weeks of age. The chickens are depressed, with ruffled feathers, and show severe prostration, watery diarrhoea, anorexia and trembling; generally, the cloaca is reddened (Sharma et al., 2000). Morbidity is typically 100%, mortality is usually 30–60% for classical IBDV strains, but can reach 90% for vvIBDV strains. The clinical disease is followed by a rapid recovery in surviving birds (Maghoub, 2012).

Birds older than 6 weeks rarely develop clinical signs (Sharma et al., 2000).

The subclinical form is observed when variant strains are involved or when the infection occurs in birds of 1–14 days of age, with maternal Abs against IBDV. The subclinical form of the disease is characterised by the absence of specific clinical signs. However, severe immunosuppression, due to the damage of the BF, occurs anyway, and the birds also show impaired feed conversion (Maghoub, 2012).

Birds of less than 2 weeks of age, although repopulation of the BF with B cells can occur afterwards, reduced B lymphocyte seeding of secondary lymphoid aggregates, resulting in a permanently defective humoral immunity (Maghoub, 2012).

In chickens older than 14 days, the immunosuppression caused by IBD is transient (Hoerr, 2010).

Infected chickens with immunosuppression have a high degree of susceptibility to concurrent or secondary bacterial, viral and parasitic infections and also show a poor immune response to vaccines. The chicken's susceptibility to bacterial infections such as gangrenous dermatitis (Rosenberger et al., 1975; McIlroy et al., 1989), colibacillosis (Nakamura et al., 1990) or salmonellosis (Hoerr, 2010) or other intestinal pathogens (Li et al., 2018) can be enhanced.

### 1.3.2 Gross and microscopic lesions

#### 1.3.2.1 Macroscopic lesions

At post-mortem examination, in both clinical and subclinical forms, the carcasses show dehydration and haemorrhages in the thigh and pectoral muscles (Fig. 5). Dehydration may lead to renal lesions (Hoerr, 2010). The spleen may be slightly enlarged, with small grey foci on the surface (Rautenschlein et al., 2002). Occasionally, haemorrhages are observed at the juncture between *proventriculus* and *ventriculus* (Stoute et al., 2009). The Harderian gland shows depletion of plasma cells (Dohms et al., 1988).

As the BF is the target organ of IBDV infection, it is the most affected organ (Cheville, 1967; Mahgoub, 2012) (Fig. 5). Throughout the acute phase of the disease, the BF increases in size and weight as a result of oedema, reaching twice its normal weight at 2-3 days post infection. A gelatinous yellowish transudate covers the serosal surface of the BF (Fig. 5), longitudinal striations on the surface become prominent, and the normal colour (white) turns to cream. Afterwards, the BF begins to decrease in size and reaches its normal weight, the transudate disappears and the organ becomes grey (period of atrophy). In this phase, the BF continues to atrophy, reaching approximately one-third of its original weight at 8 days p.i. (Cheville, 1967; Mahgoub, 2012).

#### **1.3.2.2 Microscopic lesions**

In the early stages of the infection, the spleen shows hyperplasia of reticuloendothelial cells around the adenoid sheath arteries and lymphoid necrosis of the germinal follicles and the periarteriolar lymphoid sheath. Thymus and cecal tonsils show a cellular reaction of the lymphoid tissues.


In general, throughout the acute phase of IBDV infection, in the BF, degeneration and necrosis of lymphocytes in the medullary area of follicles and inflammatory infiltration (heterophils and hyperplastic reticuloendothelial cells) may be observed (Sharma et al., 1989) (Fig. 6). Afterwards, subserosal and intra-follicular oedema, hyperaemia and marked accumulation of heterophils and/or plasma cells occur (Cheville, 1967). Because of degeneration and necrosis, the follicles are similar to necrotic centres surrounded from accumulations of heterophiles. In the phase of BF atrophy, necrosis and phagocytosis of heterophiles and plasma cells occur, developing cystic cavities in the follicles and making them similar to cysts surrounded by columnar epithelial cells (glandular) (Fig. 6) (Stoute et al., 2009). In this phase, the inflammatory reaction declines and fibroplasia in interfollicular connective tissue occurs. The epithelium of the bursa becomes proliferative, forming a glandular-like structure (columnar epithelium containing globules of mucin) (Fig. 6). Scattered lymphocyte foci appear, but cannot form healthy follicles during the period of 18 d.p.i. (Cheville, 1967). Through the period of 1–8 weeks p.i., for individual follicles, two sequelae are histologically observed: large reconstituted follicles with numerous lymphocytes in the cortex and medulla and small, poorly developed, non-functional follicles with indiscernible cortex and medulla (Hoerr, 2010).

Based on the IBDV strain involved, different lesions have been described.


Variant strains induce atrophy and lymphocyte depletion of the BF in less time than classic and vvIBDV strains (Sharma et al., 1989). In addition, variants do not induce an inflammatory response (Sharma et al., 1989), except the IN variant (Hassan et al., 1996).

The vvIBDV strains cause lesions similar to those caused by classic strains, although the atrophy of the BF occurs quickly. Moreover, vvIBDV strains cause severe thymic atrophy and more severe lesions in the cecal tonsils, thymus, spleen and bone marrow, as well as haemorrhages in bursal tissue

(Tanimura et al., 1995; Jackwood et al., 2009). Because the pathogenicity is correlated with lesions in non-bursal lymphoid organs, the degree of pathogenicity of an IBDV strain may be correlated with antigen distribution in non-bursal lymphoid organs (Tanimura et al., 1995).



*Figure 5. Lesions of the BF in the course of IBD. Yellowish substance covering the serosal surface of BF and enhanced size of BF (A). Hemorrhages in the thigh muscles (B) (Avian Pathology Service, University of Bologna, photo archive).*



*Figure 6. Chicken, BF, hematoxylin eosin, object 10x. Depletion of cortical follicles and interfollicular oedema with inflammatory cells are observed. epithelial cells contain globules of mucin (arrow) (A). Severe atrophy of BF, fibroplasia of interfollicular space, follicles with debris inside resulting from necrosis and apoptosis of lymphoid cells (\*), follicles similar to cysts surrounded by columnar epithelial cells (\*\*) (B) (Avian Pathology Service, University of Bologna, photo archive).*

## **1.4 Diagnosis**

When present, clinical signs, gross and microscopic lesions, especially those found in the BF, are highly indicative of IBD. In the subclinical form, when only atrophy of the BF is observed, the diagnosis of IBD is more difficult (Müller et al., 2003). The laboratory investigations needed to confirm IBD diagnosis are shown below.

### **1.4.1 Isolation and identification of IBDV**

The virus can be detected in bursal tissue homogenate by isolation, molecular methods and antigen-capture ELISA (AC-ELISA), in pieces of the bursal tissue by agar gel immunodiffusion (AGID) or in sections of the bursa prepared using a microtome cryostat by an immunofluorescent test (OIE, 2016).

#### **1.4.1.1 Virus isolation**

The BF and spleen are the preferable tissue samples to attempt IBDV isolation; the bursa contains the highest virus titres compared to the spleen. During the first 5-6 days after the infection, the virus can also be isolated from other lymphoid tissues (Rosenberger et al., 2009).

Virus isolation is performed in embryonated SPF eggs or cell cultures. Hitchner and Hirai (1979) have demonstrated that the chorioallantoic membrane (CAM) of 9- to 11-day-old embryos is the most sensitive route of inoculation for isolation of IBDV. Inoculated eggs should be incubated for 5-7 days and candled daily. Dead embryos should be observed for the presence of specific lesions (Senne et al., 2009).

Mortality rate and embryo lesions vary among IBDV strains. Classical strains kill embryos in 3-5 days. The embryos appear congested with haemorrhages, petechiae and ecchymosis on CAM, liver and spleen are pale and can show small necrotic areas (Rosenberger et al., 2009).

Variant strains usually do not kill the embryos, but lesions can be observed. Embryos can have a creamy colour, be stunted, congested or haemorrhagic; the liver can have a bile staining and be necrotic; the spleen can be enlarged, and cerebral and abdominal oedema can be seen (Rosenberger et al., 2009).

The BF, kidney or fibroblast primary cells derived from chicken embryos or continuous cell lines of B-cell origin can be used for virus isolation. The virus may be adapted by blind passages to those cell cultures before producing cytopathic effects (Rosenberger et al., 2009; Etteradossi and Saif, 2013).

#### **1.4.1.2 IBDV Molecular detection and characterisation**

The detection of the IBDV genome can be performed by *reverse-transcription polymerase chain reaction (RT-PCR)* (OIE, 2016) or *quantitative RT-PCR (qRT-PCR)* (Moody et al., 2000).

In addition, *RFLP* assays can be used for to detect and differentiate IBDV strains (OIE, 2016). This method allows to identify a genetic marker correlated to specific antigenic or pathogenic characteristics of the virus; for example, the *SspI* restriction site, located in the hvVP2, has been proposed and used to identify vvIBDV strains (Lin et al., 1993; Abdel-Alim et al., 2003).

Nucleotide sequencing of a 742-bp (nt 737-1479) *RT-PCR* product of VP2 amplification is widely used for the detection and characterisation of IBDV strains (Müller et al., 2003; Jackwood et al., 2008; OIE, 2016). In particular, the hypervariable region of the VP2 gene is the target sequence to differentiate different strains of IBDV (Jackwood, 2004). As VP1 is an important determinant of virulence (Escaffre et al., 2013), and because reassortant viruses have been identified, the molecular characterisation of IBDV strains should be also be based on the sequencing of segment B (OIE, 2016). Quantitative RT-PCR methods allow the rapid detection of IBDV and provide a measure of the viral load. Quantitative RT-PCR for IBDV, using the TaqMan method (Moody et al., 2000) or SYBR green I dye (Kong et al., 2004), have been developed. This method has been also used for the differentiation of IBDV subtypes on the basis of sequence differences among IBDV strains (Jackwood and Sommer, 2005 and Ching Wu et al., 2007).

#### **1.4.1.3 Antigen-capture (AC-ELISA)**

This method is applied to samples containing live viruses (OIE, 2016); the first protocol was developed by Snyder et al. (1988). The advantages of this method are simplicity and speed, although the preparation of Abs is labour-intensive (Ching Wu et al., 2007).

#### **1.4.2 Detection of specific Abs**

Acute and convalescent sera can be tested to detect specific Abs against IBDV by AGID (OIE, 2008) ELISA tests (Marquardt et al., 1980) and the Virus Neutralization test (Weisman and Hitchner, 1978), which is the only serological test that can differentiate IBDV isolates into antigenic serotypes and subtypes (Müller et al., 2003). The AGID is the simplest, but least sensitive test, while the VN test is more laborious and expensive than the AGID test, but is more sensitive for detecting Ab (OIE, 2016); in contrast, the ELISA provides results more rapidly than the other two tests (OIE, 2016).

## 1.5 Prevention

Because IBDV is a stable, resistant, widely distributed virus (Van den Berg, 2000), even strict biosafety measures are not sufficient to maintain a flock free from IBDV (Etteradossi and Saif, 2013).

### 1.5.1 Traditional live vaccines

Traditional live-attenuated IBDV vaccines have been, up to recently, the most used method to prevent IBD (Müller et al., 2012). They allow to achieve lifelong protection inducing cellular and humoral immunity by replicating in the BF, but possess residual pathogenicity and a relative risk of reversion to virulence (Müller et al., 2012). Live vaccines have been obtained by attenuation of field viruses by serial passage in tissue culture or eggs. Based on their grade of attenuation, the vaccines are classified into *Mild*, *Intermediate* and *Intermediate plus* or *Hot* (Tsukamoto et al., 1995; Mazariegos et al., 1990; Rautenschlein et al., 2005).

The *Mild* vaccines have a low residual pathogenicity; they are efficacious only in the presence of low titres of maternal Ab (maternal Ab < 4 log<sub>2</sub> by VN test) and have a poor efficacy against vvIBDV.

The *Intermediate* and *Intermediate plus* or *Hot* vaccines may break higher levels of maternal Ab (maternal Ab < 6–7 log<sub>2</sub> and < 8-9 log<sub>2</sub> by VN test), but may induce severe bursal lesions (OIE, 2016).

Nevertheless, they are not fully protecting from vv or variant IBDV strains (Giambrone and Closser, 1990).

The choice of the correct time for vaccination is crucial to avoid interferences with MDA, which will neutralise the vaccine and adversely affect the induction of protection (Van den Berg, 2000). On the other hand, allowing too much time before vaccination could leave the chickens unprotected. The so-called “Deventer formula” has been developed by de Wit (2001) for estimating the correct age for vaccination. It consists in measuring the level of MDA at a very young age in order to predict the time when the lower level of MDA will occur, allowing efficient vaccination (de Wit, 2001).

*Intermediate* or *intermediate plus* vaccines are used to elicit protection in broilers, commercial laying hens or as priming in breeding birds. They are sometimes administered to 1-day-old birds via a coarse spray. Vaccination is usually repeated one or two times (10-14 and at 17-24 days of age), especially when the risk of exposure to the disease is high (OIE, 2016).

### 1.5.2 Inactivated vaccine

Inactivated vaccines are formulated as water-in-oil emulsions and used in breeding birds as booster (at 16-20 weeks of age) after the priming with an attenuated live IBDV vaccine (at 8 weeks of age) (Müller et al., 2012; OIE, 2016); they are used to obtain a passive immunity in the progeny (Van den

Berg, 2000). The protection of broilers relies on an early passive protection conferred through MDA and vaccination with live-attenuated vaccines (Flensburg et al., 2002)

### 1.5.3 New-generation vaccines

While live-attenuated vaccines have limitations, recently, a range of new-generation vaccines have been developed, including immune-complex and live viral vector vaccines, which became, in the last few years, commercially available.

*Subunit vaccines.* Different expression systems have been used, such as *Escherichia coli*, yeast, fowlpox virus, baculovirus, Semliki Forest virus and plant expression system to express VP2, which is the most immunogenic protein of IBDV (Alkie and Rautenschlein, 2017). Three vaccines based on the VP2 subunit are commercially available: VP2, expressed either in the baculovirus system, in *E. coli* or in the yeast *Pichia pastoris* (Pitcovski et al., 2003).

*Virus-like-particle (VLP).* This vaccine is constituted by VLP structurally identical to the original viral capsid, but lacking the nucleic acid and non-structural viral proteins (Jackwood, 2017).

The IBDV *immune complex* vaccines consist of a mixture of IBDV-specific Abs and an IBD vaccine virus; Abs are not sufficient to neutralise the infectivity of the vaccine virus, but are sufficient to delay the pathological effect (Müller et al., 2012). Young chicks can be vaccinated *in ovo* or at hatching, with IBDV *immune complex* vaccines in the presence of passive immunity (Giambrone et al., 2001; Ivan et al., 2005). The major advantages of these types of vaccines are that administration can be automated and that the vaccines are effective in the presence of MDA (Giambrone et al., 2001; Ivan et al., 2005).

*Live viral vector* vaccines are genetically engineered vaccines in which a gene from one donor organism is inserted into the genome of a vector organism to elicit a protective immune response against both organisms (Müller et al., 2012). Several vectors have been experimentally used for expressing the VP2 of IBDV: fowlpox virus, Newcastle disease virus, herpes virus of turkey (HVT), Marek's disease virus, avian adenovirus and T4 bacteriophage (Heine and Boyle, 1993; Darteil et al., 1995; Huang et al., 2004; Cao et al., 2005; Perozo et al., 2008; Li et al., 2017). Several "HVT plus IBDV-VP2" vector vaccines have been developed for application *in ovo* or subcutaneously in 1-day-old chickens and are commercially available (Darteil et al., 1995; Perozo et al., 2009).

The *DNA vaccines* consist of a tract of DNA encoding the VP2 protein or the entire viral polyprotein. Several studies have been conducted for IBDV (Fodor et al., 1999; Chang et al., 2001) and on the use of interleukin as adjuvant for DNA vaccine (Kumar et al., 2009; Huo et al., 2016).

Another approach to improve vaccine efficacy is the targeting of specific immunological compartments, for example the mucosal immunitary system (Zhai et al., 2014).





**CHAPTER II.**  
***MYCOPLASMA GALLISEPTICUM AND***  
***MYCOPLASMA SYNOVIAE***

## 2.1 Aetiology

### 2.1.1 Taxonomy

*Mycoplasma gallisepticum* (MG) and *Mycoplasma synoviae* (MS) represent the most important avian *Mycoplasma* species, causing considerable economic losses in the poultry industry (Mohammed et al., 1987).

*Mycoplasma* species belong to the class Mollicutes, order Mycoplasmatales, family Mycoplasmataceae, genus *Mycoplasma* (<https://www.ncbi.nlm.nih.gov.ezproxy.unibo.it/taxonomy/?term=Mollicutes>). *Mollicutes* are the smallest, simplest free-living and self-replicating eubacteria. They lack a cell wall, have an internal cytoskeleton and are chemotactic and motile, but without flagella (Trachtenberg, 1998). Complete genome sequences of MG and MS are available (Papazisi et al., 2003; Vasconcelos et al., 2005).

Apart from the previously mentioned Mycoplasmas, several minor *Mycoplasma* species have been isolated from avian hosts.

### 2.1.2 Morphology and growth requirements

The MG and MS are coccoid and have a size of approximately 0.25-0.5 and 0.2  $\mu\text{m}$ , respectively. Because they are obligatory intracellular pathogens and show a limited capacity for biosynthesis, they require cholesterol, amino acids, fatty acids, vitamins, nucleotides and other nutrients from their host or from the *medium* in which they are grown (Benčina, 2002).

*Mycoplasma medium* generally contains a protein digest and a meat-infusion base, supplemented with serum, yeast factors, glucose and other bacterial or fungal inhibitors.

In particular, MG requires a complex *medium* enriched with 10-15% of swine, horse or avian serum. Frey et al. (1968) have formulated both a liquid and an agar culture media including yeast autolysate and glucose. Thallous acetate and penicillium are essential for controlling bacterial or fungal contamination. Both species are able to ferment glucose, and therefore, phenol red (pH indicator) is included in the broth; the colour change from red to orange/yellow indicates fermentation and MG and MS growth (OIE, 2008; Raviv and Ley, 2013). To grow, MS requires the addition of nicotinamide adenine dinucleotide (NAD) (OIE, 2008).

Colony morphology on agar plates is typical and similar to that of a “fried egg”; the colonies are 0.2-0.3 mm and 1-3 mm in diameter for MG and MS, respectively. Colonies of MG are smooth and translucent, often with a dense central area; neighbouring colonies tend to become coalescent. In contrast, MS colonies are in relief, with or without a dense central area (Raviv and Ley, 2013; Ferguson-Noel and Noormohammadi et al., 2013).

### 2.1.3 Biochemical properties

Both species ferment glucose and maltose and are phosphatase-negative. Most MS and MG isolates are able to hemagglutinate turkey and chicken erythrocytes. Moreover, MG and MS cause haemolysis of horse erythrocytes; in fact, hemagglutinating antigens are used for hemagglutination-inhibition serologic tests (Raviv and Ley, 2013; Ferguson-Noel and Noormohammadi et al., 2013).

### 2.1.4 Structure and interactions with the host

#### 2.1.4.1 Structure

Both species have a small genome of about 1,000 or 900 kilobase pairs, respectively, being constituted by a high proportion of genes encoding putative lipoproteins (Benčina, 2002).

The surface lipoproteins are essential for the interactions with the host.

The variable lipoprotein hemagglutinin (*vlhA*) and one putative cytoadhesin (*pvpA*) gene encode the major surface proteins of MG. Of these, *VlhA* encodes for the hemagglutinin responsible of virulence mechanisms, antigenic variation and immune evasion through chronic infections (Noormohammadi et al., 2007; Tulman et al., 2012), while the *pvpA* gene encodes a putative surface cytoadhesin-related protein; it shows polymorphisms and is characterised by size variation among different MG strains (Boguslavsky et al., 2000; Bradbury, 2005).

Other adhesins are the *gapA* and the *mgc2*, both involved in the motility of MG (Indikova et al., 2014). Of these, *GapA* is thought to be the primary cytoadhesin molecule in MG (Papazisi et al., 2000).

The *vlhA* protein of MS is cleaved in two major phase-variable and size-variable antigens: MS protein A (MSPA) and MS protein B (MSPB); MSPB protein shows variations in length and is responsible for antigenic variations among MS strains (Benčina et al., 1999) (Fig. 1).

#### 2.1.4.2 Virulence factors

There are virulence variations among MG and MS strains. To date, the bases of virulence are not completely known. In general, virulence factors associated with MG are motility, cytoadhesin, variation of surface components, ability to invade cells (Ferguson-Noel and Noormohammadi et al., 2013). Inoculation in chicken with a hemagglutination-positive MS strain induces acute synovitis more frequently than the inoculation of a hemagglutination-negative MS strain (Narat et al., 1998). Cell invasion ability, attachment and colonisation of the upper respiratory tract are considered virulence factors in MS (Lockaby et al., 1999).

### 2.1.5 Susceptibility to chemical and physical agents

Knowledge on the persistence of mycoplasmas under various environmental conditions can contribute to implement efficacious prevention measures in the field. Christensen et al. (1994) have

published an exhaustive study on the survival of MG and MS on different materials. Both MG and MS survived up to 4 and 3 days, respectively, on feathers, up to 3 days on hair and 1 day in the nose. Survival times were shorter in other materials such as cotton, rubber and straw.

Another study compared the survival of MG at different temperatures. On dry paper discs, MG survived for 28 and 14 days at 4 and 30°C, respectively, and in *media* for 86 and 7 days at room temperature (T = 2-33°C) and 4°C, respectively. Also, 14 MG isolates persisted for similar periods compared to those of type strains (Nagatomo et al., 2001).

Recently, one author has focused on MG and MS viability in natural and synthetic hairs, concluding that a disinfectant shampoo was able to eliminate mycoplasmas on both natural and synthetic hair (Abolnik and Gouws, 2014).

In broth culture, if kept at -30°C, MG can stay viable for 2-4 years; lyophilised broth culture can maintain the viability of MG and MS over up to 10-15 years (Yoder et al., 1964). If stored at -63°C, MS can remain viable in yolk material for up to 7 years (Ferguson-Noel and Noormohammadi et al., 2013).

Chemical disinfectants are, in general, effective against MG and MS (Raviv and Ley, 2013).




Figure 1. Structure of the VlhA protein of MS (Noormohammadi, 2007).

## 2.2 Epidemiology and pathogenesis

### 2.2.1 MG and MS distribution

The prevalence of MG is generally low in breeding flocks in Europe, which usually maintain a mycoplasma-free *status* thanks to monitoring and eradication plans (Papanikolaou, 2002; Lobova et al., 2012; Michiels et al., 2016). In other countries, such as Iran, the prevalence is also low (Gharibi et al., 2018). Likewise, in the United States, the presence of MG in commercial poultry flocks is decreasing as the result of extensive control programs under the National Poultry Improvement Plan (NPIP) (Ferguson-Noel and Noormohammadi et al., 2013). In the Netherlands, since layers and meat turkeys have been included in the control and eradication program, the incidence of MG in these categories has decreased (Feberwee and Landman, 2012). High seroprevalence has reported in layers and broiler flocks in Algeria (Heleili et al., 2012) and in broiler and layer flocks in Serbia (Kapetanov et al., 2010), while low seroprevalence has been reported in broiler and layer flocks in Belgium (Michiels et al., 2016); in France, no positive layer flocks have been reported (Dufour-Gesber et al., 2006).

In other countries such as Egypt and Bangladesh, MG is widespread both in breeding (Khalifa et al., 2014) and layer flocks (Hossain et al., 2007; Ali et al., 2015).

The MS prevalence is becoming higher than the MG prevalence, especially in industrial layer flocks. A Dutch report (Feberwee et al., 2008) has described the sero-prevalence of MS in different categories of commercial poultry and confirmed that it was relatively high, especially in layer farms (Landman et al., 2014).

The MS circulation has been reported in breeder broilers in Portugal (Moreira et al., 2015) and the Middle East (Amer et al., 2012), in layers in France (Dufour-Gesbert et al., 2006) and in Australia (Gole et al., 2012) as well as in broiler in Jordan (Roussan et al., 2015) and Belgium (Michiels et al., 2016).

Based on Benčina et al. (2001), using MS typing, the most recent type strains identified are L and K types in Thailand (Limpavithayakul et al., 2016) and China, respectively (Sun et al., 2017). Most of the European type strains have been reported by Hammond et al. (2009); in particular, in Italy, types A, C, D, E, F, H and G have been detected (Moronato et al., 2014).

In the Italian commercial poultry, MG prevalence is lower than MS prevalence, mainly because of eradication programs on most Italian farms (Catania et al., 2010b).

However, both species are detected in several other categories of poultry. For example, MG detection has been reported in turkeys, layers, broilers and broiler breeders (Catania et al., 2010b; Taddei et al., 2012), while MS has been reported in broiler breeders, layers, pullets and some minor poultry species

(Catania et al., 2010a, Catania et al., 2016a, Catania et al., 2017; Massi et al., 2014; Moronato et al., 2014).

The detection of MG and/or MS in backyard poultry has been reported in Belgium (Haesendonck et al., 2014), California (Derksen et al., 2018), Iran (Rasoulinezhad et al., 2018) and Maryland (Madsen et al., 2013).

### **2.2.2 Natural hosts and transmission**

Natural hosts of MG and MS are chickens and turkeys, but also ducks, geese (Stipkovits and Szathmary, 2012), pigeons (Michiels et al., 2016), Japanese quails (Benčina et al., 1987), pheasants and partridges (Ganapathy and Bradbury, 1998; Bradbury et al., 2001).

Moreover, guinea fowl (Pascucci et al., 1976) and lesser flamingos (Catania et al., 2016b) may be naturally infected with MS, while chukar partridges, parrots, rooks and finches can carry MG (Ferguson-Noel and Noormohammadi et al., 2013). Other birds could be artificially infected.

In general, MG infects susceptible birds at any age, while MS infection occurs in chickens and turkeys at 4-16 weeks (wks) and 10-24 wks of age, respectively; afterwards, the infection becomes chronic (Ferguson-Noel and Noormohammadi et al., 2013; Raviv and Ley, 2013).

Both MG and MS are transmitted vertically from infected breeding birds to the progeny. A study has reported the highest rate of MG transmission (more than 50% of the produced eggs) at 3-6 wks post-infection (p.i.) (Sasipreeyajan et al., 1987; Armour and Ferguson-Noel, 2015). Egg transmission of MS was highest during the first 4-6 wks p.i. (Ferguson-Noel and Noormohammadi et al., 2013).

Horizontal transmission occurs via aerosols, feed, fomites or direct contact with clinically or subclinically infected birds, resulting in a high prevalence of infection within the flocks (Dhondt et al., 2007). Infection occurs via the respiratory route (Jordan, 1975).

McMartin et al. (1987) have reported a multiphased pattern of MG transmission: a latent phase of 12-21 days before the antibody was detected in MG-infected birds, a phase of 1-21 days, in which the infection appeared in 10% of the birds, a period of 7-32 days, in which 95% of the remaining birds developed ab, and the last phase of 3-19 days, in which the remaining birds became positive. In a second experiment, MG detection or isolation was used to detect the MG spread from infected turkeys to susceptible birds; MG was detected within 4-7 days in birds, but seroconverted after 1-2 wks (Levisohn, 2000).

Flock-to-flock transmission follows direct or indirect contact with infected flocks via the movement of birds, people or fomites (Dhondt et al., 2007).

Potential reservoirs of MG and MS are backyard flocks (Derksen et al., 2017), multiple-age layer flocks and free-range songbird species (Ferguson-Noel and Noormohammadi et al., 2013; Raviv and Ley, 2013).

### **2.2.3 Virulence factors and interaction with the immune system**

Both MG and some MS strains cause loss of ciliary activity in the respiratory tract and colonise the host cell (Bradbury, 2005).

Adherence of mycoplasmas to the mucosal epithelium is the first stage of infection and the major virulence factor (Rosengarten et al., 2000). The lack of a cell wall promotes the mycoplasma's approach to the membrane of the host cell (Rottem, 2002). The expression of both *gapA* gene and at least one other cytoadherence-related molecule (CrmA), including *vlhA* lipoprotein and the *pvpA* protein, is required for cytoadherence (Bradbury, 2005). Gliding motility is a characteristic typical of mycoplasmas and enables the binding and moving on solid surfaces (Umar et al., 2017); it also allows mycoplasmas to escape mucociliary clearance, facilitating the access to epithelial cells (Indikova et al., 2014).

The MG also has the ability to invade non-phagocytic cells, resulting in the evasion of immune responses and dissemination (Bradbury, 2005). Mycoplasmas are able to persist in the host despite the immune response, most likely because of the intracellular location of some mycoplasmas and the ability of some pathogenic mycoplasma species, including MS and MG, to undergo antigenic variation (Bradbury, 2005).

Mycoplasmas stimulate a lymphoproliferative response of the mucosal epithelium.

The initial response after MG infection is characterised by CD8<sup>+</sup> lymphocyte infiltration. After the first week, they are replaced by CD4<sup>+</sup> lymphocytes and later by B lymphocytes, suggesting the evolution of the infection to a chronic stage. Moreover, MG has a systemic immunosuppressive effect; the macrophages infiltrating the sites of MG infection do not produce high levels of cytokines, confirming an immunomodulatory effect of mycoplasmas (Browning et al., 2011).



## 2.3 Clinical signs and lesions

In general, infections caused by MG result in chronic respiratory disease in chickens and infectious sinusitis in turkeys (Kleven, 1998); MS causes a condition of denominated infectious synovitis in both species.

### 2.3.1 Clinical signs

In natural infections of chickens and turkeys, the MG incubation period varies from 6-21 days. However, under natural conditions, it is extremely difficult to estimate the incubation period because of the high number of factors influencing the onset of the clinical disease (Raviv and Ley, 2013).

Morbidity is usually very high. Clinical signs are more severe and last longer in young birds. Mortality may be negligible in adult laying flocks, but can reach 30% in broilers in complicated outbreaks (Raviv and Ley, 2013).

Clinical signs caused by MG in adult chickens consist of respiratory rales, coughing, nasal discharge, tracheal rales and conjunctivitis, decreased feed consumption and, in laying birds, decreased egg production and hatchability (Stipkovits and Kempf, 1996). The disease is more severe during the winter. Interactions between MG and other pathogens such as the Newcastle disease virus, Infectious Bronchitis virus, Laryngotracheitis virus, Adenovirus, Reovirus, *Escherichia Coli* or *Avibacterium paragallinarum* result in a synergistic effect, leading to a more severe disease (Kleven, 1998).

Turkeys are more susceptible to MG than chickens and commonly develop more severe clinical signs, including sinusitis and respiratory distress. Mild respiratory signs may progress in a few days to a severe cough in almost all turkeys in a flock, and swollen sinuses with nasal discharge may affect 1-70% of the birds in an affected flock (Raviv and Ley, 2013). The disease is characterised by nasal discharge, foamy eye secretions and swelling of infraorbital sinuses (Fig. 2a) (Jordan, 1975). Neurological signs caused by neurotropic MG strains have been reported in turkeys (Cordy and Adler, 1965; Wyrzykowski et al., 2013).

In general, two clinical forms of MS could be observed: lameness and respiratory disease. Usually, MS infection does not result in respiratory signs, but concomitant infections or more virulent MS strains can favour the occurrence of respiratory signs (Kleven et al., 1975; Lockaby et al., 1999). In this case, morbidity can reach 100% of the flock, with a mortality of up to 10% (Stipkovits and Kempf, 1996; Ferguson-Noel and Noormohammadi et al., 2013).

Commonly, chickens are affected at the age of 4-16 wks, with an incubation period of 11-21 days. Chicks infected by egg transmission can show clinical signs in the first week of life, consisting of stunting, joint swelling, (more frequently affecting the hock joint; Fig. 2b), lameness, a shrunken,

pale comb, ruffled feathers and breast blisters (Morrow et al., 1990; Stipkovits and Kempf, 1996; Lockaby et al., 1998).

Recently, a condition named “eggshell apex abnormality” has been associated with infection with some MS strains and reported in layer chickens. It is characterised of the production of eggs with an altered surface of the eggshell apex, which appears thin, translucent, with cracks and breaks (Feberwee et al., 2009; Catania et al., 2010a; Strugnell et al., 2011).

Strains of MS associated with amyloid arthropathy have also been reported (Landman and Feberwee, 2001).

Clinical signs in turkeys affected by MS are generally the same as those observed in chickens. In particular, turkeys show no respiratory clinical signs, and lameness may be the most important clinical sign (Kang et al., 2002), sometimes accompanied by lesions of pneumonia (Osorio et al., 2007).

### **2.3.2 Gross and microscopic lesions**


Gross lesions, observed after MG infection, include mucus or catarrhal exudates in naris, sinuses, trachea, bronchi and lungs and airsacculitis with caseous exudates in the air sac, conjunctivitis and caseous salpingitis. When secondary infection with *E. Coli* occurs, other lesions are observed, such as pericarditis or perihepatitis (Jordan, 1975; Stipkovits and Kempf, 1996).

Microscopic lesions of MG mostly occur in the upper respiratory tract. Marked thickening of the mucous membranes due to infiltration with mononuclear cells and hyperplasia of the mucous glands, germinal centres and plasma cells, macrophages and heterophils are seen in the lamina propria; swelling and deciliation of the epithelial cells are observed in the trachea (Jordan, 1975; Ferguson-Noel and Noormohammadi et al., 2013). Moreover, hyperplasia of synovial epithelial cells, oedema, marked infiltration of monocytes into synovial and adjacent tissues can be observed (Jordan, 1975). Periocular swelling and conjunctivitis are typical in house finches and other songbirds (Dhondt et al., 2012).

Neurotropic MG strains do not cause macroscopic brain lesions, but histological lesions may be observed. In particular, acute to subacute multifocal parenchymal necrosis, perivascular cuffing, leptomeningitis and vasculitis (Wyrzykowski et al., 2013).

During MS infection, synoviae and joints show an accumulation of creamy to caseous exudate (Fig. 2b). Hepatomegaly, splenomegaly, swollen and pale kidneys, sternal bursitis, airsacculitis, atrophy of the bursae of the Fabricius and thymus may also be observed. Some MS strains can cause amyloidosis (Kerr and Olson, 1970; Stipkovits and Kempf, 1996; Morrow et al., 1997; Lockaby et al., 1998). Lesions of the respiratory tract are similar to those observed during MG infection, but milder (Jordan, 1975).

Microscopic lesions caused by MS mostly affect the joints and air sacs. The joints show infiltrates of heterophils and fibrin into joint spaces; the synovial membrane appears hypertrophic and hyperplastic, with infiltration of lymphocytes and macrophages. The articular cartilage is thinned. The air sacs may show oedema, heterophils, hyperplasia of epithelial cells, infiltrates of mononuclear cells and necrosis (Kerr and Olson, 1970; Ghazikhanian et al., 1973; Fletcher et al., 1976; Morrow et al., 1997).



*Figure 2. MG infection in Turkeys: nasal discharge and swollen infraorbital sinus (<https://www.merckvetmanual.com/poultry/mycoplasmosispoultry>) (A). Chickens affected by infectious synovitis: Swollen foot pad and swollen hock joint (<https://www.merckvetmanual.com/poultry/mycoplasmosispoultry>) (B).*

## **2.4 Diagnosis**

### **2.4.1 Isolation and identification of MG and MS**

#### **2.4.1.1 Isolation**

The gold standard for MG and MS diagnosis is isolation and identification of the organism.

To culture MG or MS, palatine fissure, trachea, air sac or fluid sinus exudates, turbinates and lungs should be sampled (OIE, 2008). The sampling of 5-20 birds can be sufficient to isolate the strain (Levisohn and Dykstra, 1987; Kleven, 2009).

To increase the rate of a successful culture, samples should be processed as soon as possible after collection. Mycoplasma broth (MB) should be inoculated and immediately incubated. If transportation is necessary, swabs should be stored in a suitable transport media. For preserving the viability of MG and/or MS, the samples should be transported at a low temperature (Kleven, 2009). In general, swab samples are inoculated on both mycoplasma agar and broth, but culture in broth is more sensitive. Inoculated plates should be inverted and incubated at 37°C and 5% CO<sub>2</sub> and examined daily for the first few days by observing the colonies with a stereoscopic microscope. Any observable growth is immediately subcultured onto solid medium.

Although the growth is usually evident in 3-5 days, cultures from field material should not be discarded as negative for at least 20 days (OIE, 2008; Raviv and Ley, 2013; Ferguson-Noel and Noormohammadi et al., 2013).

Although biochemical reactions such as fermentation of glucose help in the interpretation of results, they are not specific for MG and/or MS, and therefore, further immunological or molecular tests are necessary.

For mycoplasma isolation, inoculation via the yolk sac route of SPF eggs of 5-6 days could be used. The inoculated eggs are incubated for 5 days, and the yolk must to be subcultured in both MB and MA medium (OIE, 2008).

#### **2.4.1.2 Molecular methods**

Diagnostic tools based on PRC have been developed for rapid detection and identification of avian mycoplasmas (OIE, 2008).

Several random amplifications of polymorphic DNA (RAPD) protocols have initially been developed (Fan et al., 1995; Ley et al., 1997a) and applied for MG epidemiological investigations and for the identification of vaccine MG strains. This method is, however, limited by the difficulties in standardizing and reproducibility (Tyler et al., 1997).

Commonly, PCRs targeting of a fragment of *mgc2* of MG (García et al., 2005) and *vlhA* genes of MS (Hong et al., 2004), and the subsequent sequencing of the PCR products, have been used for preliminary strain identification.

The intergenic spacer region (IGSR) between the 16S and 23S rRNA genes, being shown to be variable in sequence, has been used for genotyping MG strains (Raviv et al., 2007).

Recently, a combination of PCRs targeting *vlhA3.05*, *mg0359* and *vlhA3.04a* genes has been developed for differentiating MG ts-11 vaccine from MG field strains (Ricketts et al., 2017).

Multilocus sequence analysis (MLST) schemes have been developed to differentiate MS strains using loci housekeeping (Ghanem and El-Gazzar, 2018).

Several real-time PCR protocols for the identification of MG and MS have been established (Jarquin et al., 2009; Sprygin et al., 2010; Ghorashi et al., 2010; Ghorashi et al., 2013).

#### **2.4.1.2.1 Typing of MG strains: gene target sequencing method**

A gene-targeted sequencing (GTS) approach to identify and differentiate MG strains has been developed, consisting in PCRs targeting the fragments of four genes encoding four surface proteins: three genes (*gapA*, *mgc2*, *pvpA*) and one gene (MGA\_0319) encoding a predicted MG surface protein (Ferguson-Noel et al., 2005). The four gene sequences were identified in the genome of the MG R<sub>low</sub> strain (Papazisi et al., 2003). After amplicon sequencing and alignment, the dendrogram for individual and multiple gene sequences was constructed, and the discriminatory power, the measure of the probability that two unrelated strains will be in different clusters, was calculated. The GTS analysis of multiple genes (*gapA/mgc2/pvpA/MGA\_0319*) showed better discriminatory power than the individual gene dendrogram (Ferguson-Noel et al., 2005). This method allows the development of a reference database and ensures a global comparison between laboratories (Ferguson-Noel et al., 2005; Armour et al., 2013).

#### **2.4.1.2.2 Typing of MS strains**

The 5'-end region of the *vlhA* gene (approximately 400 bp) exists as a single copy, and the sequence is different among strains. The gene includes tandem repeats that encode the proline-rich repeats (PRR) area and also a region highly polymorphic (RIII) (Fig. 3). Sequencing and analysis of this region were used as typing tools of MS strains (Benčina et al., 2001). Based on the number of nucleotides (nct)/amino acids (aa) that constitute the PRR region, each strain was marked with a letter (type) and based on nct/aa mutations; in respect to the reference type strain WVU1853, a number (subtype) was added to the letter (Benčina et al., 2001; Hammond et al., 2009). This typing and subtyping method is commonly used and is a quick and reproducible method to characterise MS strains (Benčina et al., 2001; Hammond et al., 2009; Sun et al., 2017).

#### **2.4.2 Detection of specific Abs**

The serological tests, MG and/or MS are useful for flock free-status monitoring.

*Serum plate agglutination (SPA)* is a quick and inexpensive test, albeit with a low specificity (Kleven, 2009). In particular, false-positive reactions can be observed when birds have previously been vaccinated with inactivated vaccines in oil-emulsion against other avian pathogens. Moreover, cross-reactive antigens are shared between mycoplasmas and other bacteria as well as between MG and MS (Kleven, 2009).

The *haemagglutination inhibition (HI)* test has been developed and used, but is time-consuming and requires avian erythrocytes (Kleven, 2009).

In contrast, the ELISA test is more sensitive and specific than the SPA and HI tests (Ewing et al., 1996). Several commercial kits are available, including multiplex ELISA assays to simultaneously detect antibodies against MG or MS (Opitz et al., 1983). A certain level of false-positive reactions can be expected in any serologic test for MG and MS, included the ELISA tests (Feberwee et al., 2005).

## 2.5 Prevention and control

The control of mycoplasma infections consists of three general aspects: management, vaccination and medication.

### 2.5.1 Management procedures

Because both MG and MS are vertically transmitted, the maintaining of a mycoplasma-free status of breeding birds is essential. To obtain this, adequate biosecurity measures and monitoring programs, using serology or molecular methods, should be applied (Kleven, 2008).

### 2.5.2 Vaccination

Vaccination may be the most practical option in an area where the maintaining of a mycoplasma-free *status* is not feasible or field exposure is inevitable, such as in multi-age commercial layer facilities and large poultry populations reared in small geographic areas (Branton et al., 1988; Kleven et al., 1984). Various types of vaccines are available and used against MG; they include inactivated oil-emulsion bacterins, live-attenuated vaccines (F, ts-11, 6/85 strains) and recombinant live poxvirus vaccines.

*Inactivated vaccines.* There are several studies reporting the effectiveness of inactivated MG vaccines (Glisson and Kleven, 1984; Panigraphy et al., 1981), but also the lack of detectable efficacy (Sasipreeyajan et al., 1987). The major disadvantages of inactivated MG vaccines are the costs of individual bird administration and the need for more than one application (Kleven, 2008).

*F vaccine strain.* Virulence of the F strain is moderate (Rodriguez and Kleven, 1980). It is used commonly in some countries for MG vaccination of commercial layers because it is effective in preventing clinical respiratory signs and decreased egg production (Kleven et al., 1998; Evans et al., 2012; Liu et al., 2013). Unfortunately, it is pathogenic for broilers (Rodriguez and Kleven, 1980) and turkeys (Lin and Kleven, 1982) and can potentially circulate among unvaccinated flocks (Gharaibeh et al., 2011; Khalifa et al., 2014). The F strain vaccine can be administered via eye drops, drinking water and as a coarse spray (Kleven, 2008).

*6/85 vaccine strain.* The 6/85 strain is avirulent for both chickens (Evans and Hafez, 1992) and turkeys (Zaki et al., 2004) and protects against air sac lesions (Evans and Hafez, 1992). Moreover, it does not impact egg production, egg size distribution or ovary/oviduct function (Branton et al., 2002). The 6/85 vaccine strain can be recovered from the trachea of vaccinated chickens up to 105 day post infection (Ley et al., 1997b).

Although the 6/85 vaccine has a low potential for transmission from vaccinated to unvaccinated chickens (Ley et al., 1997b), it was found in commercial layers affected by clinical signs (Throne et al., 2003).

*Ts-11 vaccine strain.* The temperature-sensitive *Ts-11* vaccine strain, which grows better at 33 than at 37°C, originated from an Australian field strain after passage culture (Whithear et al., 1990). The ts-11 vaccine strain is safe and effective in chickens (Whithear et al., 1990) and poorly transmissible to unvaccinated birds (Collett et al., 2005).

The Ts-11 vaccine strain can be recovered from the trachea from vaccinated chickens up to 105 days p.i. (Ley et al., 1997b); it induces a low antibody response (Birò et al., 2005) and long-lived immunity in vaccinated chickens (Whithear, 1996). It should be administered via eye drops (Whithear, 1996). Recently, it has been reported that ts-11-like strains are vertically transmissible and able to cause disease in birds (El-Gazzar et al., 2011; Armour and Ferguson-Noel, 2015).

The vaccines 6/85 and ts-11 are safer than the F strain, but can induce a weaker level of protection (OIE, 2008).

Recently, several authors have focused on the selection of other MG strains able to be used like vaccines: the K strain showed no increase in the virulence of the K-strain when it was back-passaged five times through chickens and no vertical transmission; it was safe and protected the birds from air sac, tracheal and reproductive tract lesions (Ferguson-Noel et al., 2012; Ferguson-Noel and Williams, 2015). The GapA positive clone ts-11-derived MG ts-304 has been shown to be effective and safe in chickens (Kanci et al., 2018).

Moreover, it has been reported that eye drop vaccination is significantly more effective than nasal vaccination for MG (Leigh et al., 2018). Recombinant MG vaccines have been reported as a recombinant of fowl pox vaccines and a recombinant adenovirus (Ferguson-Noel et al., 2012; Leigh et al., 2013; Zhang et al., 2018).

A live vaccine for MS (MS-H) is available in several countries for use in broiler, breeding and laying chickens. It is produced from a temperature-sensitive mutant and similar to the ts-11 MG vaccine in terms of application and characteristics (Kleven, 2008). It colonises only their upper respiratory tract and establishes a protection against wild-type *M. synoviae* (Kleven, 2008).

### **2.5.3 Medication**

The treatment of birds with antibiotics is not the first-choice method for controlling mycoplasmosis because of the emergence of antibiotic resistance and the persistence of the infection in birds after treatment (Nhung et al., 2017). However, it is effective in preventing economic losses associated with mycoplasma infection. To reduce egg transmission and improve the hatchability of eggs produced by infected breeding flocks, antibiotic treatment of eggs, by dipping or injection, has been used.

Both MG and MS are sensitive to macrolides, tetracyclines, fluoroquinolones, tylosin and tetracyclines, which are most commonly used.



## 2.6 Sitography

1. <https://www-ncbi-nlm-nih-gov.ezproxy.unibo.it/taxonomy/?term=Mollicutes>, (day of access: 17/09/2018)
2. <https://www.merckvetmanual.com/poultry/mycoplasmosispoultry> (day of access: 18/09/2018)
3. (<http://www.fao.org/poultry-production-products/production/en/>
4. <https://www.unaitalia.com/mercato/annata-avicola/>
5. CABI, Invasive species Compendium, <https://www.cabi.org/isc/datasheet/80665>, (day of access: 06/09/2018)
6. International Committee on Taxonomy of Viruses ICTV, <https://talk.ictvonline.org/taxonomy/>, (day of access: 01/09/2018)
7. Jackwood, Overview of Infectious Bursal Disease in Poultry (Gumboro disease), <https://www.msdsvetmanual.com/poultry/infectious-bursal-disease/overview-of-infectious-bursal-disease-in-poultry> (day of access: 09/09/2018)
8. Viral zone, Avibirnavirus, [https://viralzone.expasy.org/162?outline=all\\_by\\_species](https://viralzone.expasy.org/162?outline=all_by_species), (day of access: 06/09/2018)

## 2.7 References

1. Abdel-Alim, G.A., Awaad, M.H.H., Saif, Y.M., 2003. Characterization of Egyptian Field Strains of Infectious Bursal Disease Virus. *Avian Diseases* 47, 1452–1457. doi:10.1637/7032.
2. Abolnik, C., Gouws, J., 2014. Extended survival times of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* on kanekalon synthetic hair fibres. *Poult Sci* 93, 8–11. doi:10.3382/ps.2013-03457
3. Ali, M.Z., Rahman, M.M., Sultana, S., 2015. Seroprevalence of *Mycoplasma gallisepticum* antibody by ELISA and serum plate agglutination test of laying chicken. *Vet World* 8, 9–14. doi:10.14202/vetworld.2015.9-14
4. Alkie, T.N., Rautenschlein, S., 2016. Infectious bursal disease virus in poultry: current status and future prospects. *Veterinary Medicine: Research and Reports* 9. doi:10.2147/VMRR.S68905
5. Amer, M.M., Zohair, G. A., EL-Bayomi, Kh. M., Amin Girh, Z.M.S., 2012. Effect of Tilmicosin in Control of Mycoplasmosis in Broiler Chickens from Infected Breeders Using Elisa Test for Evaluation. *Journal of American Science*, 8 (3), 696-700.
6. Aricibasi, M., Jung, A., Heller, E.D., Rautenschlein, S., 2010. Differences in genetic background influence the induction of innate and acquired immune responses in chickens depending on the virulence of the infecting infectious bursal disease virus (IBDV) strain. *Veterinary Immunology and Immunopathology* 135, 79–92. doi:10.1016/j.vetimm.2009.11.005
7. Armour, N.K., Ferguson-Noel, N., 2015. Evaluation of the egg transmission and pathogenicity of *Mycoplasma gallisepticum* isolates genotyped as ts-11. *Avian Pathology* 44, 296–304. doi:10.1080/03079457.2015.1044890
8. Armour, N.K., Laibinis, V.A., Collett, S.R., Ferguson-Noel, N., 2013. The development and application of a *Mycoplasma gallisepticum* sequence database. *Avian Pathology* 42, 408–415. doi:10.1080/03079457.2013.819486
9. Asdrubali, G., Franciosini, M.P., 1993. Recenti acquisizioni sulla malattia di Gumboro. *Rivista di avicoltura*, 7, 43–46.
10. Benčina, D., 2002. Haemagglutinins of pathogenic avian mycoplasmas. *Avian Pathology* 31, 535–547. doi:10.1080/0307945021000024526
11. Benčina, D., Dorrer, D., Tadina, T., 1987. *Mycoplasma* species isolated from six avian species. *Avian Pathol.* 16, 653–664. doi:10.1080/03079458708436413
12. Benčina, D., Drobnič-Valič, M., Horvat, S., Narat, M., Kleven, S.H., Dovč, P., 2001. Molecular basis of the length variation in the N-terminal part of *Mycoplasma synoviae* hemagglutinin. *FEMS Microbiol. Lett.* 203, 115–123.
13. Benčina, D., Narat, M., Dovč, P., Drobnič-Valič, M., Habe, F., Kleven, S.H., 1999. The characterization of *Mycoplasma synoviae* EF-Tu protein and proteins involved in hemadherence

- and their N-terminal amino acid sequences. *FEMS Microbiology Letters* 173, 85–94. doi:10.1111/j.1574-6968.1999.tb13488.x
14. Birghan, C., Mundt, E., Gorbalenya, A.E., 2000. A non-canonical lon proteinase lacking the ATPase domain employs the ser-Lys catalytic dyad to exercise broad control over the life cycle of a double-stranded RNA virus. *EMBO J* 19, 114–123. doi:10.1093/emboj/19.1.114
  15. Bíró, J., Povazsán, J., Korösi, L., Glávits, R., Hufnagel, L., Stipkovits, L., 2005. Safety and efficacy of *Mycoplasma gallisepticum* TS-11 vaccine for the protection of layer pullets against challenge with virulent *M. gallisepticum* R-strain. *Avian Pathology* 34, 341–347. doi:10.1080/03079450500179913
  16. Boguslavsky, S., Menaker, D., Lysnyansky, I., Liu, T., Levisohn, S., Rosengarten, R., García, M., Yogev, D., 2000. Molecular Characterization of the *Mycoplasma gallisepticum* pvpA Gene Which Encodes a Putative Variable Cytadhesin Protein. *Infection and Immunity* 68, 3956–3964. doi:10.1128/IAI.68.7.3956-3964.2000
  17. Böttcher, B., Kiselev, N.A., Stel'Mashchuk, V.Y., Perevozchikova, N.A., Borisov, A.V., Crowther, R.A., 1997. Three-dimensional structure of infectious bursal disease virus determined by electron cryomicroscopy. *J Virol* 71, 325–330.
  18. Bradbury, J.M., 2005. Poultry mycoplasmas: sophisticated pathogens in simple guise. *British Poultry Science* 46, 125–136. doi:10.1080/00071660500066282
  19. Bradbury, J.M., Yavari, C.A., Dare, C.M., 2001. Mycoplasmas and respiratory disease in pheasants and partridges. *Avian Pathology* 30, 391–396. doi:10.1080/03079450120066395
  20. Brandt, M., Yao, K., Liu, M., Heckert, R.A., Vakharia, V.N., 2001. Molecular Determinants of Virulence, Cell Tropism, and Pathogenic Phenotype of Infectious Bursal Disease Virus. *Journal of Virology* 75, 11974–11982. doi:10.1128/JVI.75.24.11974-11982.2001
  21. Browning, G.F., Marena, M.S., Noormohammadi, A.H., Markham, P.F., 2011. The central role of lipoproteins in the pathogenesis of mycoplasmoses. *Veterinary Microbiology* 153, 44–50. doi:10.1016/j.vetmic.2011.05.031
  22. Busnadiego, I., Maestre, A.M., Rodríguez, D., Rodríguez, J.F., 2012. The Infectious Bursal Disease Virus RNA-Binding VP3 Polypeptide Inhibits PKR-Mediated Apoptosis. *PLoS One* 7. doi:10.1371/journal.pone.0046768
  23. Cao, Y.-C., Shi, Q.-C., Ma, J.-Y., Xie, Q.-M., Bi, Y.-Z., 2005. Vaccination against Very Virulent Infectious Bursal Disease Virus Using Recombinant T4 Bacteriophage Displaying Viral Protein VP2. *Acta Biochimica et Biophysica Sinica* 37, 657–664. doi:10.1111/j.1745-7270.2005.00101.x
  24. Catania, S., Bilato, D., Gobbo, F., Granato, A., Terregino, C., Iob, L., Nicholas, R.A.J., 2010a. Treatment of eggshell abnormalities and reduced egg production caused by *Mycoplasma synoviae* infection. *Avian Dis.* 54, 961–964.

25. Catania, S., Ceruti, R., Mingardo, M., Ortali, G., Terregino, C., Iob, L., 2010b. Indagine preliminare sulla presenza di *Mycoplasma gallisepticum* e *Mycoplasma synoviae* in allevamenti avicoli italiani. *Atti Della Società Italiana di Patologia Aviaria*, 117–120.
26. Catania, S., Gobbo, F., Bilato, D., Gagliazzo, L., Moronato, M.L., Terregino, C., Bradbury, J.M., Ramirez, A.S., 2016a. Two strains of *Mycoplasma synoviae* from chicken flocks on the same layer farm differ in their ability to produce eggshell apex abnormality. *Vet. Microbiol.* 193, 60–66.
27. Catania, S., Gobbo, F., Ramirez, A.S., Guadagnini, D., Baldasso, E., Moronato, M.L., Nicholas, R.A.J., 2016b. Laboratory investigations into the origin of *Mycoplasma synoviae* isolated from a lesser flamingo (*Phoeniconaias minor*). *BMC Vet Res* 12. doi:10.1186/s12917-016-0680-1
28. Catania, S., Mainenti, M., Zanardello, C., Picchi, M., Matucci, A., Gobbo, F., 2017. *Mycoplasma synoviae*: un ottimo esempio di patogeno adattabile alle condizioni dell'ospite. Caso clinico. *Atti Della Società Italiana di Patologia Aviaria*, 199–203.
29. Chang, H.C., Lin, T.L., Wu, C.C., 2001. DNA-mediated vaccination against infectious bursal disease in chickens. *Vaccine* 20, 328–335. [https://doi.org/10.1016/S0264-410X\(01\)00376-0](https://doi.org/10.1016/S0264-410X(01)00376-0).
30. Cheville, n.f., 1967. Studies on the pathogenesis of gumboro disease in the bursa of fabricius, spleen, and thymus of the chicken. *Am j pathol.* 51(4):527-51.
31. Chi, J., You, L., Li, P., Teng, M., Zhang, G., Luo, J., Wang, A., 2018. Surface IgM  $\lambda$  light chain is involved in the binding and infection of infectious bursal disease virus (IBDV) to DT40 cells. *Virus Genes* 54, 236–245. doi:10.1007/s11262-018-1535-6
32. Ching Wu, C., Rubinelli, P., Long Lin, T., 2007. Molecular Detection and Differentiation of Infectious Bursal Disease Virus. *Avian Diseases* 51, 515–526. doi:10.1637/0005-2086(2007)51[515:MDADOI]2.0.CO;2
33. Christensen, N.H., Yavari, C.A., McBain, A.J., Bradbury, J.M., 1994. Investigations into the survival of *Mycoplasma gallisepticum*, *Mycoplasma synoviae* and *Mycoplasma iowae* on materials found in the poultry house environment. *Avian Pathology* 23, 127–143. doi:10.1080/03079459408418980
34. Collett, S.R., Thomson, D.K., York, D., Bisschop, S.P.R., 2005. Floor Pen Study to Evaluate the Serological Response of Broiler Breeders After Vaccination with ts-11 Strain *Mycoplasma gallisepticum* Vaccine. *Avian Diseases* 49, 133–137. doi:10.1637/7239-071304R
35. Cordy, D.R., Adler, H.E., 1965. Brain and muscle lesions caused by *mycoplasma gallisepticum* in turkey poults. *Am. J. Vet. Res.* 26, 186–190.
36. Coulibaly, F., Chevalier, C., Delmas, B., Rey, F.A., 2010. Crystal Structure of an Aquabirnavirus Particle: Insights into Antigenic Diversity and Virulence Determinism. *J Virol* 84, 1792–1799. doi:10.1128/JVI.01536-09

37. Coulibaly, F., Chevalier, C., Gutsche, I., Pous, J., Navaza, J., Bressanelli, S., Delmas, B., Rey, F.A., 2005. The Birnavirus Crystal Structure Reveals Structural Relationships among Icosahedral Viruses. *Cell* 120, 761–772. doi:10.1016/j.cell.2005.01.009
38. Cubas-Gaona, L.L., Diaz-Beneitez, E., Ciscar, M., Rodríguez, J.F., Rodríguez, D., 2018. Exacerbated Apoptosis of Cells Infected with Infectious Bursal Disease Virus upon Exposure to Interferon Alpha. *Journal of Virology* 92. doi:10.1128/JVI.00364-18
39. Darteil, R., Bublot, M., Laplace, E., Bouquet, J.-F., Audonnet, J.-C., Rivière, M., 1995. Herpesvirus of Turkey Recombinant Viruses Expressing Infectious Bursal Disease Virus (IBDV) VP2 Immunogen Induce Protection against an IBDV Virulent Challenge in Chickens. *Virology* 211, 481–490. doi:10.1006/viro.1995.1430
40. de Wit S, 2001. Gumboro Disease: estimation of optimal time of vaccination by the deventer formula. *Annual Report and Proceedings of COST Action 839: Immunosuppressive Viral Diseases in Poultry*, pp 170-178.
41. Derksen, T., Lampron, R., Hauck, R., Pitesky, M., Gallardo, R.A., 2017. Biosecurity Assessment and Seroprevalence of Respiratory Diseases in Backyard Poultry Flocks Located Close to and Far from Commercial Premises. *Avian Diseases* 62, 1–5. doi:10.1637/11672-050917-Reg.1
42. Dhondt, A.A., Dhondt, K.V., Hawley, D.M., Jennelle, C.S., 2007. Experimental evidence for transmission of *Mycoplasma gallisepticum* in house finches by fomites. *Avian Pathology* 36, 205–208. doi:10.1080/03079450701286277
43. Dhondt, A.A., States, S.L., Dhondt, K.V., Schat, K.A., 2012. Understanding the origin of seasonal epidemics of mycoplasmal conjunctivitis. *Journal of Animal Ecology* 81, 996–1003. doi:10.1111/j.1365-2656.2012.01986.x
44. Dobos, P., Hill, B.J., Hallett, R., Kells, D.T.C., Becht, H., Teninges, D., 1979. Biophysical and Biochemical Characterization of Five Animal Viruses with Bisegmented Double-Stranded RNA Genomes. *J. VIROL.* 32, 13.
45. Dohms, J.E., Lee, K.P., Rosenberger, J.K., Metz, A.L., 1988. Plasma Cell Quantitation in the Gland of Harder during Infectious Bursal Disease Virus Infection of 3-Week-Old Broiler Chickens. *Avian Diseases* 32, 624–631. doi:10.2307/1590976
46. Dohms, J.E., Saif, Y.M., 1984. Criteria for evaluating immunosuppression. *Avian Dis.* 28, 305–310.
47. Dufour-Gesbert, F., Dheilily, A., Marois, C., Kempf, I., 2006. Epidemiological study on *Mycoplasma synoviae* infection in layers. *Veterinary Microbiology* 114, 148–154. doi:10.1016/j.vetmic.2005.10.040
48. Edgar, S.A., Cho, Y., 1976. The epizootiology of infectious bursal disease and prevention of it by immunization. *Dev. Biol. Stand.* 33, 349–356.

49. El Gazzar, M., Laibinis, V.A., Ferguson-Noel, N., 2011. Characterization of a ts-11–like *Mycoplasma gallisepticum* Isolate from Commercial Broiler Chickens. *Avian Diseases* 55, 569–574. doi:10.1637/9689-021711-Reg.1
50. Escaffre, O., Le Nouen, C., Amelot, M., Ambroggio, X., Ogden, K.M., Guionie, O., Toquin, D., Muller, H., Islam, M.R., Etteradossi, N., 2013. Both Genome Segments Contribute to the Pathogenicity of Very Virulent Infectious Bursal Disease Virus. *Journal of Virology* 87, 2767–2780. doi:10.1128/JVI.02360-12
51. Etteradossi, N., and Y. M. Saif. 2013. Infectious Bursal Disease. Pages 219–246 in *Disease of Poultry*. 13th edn. D.E Swayne, J.R. Glisson, L.R. McDougald, L.K Nolan, D.L Suarez, and N Venugopal (eds). Ames, Iowa State Press.
52. Feberwee, A., de Vries, T.S., Landman, W.J.M., 2008. Seroprevalence of *Mycoplasma synoviae* in Dutch commercial poultry farms. *Avian Pathol.* 37, 629–633. doi:10.1080/03079450802484987
53. Feberwee, A., Landman, W.J.M., 2012. The successful implementation of *Mycoplasma gallisepticum* monitoring and control programmes in Dutch commercial poultry: a declining seroincidence during an eleven year period. In *Proceedings of the 19th Congress of the International Organization for Mycoplasmaology*. Toulouse, France, 153.
54. Feberwee, A., Wit, J.J. de, Landman, W.J.M., 2009. Induction of eggshell apex abnormalities by *Mycoplasma synoviae*: field and experimental studies. *Avian Pathology* 38, 77–85. doi:10.1080/03079450802662772
55. Ferguson-Noel N. and Noormohammadi A. H., 2013. *Mycoplasma synoviae* infection. In: Swayne D.E., Glisson J.R., McDougald L.R., Nolan L.K., Suarez D.L., Venugopal N. (Eds.), *Disease of Poultry - Wiley-Blackwell by John Wiley & Sons, Inc., AAAP, Ames, Iowa*. pp. 900–906.
56. Ferguson-Noel, M., Hepp, D., Sun, S., Ikuta, N., Levisohn, L., Kleven, S.H., Garcia, M., 2005. Use of molecular diversity of *Mycoplasma gallisepticum* by gene-targeted sequencing (GTS) and random amplified polymorphic DNA (RAPD) analysis for epidemiological studies. *Microbiology*. 151, 1883–1893.
57. Ferguson-Noel, N., Cookson, K., Laibinis, V.A., Kleven, S.H., 2012. The Efficacy of Three Commercial *Mycoplasma gallisepticum* Vaccines in Laying Hens. *Avian Diseases* 56, 272–275. doi:10.1637/9952-092711-Reg.1
58. Ferrero, D., Garriga, D., Navarro, A., Rodríguez, J.F., Verdager, N., 2015. Infectious Bursal Disease Virus VP3 Upregulates VP1-Mediated RNA-Dependent RNA Replication. *Journal of Virology* 89, 11165–11168. doi:10.1128/JVI.00218-15
59. Flensburg, M.F., Ersbøll, A.K., Jørgense, P.H., 1998. Risk factors associated with the introduction of acute clinical infectious bursal disease among Danish broiler chickens. *Avian Pathology: Vol 31(1)*: 23-9. DOI:10.1080/03079450120106000.

60. Flensburg, M.F., Ersboll, A.K., Jorgensen, P.H., 2002. Risk factors associated with the introduction of acute clinical infectious bursal disease among Danish broiler chickens in 1998. *Avian Pathology* 31, 23–29. doi:10.1080/03079450120106000a
61. Fletcher, O.J., Anderson, D.P., Kleven, S.H., 1976. Histology of Air Sac Lesions Induced in Chickens by Contact Exposure to *Mycoplasma synoviae*. *Veterinary Pathology* 13, 303–314. doi:10.1177/030098587601300407
62. Fodor, N., Dube, S.K., Fodor, I., Horváth, E., Nagy, E., Vakharia, V.N., Rencendorsh, A., 1999. Induction of protective immunity in chickens immunised with plasmid dna encoding infectious bursal disease virus antigens. *Acta Veterinaria Hungarica* 47, 481–492. doi:10.1556/AVet.47.1999.4.8
63. Frey, M.L., Hanson, R.P., Anderson, D.P., 1968. A medium for the isolation of avian mycoplasmas. *Am J Vet Res.* 29(11):2163-71.
64. Galloux, M., Libersou, S., Morellet, N., Bouaziz, S., Costa, B.D., Ouldali, M., Lepault, J., Delmas, B., 2007. Infectious Bursal Disease Virus, a Non-enveloped Virus, Possesses a Capsid-associated Peptide That Deforms and Perforates Biological Membranes. *J. Biol. Chem.* 282, 20774–20784. doi:10.1074/jbc.M701048200
65. Ganapathy, K., Bradbury, J.M., 1998. Pathogenicity of *Mycoplasma gallisepticum* and *Mycoplasma imitans* in red-legged partridges (*Alectoris rufa*). *Avian Pathology* 27, 455–463. doi:10.1080/03079459808419369
66. Ganguly, B., Rastogi, S.K., 2018. Structural and functional modeling of viral protein 5 of Infectious Bursal Disease Virus. *Virus Research* 247, 55–60. doi:10.1016/j.virusres.2018.01.017
67. Garriga, D., Navarro, A., Querol-Audi, J., Abaitua, F., Rodriguez, J.F., Verdaguer, N., 2007. Activation mechanism of a noncanonical RNA-dependent RNA polymerase. *Proceedings of the National Academy of Sciences* 104, 20540–20545. doi:10.1073/pnas.0704447104
68. Gharibi, D., Ghadimipour, R., Mayahi, M., 2018. Detection of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* among Commercial Poultry in Khouzestan Province, Iran. *Arch Razi Inst* 73, 139–146. doi:10.22092/ari.2018.116164
69. Ghazikhanian, G., Yamamoto, R., Cordy, D.R., 1973. Response of turkeys to experimental infection with *Mycoplasma synoviae*. *Avian Dis.* 17(1), 122-36.
70. Giambrone, J.J., Closser, J., 1990. Efficacy of live vaccines against serologic subtypes of infectious bursal disease virus. *Avian Dis.* 34, 7–11.
71. Giambrone, J.J., Dormitorio, T., Brown, T., 2001. Safety and efficacy of in ovo administration of infectious bursal disease viral vaccines. *Avian Dis.* 45, 144–148.

72. Gole, V.C., Chousalkar, K.K., Roberts, J.R., 2012. Prevalence of antibodies to *Mycoplasma synoviae* in laying hens and possible effects on egg shell quality. *Preventive Veterinary Medicine* 106, 75–78. doi:10.1016/j.prevetmed.2012.02.018
73. Guo, X., Wang, L., Cui, D., Ruan, W., Liu, F., Li, H., 2012. Differential expression of the Toll-like receptor pathway and related genes of chicken bursa after experimental infection with infectious bursa disease virus. *Arch Virol* 157, 2189–2199. doi:10.1007/s00705-012-1403-y
74. Haesendonck, R., Verlinden, M., Devos, G., Michiels, T., Butaye, P., Haesebrouck, F., Pasmans, F., Martel, A., 2014a. High Seroprevalence of Respiratory Pathogens in Hobby Poultry. *Avian Diseases* 58, 623–627. doi:10.1637/10870-052314-ResNote.1
75. Hassan, M.K., Al-Natour, M.Q., Ward, L.A., Saif, Y.M., 1996. Pathogenicity, attenuation, and immunogenicity of infectious bursal disease virus. *Avian Dis.* 40, 567–571.
76. Heine, H.G., Boyle, D.B., 1993. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. *Arch. Virol.* 131, 277–292.
77. Heleili, N., Ayachi, A., Mamache, B., Chelihi, A., 2012. Seroprevalence of *Mycoplasma synoviae* and *Mycoplasma gallisepticum* at Batna Commercial poultry farms in Algeria. *Veterinary World* 5, 709. doi:10.5455/vetworld.2012.709-712
78. Hitchner, S.B., Hirai, K., 1979. Isolation and growth characteristics of psittacine viruses in chicken embryos. *Avian Dis.* 23, 139–147.
79. Hoerr, F.J., 2010. Clinical Aspects of Immunosuppression in Poultry. *Avian Diseases* 54, 2–15. doi:10.1637/8909-043009-Review.1
80. Hossain, K.M.M., Ali, M.Y., Haque, M.I., 2007. Seroprevalence of *Mycoplasma gallisepticum* infection in chicken in the greater Rajshahi district of Bangladesh. *Bangladesh Journal of Veterinary Medicine* 5, 9–14. doi:10.3329/bjvm.v5i1.1302
81. Huang, Z., Elankumaran, S., Yunus, A.S., Samal, S.K., 2004. A Recombinant Newcastle Disease Virus (NDV) Expressing VP2 Protein of Infectious Bursal Disease Virus (IBDV) Protects against NDV and IBDV. *Journal of Virology* 78, 10054–10063. doi:10.1128/JVI.78.18.10054-10063.2004
82. Huo, S., Zuo, Y., Li, N., Li, X., Zhang, Y., Wang, L., Liu, H., Zhang, J., Cui, D., He, P., Xu, J., Li, Y., Zhu, X., Zhong, F., 2016. Chicken IL-7 as a potent adjuvant enhances IBDV VP2 DNA vaccine immunogenicity and protective efficacy. *Veterinary Microbiology* 193, 145–155. doi:10.1016/j.vetmic.2016.08.016
83. Identification of a strain of infectious bursal disease virus isolated from mosquitoes. [WWW Document], n.d. URL <https://www.ncbi.nlm.nih.gov.ezproxy.unibo.it/pmc/articles/PMC1320226/> (accessed 10.21.18).



84. Indikova, I., Vronka, M., Szostak, M.P., 2014. First identification of proteins involved in motility of *Mycoplasma gallisepticum*. *Vet Res* 45. doi:10.1186/s13567-014-0099-2
85. Ingraio, F., Rauw, F., Lambrecht, B., van den Berg, T., 2013. Infectious Bursal Disease: A complex host–pathogen interaction. *Developmental & Comparative Immunology, Chicken Immunity* 41, 429–438. doi:10.1016/j.dci.2013.03.017
86. Irigoyen, N., Garriga, D., Navarro, A., Verdaguer, N., Rodríguez, J.F., Castón, J.R., 2009. Autoproteolytic Activity Derived from the Infectious Bursal Disease Virus Capsid Protein. *Journal of Biological Chemistry* 284, 8064–8072. doi:10.1074/jbc.M808942200
87. Iván, J., Velhner, M., Ursu, K., Germán, P., Mató, T., Drén, C.N., Mészáros, J., 2005. Delayed vaccine virus replication in chickens vaccinated subcutaneously with an immune complex infectious bursal disease vaccine: Quantification of vaccine virus by real-time polymerase chain reaction. *Can J Vet Res* 69, 135–142.
88. Jackwood, D.H., Saif, Y.M., 1987. Antigenic diversity of infectious bursal disease viruses. *Avian Dis.* 31, 766–770.
89. Jackwood, D.J., 2004. Recent trends in the molecular diagnosis of infectious bursal disease viruses. *Animal Health Research Reviews* 5, 313–316. doi:10.1079/AHR200490
90. Jackwood, D.J., 2017. Advances in vaccine research against economically important viral diseases of food animals: Infectious bursal disease virus. *Veterinary Microbiology* 206, 121–125. doi:10.1016/j.vetmic.2016.11.022
91. Jackwood, D.J., Hanes, G., Miller, S.H., 1996. Infectious bursal disease viral RNA amplification using RT/PCR from bursa tissue following phenol: chloroform inactivation of the virus. *Avian Dis.* 40, 457–460.
92. Jackwood, D.J., Schat, K.A., Michel, L.O., Wit, S. de, 2018. A Proposed Nomenclature for Infectious Bursal Disease Virus Isolates. *Avian Pathology* 0, 1–16. doi:10.1080/03079457.2018.1506092
93. Jackwood, D.J., Sommer, S.E., 2005. Molecular Studies on Suspect Very Virulent Infectious Bursal Disease Virus Genomic RNA Samples. *Avian Diseases* 49, 246–251. doi:10.1637/7294-102604R
94. Jackwood, D.J., Sommer-Wagner, S.E., 2011. Amino acids contributing to antigenic drift in the infectious bursal disease Birnavirus (IBDV). *Virology* 409, 33–37. doi:10.1016/j.virol.2010.09.030
95. Jackwood, D.J., Sommer-Wagner, S.E., Crossley, B.M., Stoute, S.T., Woolcock, P.R., Charlton, B.R., 2011. Identification and pathogenicity of a natural reassortant between a very virulent serotype 1 infectious bursal disease virus (IBDV) and a serotype 2 IBDV. *Virology* 420, 98–105. doi:10.1016/j.virol.2011.08.023

96. Jackwood, D.J., Sommer-Wagner, S.E., Stoute, S.T., Woolcock, P.R., Crossley, B.M., Hietala, S.K., Charlton, B.R., 2009. Characteristics of a Very Virulent Infectious Bursal Disease Virus from California. *Avian Diseases* 53, 592–600. doi:10.1637/8957-061109-Reg.1
97. Jackwood, D.J., Sreedevi, B., LeFever, L.J., Sommer-Wagner, S.E., 2008. Studies on naturally occurring infectious bursal disease viruses suggest that a single amino acid substitution at position 253 in VP2 increases pathogenicity. *Virology* 377, 110–116. doi:10.1016/j.virol.2008.04.018
98. Jackwood, D.J., Stoute, S.T., Crossley, B.M., 2016. Pathogenicity of Genome Reassortant Infectious Bursal Disease Viruses in Chickens and Turkeys. *Avian Diseases* 60, 765–772. doi:10.1637/11409-031116-Reg
99. Jordan, F. T. W., 1975. Avian mycoplasma and pathogenicity - A review. *Avian Pathology* 4, 165–174. doi:10.1080/03079457509353863
100. Kanci, A., Wijesurendra, D.S., Wawegama, N.K., Underwood, G.J., Noormohammadi, A.H., Markham, P.F., Browning, G.F., 2018. Evaluation of *Mycoplasma gallisepticum* (MG) ts-304 vaccine as a live attenuated vaccine in turkeys. *Vaccine* 36, 2487–2493. doi:10.1016/j.vaccine.2018.02.117
101. Kang, M.S., Gazdzinski, P., Kleven, S.H., 2002. Virulence of Recent Isolates of *Mycoplasma synoviae* in Turkeys. *Avian Diseases* 46, 102–110. doi:10.1637/0005-2086(2002)046[0102:VORIOM]2.0.CO;2
102. Kapetanov, M., Orlić, D., Potkonjak, D., Velhner, M., Milanov, D., Stojanovic, D., 2010. *Mycoplasma* in poultry flocks in the year 2009 compared to the year 2000 and significance of the control measures. *LUCRĂRI științifice MEDICINĂ VETERINARĂ VOL. XLIII (1), 2010 TIMISOARA*
103. Kerr, K.M., Olson, N.O., 1969. Pathology of Chickens Experimentally Inoculated or Contact-Infected with an Arthritis-Producing Virus. *Avian Diseases* 13, 729–745. doi:10.2307/1588581
104. Khalifa, R., Eissa, S., El-Hariri, M., Refai, M., 2014. Sequencing Analysis of *Mycoplasma gallisepticum* Wild Strains in Vaccinated Chicken Breeder Flocks. *MMB* 24, 98–104. doi:10.1159/000357733
105. King, A.M.Q., Adams, M.J., Carstens, E.B., Lefkowitz, E.J. (Eds.), 2012. Family - Birnaviridae, in: *Virus Taxonomy*. Elsevier, San Diego, pp. 499–507. doi:10.1016/B978-0-12-384684-6.00045-8
106. Kleven, S.H. 2009. *Micoplasmosi*. In L. Dufour-Zavala, D.E. Swayne, J.R. Glisson, J.E. Pearson, W.M. Reed, M.W. Jackwood & P.R. Woolcock (Eds.). *Manuale di laboratorio, Isolamento, identificazione e caratterizzazione dei patogeni aviari*. 5th edn. Madison, WI: American Association of Avian Pathologists, pp. 62-68.
107. Kleven, S.H., 1998. *Mycoplasmas* in the etiology of multifactorial respiratory disease. *Poultry Science* 77, 1146–1149. doi:10.1093/ps/77.8.1146

108. Kleven, S.H., Fletcher, O.J., Davis, R.B., 1975. Influence of strain of *Mycoplasma synoviae* and route of infection on development of synovitis or airsacculitis in broilers. *Avian Dis.* 19, 126–135.
109. Kong, L.L., Omar, A.R., Hair-Bejo, M., Aini, I., Seow, H.F., 2004. Comparative analysis of viral RNA and apoptotic cells in bursae following infection with infectious bursal disease virus. *Comparative Immunology, Microbiology and Infectious Diseases* 27, 433–443. doi:10.1016/j.cimid.2004.01.006
110. Kumar, S., Ahi, Y.S., Salunkhe, S.S., Koul, M., Tiwari, A.K., Gupta, P.K., Rai, A., 2009. Effective protection by high efficiency bicistronic DNA vaccine against infectious bursal disease virus expressing VP2 protein and chicken IL-2. *Vaccine* 27, 864–869. doi:10.1016/j.vaccine.2008.11.085
111. Landgraf, H., Vielitz, E., Kirsch, R., 1967. [Studies on the occurrence of an infectious disease involving the bursa of Fabricius (Gumboro disease)]. *Dtsch Tierarztl Wochenschr* 74, 6–10.
112. Landman, W.J.M., 2014. Is *Mycoplasma synoviae* outrunning *Mycoplasma gallisepticum*? A viewpoint from the Netherlands. *Avian Pathology* 43, 2–8. doi:10.1080/03079457.2014.881049
113. Landman, W.J.M., Feberwee, A., 2001. Field studies on the association between amyloid arthropathy and *Mycoplasma synoviae* infection, and experimental reproduction of the condition in brown layers. *Avian Pathology* 30, 629–639. doi:10.1080/03079450120092125
114. Le Nouën, C., Toquin, D., Müller, H., Raue, R., Kean, K.M., Langlois, P., Cherbonnel, M., Etteradossi, N., 2012. Different Domains of the RNA Polymerase of Infectious Bursal Disease Virus Contribute to Virulence. *PLoS ONE* 7, e28064. doi:10.1371/journal.pone.0028064
115. Lee, H.-J., Jang, I., Shin, S.-H., Lee, H.-S., Choi, K.-S., 2017. Genome Sequence of a Novel Reassortant and Very Virulent Strain of Infectious Bursal Disease Virus. *Genome Announc* 5. doi:10.1128/genomeA.00730-17
116. Leigh, S.A., Branton, S.L., Evans, J.D., Collier, S.D., 2013. Impact of fowlpox-vectored *Mycoplasma gallisepticum* vaccine Vectormune FP MG on layer hen egg production and egg quality parameters. *Poult Sci* 92, 3172–3175. doi:10.3382/ps.2013-03325
117. Leigh, S.A., Evans, J.D., Collier, S.D., Branton, S.L., 2018. The impact of vaccination route on *Mycoplasma gallisepticum* vaccine efficacy. *Poult Sci* 97, 3072–3075. doi:10.3382/ps/pey188
118. Lejal, N., Da Costa, B., Huet, J.-C., Delmas, B., 2000. Role of Ser-652 and Lys-692 in the protease activity of infectious bursal disease virus VP4 and identification of its substrate cleavage sites. *Journal of General Virology* 81, 983–992. doi:10.1099/0022-1317-81-4-983
119. Levisohn - Avian mycoplasmosis (*Mycoplasma gallisepticum*). 2000. *Rev. sci. tech. Off. int. Epiz.*, 19 (2), 425-442.

120. Levisohn, S., Dykstra, M.J., 1987. A quantitative study of single and mixed infection of the chicken trachea by *Mycoplasma gallisepticum*. *Avian Dis.* 31, 1–12.
121. Li, K., Liu, Y., Zhang, Y., Gao, L., Liu, C., Cui, H., Qi, X., Gao, Y., Zhong, L., Wang, X., 2017. Protective efficacy of a novel recombinant Marek's disease virus vector vaccine against infectious bursal disease in chickens with or without maternal antibodies. *Veterinary Immunology and Immunopathology* 186, 55–59. doi:10.1016/j.vetimm.2017.02.003
122. Li, L., Kubasová, T., Rychlik, I., Hoerr, F.J., Rautenschlein, S., 2018. Infectious bursal disease virus infection leads to changes in the gut associated-lymphoid tissue and the microbiota composition. *PLOS ONE* 13, e0192066. doi:10.1371/journal.pone.0192066
123. Li, Z., Wang, Y., Li, Xiang, Li, Xiaoqi, Cao, H., Zheng, S.J., 2013. Critical Roles of Glucocorticoid-Induced Leucine Zipper in Infectious Bursal Disease Virus (IBDV)-Induced Suppression of Type I Interferon Expression and Enhancement of IBDV Growth in Host Cells via Interaction with VP4. *J Virol* 87, 1221–1231. doi:10.1128/JVI.02421-12
124. Lin, Z., Kato, A., Otaki, Y., Nakamura, T., Sasmaz, E., Ueda, S., 1993. Sequence comparisons of a highly virulent infectious bursal disease virus prevalent in Japan. *Avian Dis.* 37, 315–323.
125. Liu, M., Vakharia, V.N., 2006. Nonstructural Protein of Infectious Bursal Disease Virus Inhibits Apoptosis at the Early Stage of Virus Infection. *Journal of Virology* 80, 3369–3377. doi:10.1128/JVI.80.7.3369-3377.2006
126. Lobova, D., Kohoutova, L., Molinkova, D., Rosenbergova, K., Kubicek, O., Celer, V., 2012. Prevalence of etiological agents of selected respiratory infections in chicken and turkey farms in the Czech Republic. *Veterinární Medicína* 57, 125–132. doi:10.17221/5852-VETMED
127. Lockaby, S.B., Hoerr, F.J., Lauerman, L.H., Smith, B.F., Samoylov, A.M., Toivio-Kinnucan, M.A., Kleven, S.H., 1999. Factors associated with virulence of *Mycoplasma synoviae*. *Avian Dis.* 43, 251–261.
128. Lohoff, M., Mak, T.W., 2005. Roles of interferon-regulatory factors in T-helper-cell differentiation. *Nat. Rev. Immunol.* 5, 125–135. doi:10.1038/nri1552
129. Lombardo, E., Maraver, A., Castón, J.R., Rivera, J., Fernández-Arias, A., Serrano, A., Carrascosa, J.L., Rodriguez, J.F., 1999. VP1, the Putative RNA-Dependent RNA Polymerase of Infectious Bursal Disease Virus, Forms Complexes with the Capsid Protein VP3, Leading to Efficient Encapsidation into Virus-Like Particles. *J Virol* 73, 6973–6983.
130. Lombardo, E., Maraver, A., Espinosa, I., Fernández-Arias, A., Rodriguez, J.F., 2000. VP5, the Nonstructural Polypeptide of Infectious Bursal Disease Virus, Accumulates within the Host Plasma Membrane and Induces Cell Lysis. *Virology* 277, 345–357. doi:10.1006/viro.2000.0595
131. Lowenthal, J. W., Bean, A.G.D., Kogut, M.H., 2013. What's so special about chicken immunology? *Developmental & Comparative Immunology, Chicken Immunity* 41, 307–309. doi:10.1016/j.dci.2013.07.012

132. Madsen, J.M., Zimmermann, N.G., Timmons, J., Tablante, N.L., 2013. Prevalence and Differentiation of Diseases in Maryland Backyard Flocks. *Avian Diseases* 57, 587–594. doi:10.1637/10423-101612-Reg.1
133. Mahgoub, H.A., 2012. An overview of infectious bursal disease. *Arch Virol* 157, 2047–2057. doi:10.1007/s00705-012-1377-9
134. Marquardt, W.W., Johnson, R.B., Odenwald, W.F., Schlotthober, B.A., 1980. An indirect enzyme-linked immunosorbent assay (ELISA) for measuring antibodies in chickens infected with infectious bursal disease virus. *Avian Dis.* 24, 375–385.
135. Massi, P., Fiorentini, L., Barbieri, I., Giovannetti, L., Casadio, M., Tosi, G., 2014. Monitoraggio della colonizzazione e persistenza del vaccino vivo attenuato per *Mycoplasma synoviae* in riproduttori pesanti. *Atti Della Società Italiana di Patologia Aviaria*, 168–169.
136. Mazariegos, L.A., Lukert, P.D., Brown, J., 1990. Pathogenicity and Immunosuppressive Properties of Infectious Bursal Disease “Intermediate” Strains. *Avian Diseases* 34, 203–208. doi:10.2307/1591353
137. McIlroy, S.G., Goodall, E.A., McCracken, R.M., 1989. Economic effects of subclinical infectious bursal disease on broiler production. *Avian Pathology* 18, 465–480. doi:10.1080/03079458908418619
138. McMartin, D.A., Khan, M.I., Farver, T.B., Christie, G., 1987. Delineation of the lateral spread of *Mycoplasma gallisepticum* infection in chickens. *Avian Dis.* 31, 814–819.
139. Mertens, J., Casado, S., Mata, C.P., Hernando-Pérez, M., de Pablo, P.J., Carrascosa, J.L., Castón, J.R., 2015. A protein with simultaneous capsid scaffolding and dsRNA-binding activities enhances the birnavirus capsid mechanical stability. *Scientific Reports* 5. doi:10.1038/srep13486
140. Michel, L.O., Jackwood, D.J., 2017. Classification of infectious bursal disease virus into genogroups. *Archives of Virology* 162, 3661–3670. doi:10.1007/s00705-017-3500-4
141. Michiels, T., Welby, S., Vanrobaeys, M., Quinet, C., Rouffaer, L., Lens, L., Martel, A., Butaye, P., 2016. Prevalence of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* in commercial poultry, racing pigeons and wild birds in Belgium. *Avian Pathology* 45, 244–252. doi:10.1080/03079457.2016.1145354
142. Mohammed, H.O., Carpenter, T.E., Yamamoto, R., 1987. Economic impact of *Mycoplasma gallisepticum* and *M. synoviae* in commercial layer flocks. *Avian Dis.* 31, 477–482.
143. Moody, A., Sellers, S., Bumstead, N., 2000. Measuring infectious bursal disease virus RNA in blood by multiplex real-time quantitative RT-PCR. *Journal of Virological Methods* 85, 55–64. doi:10.1016/S0166-0934(99)00156-1

144. Moreira, F.A., Cardoso, L., Coelho, A.C., 2015. Epidemiological survey on *Mycoplasma synoviae* infection in Portuguese broiler breeder flocks. *Vet. Ital.* 51, 93–98. doi:10.12834/VetIt.116.329.3
145. Moronato, M.L., Baldasso, E., Fincato, A., Quattieri, K., Flaminio, B., Catania, S., 2014. Circolazione di differenti genotipi di *Mycoplasma synoviae* nel settore avicolo industriale. *Atti Della Società Italiana di Patologia Aviaria*, 184–186.
146. Morrow, C., Bell, I., Walker, S., Markham, P., Thorp, B., Whithear, K., 1990. Isolation of *Mycoplasma synoviae* from infectious synovitis of chickens. *Australian Veterinary Journal* 67, 121–124. doi:10.1111/j.1751-0813.1990.tb07726.x
147. Müller, H., Islam, M.R., Raue, R., 2003. Research on infectious bursal disease—the past, the present and the future. *Veterinary Microbiology* 97, 153–165. doi:10.1016/j.vetmic.2003.08.005
148. Müller, H., Mundt, E., Etteradossi, N., Islam, M.R., 2012. Current status of vaccines against infectious bursal disease. *Avian Pathology* 41, 133–139. doi:10.1080/03079457.2012.661403
149. Müller, H., Nitschke, R., 1987. The two segments of the infectious bursal disease virus genome are circularized by a 90,000-Da protein. *Virology* 159, 174–177.
150. Mundt, E., Ller, B.K., Kretzschmar, D., 1997. VP5 of Infectious Bursal Disease Virus Is Not Essential for Viral Replication in Cell Culture. *J. VIROL.* 71, 5.
151. Nagarajan, M.M., Kibenge, F.S.B., n.d. Infectious Bursal Disease Virus: A Review of Molecular Basis for Variations in Antigenicity and Virulence 8.
152. Nagatomo, H., Takegahara, Y., Sonoda, T., Yamaguchi, A., Uemura, R., Hagiwara, S., Sueyoshi, M., 2001. Comparative studies of the persistence of animal mycoplasmas under different environmental conditions. *Veterinary Microbiology* 82, 223–232. doi:10.1016/S0378-1135(01)00385-6
153. Nakamura, K., Yuasa, N., Abe, H., Narita, M., 1990. Effect of infectious bursal disease virus on infections produced by *Escherichia coli* of high and low virulence in chickens. *Avian Pathology* 19, 713–721. doi:10.1080/03079459008418726
154. Narat, M., Ina, D.B., Kleven, S.H., Habe, F., 1998. The Hemagglutination-Positive Phenotype of *Mycoplasma synoviae* Induces Experimental Infectious Synovitis in Chickens More Frequently than Does the Hemagglutination-Negative Phenotype. *INFECT. IMMUN.* 66, 6.
155. Nhung, N.T., Chansiripornchai, N., Carrique-Mas, J.J., 2017. Antimicrobial Resistance in Bacterial Poultry Pathogens: A Review. *Front Vet Sci* 4. doi:10.3389/fvets.2017.00126
156. Nielsen, O.L., Sørensen, P., Hedemand, J.E., Laursen, S.B., Jørgensen, P.H., 1998. Inflammatory response of different chicken lines and B haplotypes to infection with infectious bursal disease virus. *Avian Pathology* 27, 181–189. doi:10.1080/03079459808419321

157. Noormohammadi, A.H., 2007. Role of phenotypic diversity in pathogenesis of avian mycoplasmosis. *Avian Pathology* 36, 439–444. doi:10.1080/03079450701687078
158. Ogawa, M., Wakuda, T., Yamaguchi, T., Murata, K., Setiyono, A., Fukushi, H., Hirai, K., 1998. Seroprevalence of Infectious Bursal Disease Virus in Free-Living Wild Birds in Japan. *Journal of Veterinary Medical Science* 60, 1277–1279. doi:10.1292/jvms.60.1277
159. OIE, Terrestrial manual 2008, chapter 2. 3. 5. Avian Mycoplasmosis (*Mycoplasma gallisepticum*, *M. synoviae*)
160. OIE, Terrestrial manual 2016, chapter 2. 3. 12. Infectious Bursal Disease (Gumboro)
161. Oña, A., Luque, D., Abaitua, F., Maraver, A., Castón, J.R., Rodríguez, J.F., 2004. The C-terminal domain of the pVP2 precursor is essential for the interaction between VP2 and VP3, the capsid polypeptides of infectious bursal disease virus. *Virology* 322, 135–142. doi:10.1016/j.virol.2004.01.025
162. Osorio, C., Fletcher, O.J., Abdul-Aziz, T., Gonder, E., Tilley, B., Ley, D.H., 2007. Pneumonia of Turkey Breeder Hens Associated with *Mycoplasma Synoviae*. *Avian Diseases* 51, 791–796. doi:10.1637/0005-2086(2007)51[791:POTBHA]2.0.CO;2
163. Ozel, M., Gelderblom, H., 1985. Capsid symmetry of viruses of the proposed Birnavirus group. *Arch. Virol.* 84, 149–161.
164. Papanikolaou (i.n. παπανικολαου), J., 2018. Epidemiological investigation of *Mycoplasmas*, *M. gallisepticum*, *M. synoviae* and *M. meleagridis* in poultry flocks in Greece. *Journal of the Hellenic Veterinary Medical Society*, 53(4), 297-303. doi:http://dx.doi.org/10.12681/jhvms.15385
165. Papazisi, L., Gorton, T.S., Kutish, G., Markham, P.F., Browning, G.F., Nguyen, D.K., Swartzell, S., Madan, A., Mahairas, G., Geary, S.J., 2003. The complete genome sequence of the avian pathogen *Mycoplasma gallisepticum* strain Rlow. *Microbiology* 149, 2307–2316. doi:10.1099/mic.0.26427-0
166. Papazisi, L., Troy, K.E., Gorton, T.S., Liao, X., Geary, S.J., 2000. Analysis of Cytadherence-Deficient, GapA-Negative *Mycoplasma gallisepticum* Strain R. *Infect Immun* 68, 6643–6649.
167. Pascucci, S., Maestrini, N., Govoni, S., Prati, A., 1976. *Mycoplasma synoviae* in the guinea-fowl. *Avian Pathology* 5, 291–297. doi:10.1080/03079457608418198
168. Perozo, F., Villegas, P., Estevez, C., Alvarado, I.R., Purvis, L.B., Williams, S., 2008. Protection against infectious bursal disease virulent challenge conferred by a recombinant avian adeno-associated virus vaccine. *Avian Dis.* 52, 315–319. doi:10.1637/8122-100207-ResNote.1
169. Perozo, F., Villegas, P., Fernandez, R., Cruz, J., Pritchard, N., 2009. Efficacy of Single Dose Recombinant Herpesvirus of Turkey Infectious Bursal Disease Virus (IBDV) Vaccination

- Against a Variant IBDV Strain. *Avian Diseases* 53, 624–628. doi:10.1637/8687-31009RESNOTE.1
170. Pitcovski, J., Gutter, B., Gallili, G., Goldway, M., Perelman, B., Gross, G., Krispel, S., Barbakov, M., Michael, A., 2003. Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens. *Vaccine* 21, 4736–4743. doi:10.1016/S0264-410X(03)00525-5
  171. Qi, X., Zhang, L., Chen, Y., Gao, L., Wu, G., Qin, L., Wang, Y., Ren, X., Gao, Y., Gao, H., Wang, X., 2013. Mutations of Residues 249 and 256 in VP2 Are Involved in the Replication and Virulence of Infectious Bursal Disease Virus. *PLoS ONE* 8, e70982. doi:10.1371/journal.pone.0070982
  172. Qin, Y., Zheng, S.J., 2017. Infectious Bursal Disease Virus-Host Interactions: Multifunctional Viral Proteins that Perform Multiple and Differing Jobs. *Int J Mol Sci* 18. doi:10.3390/ijms18010161
  173. Rasoulinezhad, S., Bozorgmehrifard, M.H., Hosseini, H., Sheikhi, N., Charkhkar, S., 2018. Molecular Detection of *Mycoplasma synoviae* from Backyard and commercial Turkeys in Some Parts of Iran. *Arch Razi Inst* 73, 79–85. doi:10.22092/ari.2018.116615
  174. Rautenschlein, S., Alkie, T.N., 2016. Infectious bursal disease virus in poultry: current status and future prospects. *Veterinary Medicine: Research and Reports* 9. doi:10.2147/VMRR.S68905
  175. Rautenschlein, S., Kraemer, C., Vanmarcke, J., Montiel, E., 2005. Protective Efficacy of Intermediate and Intermediate Plus Infectious Bursal Disease Virus (IBDV) Vaccines against Very Virulent IBDV in Commercial Broilers. *Avian Diseases* 49, 231–237.
  176. Rautenschlein, S., Yeh, H.Y., Njenga, M.K., Sharma, J.M., 2002. Role of intrabursal T cells in infectious bursal disease virus (IBDV) infection: T cells promote viral clearance but delay follicular recovery. *Arch. Virol.* 147, 285–304.
  177. Rauw, F., Lambrecht, B., Berg, T. van den, 2007. Pivotal role of ChIFN $\gamma$  in the pathogenesis and immunosuppression of infectious bursal disease. *Avian Pathology* 36, 367–374. doi:10.1080/03079450701589159
  178. Raviv, Z., Ley, D.H., 2013. *Mycoplasma gallisepticum* infection. In: Swayne, D.E., Glisson, J.R., McDougald, L.R., Nolan, L.K., Suarez, D.L., Venugopal, N. (Eds.), *Disease of Poultry*, Ames, Iowa State Press, pp. 877–893.
  179. Rinaldi, A., Cervio G., Mandelli, G., 1965. Comparsa di una nuova forma morbosa dei polli negli allevamenti avicoli della Lombardia verosimilmente identificabile con la cosiddetta Malattia di Gumboro. *Selezione Veterinaria*, 6, 207–209.



180. Rosenberger, J.K., Klopp, S., Eckroade, R.J., Krauss, W.C., 1975. The roles of the infectious bursal agent and several avian adenoviruses in the hemorrhagic-aplastic-anemia syndrome and gangrenous dermatitis. *Avian Dis.* 19, 717–729.
181. Rosenberger, J.K., Saif Y.M., Jackwood D.J., 2009. Bursite Infettiva. In L. Dufour-Zavala, D.E. Swayne, J.R. Glisson, J.E. Pearson, W.M. Reed, M.W. Jackwood & P.R. Woolcock (Eds.). *Manuale di laboratorio, Isolamento, identificazione e caratterizzazione dei patogeni aviari.* 5th edn. Madison, WI: American Association of Avian Pathologists, pp. 195-197.
182. Rosengarten, R., Citti, C., Glew, M., Lischewski, A., Droëße, M., Much, P., Winner, F., Brank, M., Spersger, J., 2000. Host-pathogen interactions in mycoplasma pathogenesis: Virulence and survival strategies of minimalist prokaryotes. *International Journal of Medical Microbiology* 290, 15–25. doi:10.1016/S1438-4221(00)80099-5
183. Rottem, S., 2002. Choline-containing lipids in mycoplasmas. *Microbes and Infection* 4, 963–968. doi:10.1016/S1286-4579(02)01622-2
184. Roussan, D.A, Khawaldeh, G., Shaheen, I.A., 2015. survey of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* with avian influenza H9 subtype in meat-type chicken in Jordan between 2011–2015. *Poult. Sci.* Jul 94(7), 1499-503. Doi: 10.3382/ps/pev119
185. Saif, Y.M., 1998. Infectious bursal disease and hemorrhagic enteritis. *Poultry Science* 77, 1186–1189. doi:10.1093/ps/77.8.1186
186. Sasipreeyajan, Jiroj, Halvorson, D.A., Newman, J.A., 1987. Effect of *Mycoplasma gallisepticum* Bacterin on Egg-Transmission and Egg Production. *Avian Diseases* 31, 776–781. doi:10.2307/1591030
187. Senne, D.A., 2009. Propagazione dei virus nelle uova embrionate. In L. Dufour-Zavala, D.E. Swayne, J.R. Glisson, J.E. Pearson, W.M. Reed, M.W. Jackwood & P.R. Woolcock (Eds.). *Manuale di laboratorio, Isolamento, identificazione e caratterizzazione dei patogeni aviari.* 5th edn. Madison, WI: American Association of Avian Pathologists, pp. 211-215.
188. Sharma, J.M., Dohms, J.E., Metz, A.L., 1989. Comparative pathogenesis of serotype 1 and variant serotype 1 isolates of infectious bursal disease virus and their effect on humoral and cellular immune competence of specific-pathogen-free chickens. *Avian Dis.* 33, 112–124.
189. Sharma, J.M., Kim, I.-J., Rautenschlein, S., Yeh, H.-Y., 2000. Infectious bursal disease virus of chickens: pathogenesis and immunosuppression. *Developmental & Comparative Immunology* 24, 223–235. doi:10.1016/S0145-305X(99)00074-9
190. Snyder, D.B., Lana, D.P., Savage, P.K., Yancey, F.S., Mengel, S.A., Marquardt, W.W., 1988. Differentiation of infectious bursal disease viruses directly from infected tissues with neutralizing monoclonal antibodies: evidence of a major antigenic shift in recent field isolates. *Avian Dis.* 32, 535–539.

191. St. Paul, M., Brisbin, J.T., Abdul-Careem, M.F., Sharif, S., 2013. Immunostimulatory properties of Toll-like receptor ligands in chickens. *Veterinary Immunology and Immunopathology* 152, 191–199. doi:10.1016/j.vetimm.2012.10.013
192. Stipkovits, L., Kempf, I., 1996. Mycoplasmoses in poultry. *Rev. Sci. Tech.* 15 (4), 1495–1525.
193. Stipkovits, L., Szathmary, S., 2012. Mycoplasma infection of ducks and geese. *Poult Sci* 91, 2812–2819. doi:10.3382/ps.2012-02310
194. Stoute, S.T., Jackwood, D.J., Sommer-Wagner, S.E., Cooper, G.L., Anderson, M.L., Woolcock, P.R., Bickford, A.A., Senties-Cué, C.G., Charlton, B.R., 2009. The diagnosis of very virulent infectious bursal disease in California pullets. *Avian Dis.* 53, 321–326. doi:10.1637/8684-030909-Case.1
195. Strugnell, B.W., McMullin, P., Wood, A.M., Nicholas, R. a. J., Ayling, R., Irvine, R.M., 2011. Unusual eggshell defects in a free-range layer flock in Great Britain. *Veterinary Record* 169, 237–238. doi:10.1136/vr.d5430
196. Tacken, M.G., Van Den Beuken, P.A., Peeters, B.P., Thomas, A.A., Rottier, P.J., Boot, H.J., 2003. Homotypic interactions of the infectious bursal disease virus proteins VP3, pVP2, VP4, and VP5: mapping of the interacting domains. *Virology* 312, 306–319. doi:10.1016/S0042-6822(03)00206-X
197. Taddei, R., Tosi, G., Barbieri, I., Casadio, M., Fiorentini, L., Massi, P., 2012. Tipizzazione molecolare di ceppi di *Mycoplasma gallisepticum* circolanti in Italia tra il 2010 ed il 2012. *Atti Della Società Italiana di Patologia Aviaria*, 342–349.
198. Tanimura, N., Tsukamoto, K., Nakamura, K., Narita, M., Maeda, M., 1995. Association between Pathogenicity of Infectious Bursal Disease Virus and Viral Antigen Distribution Detected by Immunohistochemistry. *Avian Diseases* 39, 9–20. doi:10.2307/1591976
199. Throne Steinlage, S.J., Ferguson, N., Sander, J.E., García, M., Subramanian, S., Leiting, V.A., Kleven, S.H., 2003. Isolation and Characterization of a 6/85-like *Mycoplasma gallisepticum* from Commercial Laying Hens. *Avian Diseases* 47, 499–505. doi:10.1637/0005-2086(2003)047[0499:IACOAL]2.0.CO;2
200. Tippenhauer, M., Heller, D.E., Weigend, S., Rautenschlein, S., 2013. The host genotype influences infectious bursal disease virus pathogenesis in chickens by modulation of T cells responses and cytokine gene expression. *Developmental & Comparative Immunology* 40, 1–10. doi:10.1016/j.dci.2012.10.013
201. Trachtenberg, S., 1998. Mollicutes—Wall-less Bacteria with Internal Cytoskeletons. *Journal of Structural Biology* 124, 244–256. doi:10.1006/jsbi.1998.4063
202. Tsukamoto, K., Tanimura, N., Kakita, S., Ota, K., Mase, M., Imai, K., Hihara, H., 1995. Efficacy of three live vaccines against highly virulent infectious bursal disease virus in chickens with or without maternal antibodies. *Avian Dis.* 39, 218–229.

203. Tulman, E.R., Liao, X., Szczepanek, S.M., Ley, D.H., Kutish, G.F., Geary, S.J., 2012. Extensive variation in surface lipoprotein gene content and genomic changes associated with virulence during evolution of a novel North American house finch epizootic strain of *Mycoplasma gallisepticum*. *Microbiology* 158, 2073–2088. doi:10.1099/mic.0.058560-0
204. Umar, S., Munir, M.T., Ur-Rehman, Z., Subhan, S., Azam, T., Shah, M.A.A., 2017. Mycoplasmosis in poultry: update on diagnosis and preventive measures. *World's Poultry Science Journal* 73, 17–28. doi:10.1017/S0043933916000830
205. Van den Berg, T.P. Gonze, M., Meulemans, G., 1991. Acute infectious bursal disease in poultry: Isolation and characterisation of a highly virulent strain. *Avian Pathology* 20, 133–143. doi:10.1080/03079459108418748
206. Van den Berg, T.P., 2000. Acute infectious bursal disease in poultry: A review. *Avian Pathology* 29, 175–194. doi:10.1080/03079450050045431
207. Van den Berg, T.P., Morales, D., Eterradossi, N., Rivallan, G., Toquin, D., Raue, R., Zierenberg, K., Zhang, M.F., Zhu, Y.P., Wang, C.Q., Zheng, H.J., Wang, X., Chen, G.C., Lim, B.L., Müller, H., 2004. Assessment of genetic, antigenic and pathotypic criteria for the characterization of IBDV strains. *Avian Pathology* 33, 470–476. doi:10.1080/03079450400003650
208. Vasconcelos, A.T.R., Ferreira, H.B., Bizarro, C.V., Bonatto, S.L., Carvalho, M.O., Pinto, P.M., Almeida, D.F., Almeida, L.G.P., Almeida, R., Alves-Filho, L., Assunção, E.N., Azevedo, V.A.C., Bogo, M.R., Brigido, M.M., Brocchi, M., Burity, H.A., Camargo, A.A., Camargo, S.S., Carepo, M.S., Carraro, D.M., de Mattos Cascardo, J.C., Castro, L.A., Cavalcanti, G., Chemale, G., Collevatti, R.G., Cunha, C.W., Dallagiovanna, B., Dambrós, B.P., Dellagostin, O.A., Falcão, C., Fantinatti-Garborggini, F., Felipe, M.S.S., Fiorentin, L., Franco, G.R., Freitas, N.S.A., Frías, D., Grangeiro, T.B., Grisard, E.C., Guimarães, C.T., Hungria, M., Jardim, S.N., Krieger, M.A., Laurino, J.P., Lima, L.F.A., Lopes, M.I., Loreto, É.L.S., Madeira, H.M.F., Manfio, G.P., Maranhão, A.Q., Martinkovics, C.T., Medeiros, S.R.B., Moreira, M.A.M., Neiva, M., Ramalho-Neto, C.E., Nicolás, M.F., Oliveira, S.C., Paixão, R.F.C., Pedrosa, F.O., Pena, S.D.J., Pereira, M., Pereira-Ferrari, L., Piffer, I., Pinto, L.S., Potrich, D.P., Salim, A.C.M., Santos, F.R., Schmitt, R., Schneider, M.P.C., Schrank, A., Schrank, I.S., Schuck, A.F., Seuanez, H.N., Silva, D.W., Silva, R., Silva, S.C., Soares, C.M.A., Souza, K.R.L., Souza, R.C., Staats, C.C., Steffens, M.B.R., Teixeira, S.M.R., Urmenyi, T.P., Vainstein, M.H., Zuccherato, L.W., Simpson, A.J.G., Zaha, A., 2005. Swine and Poultry Pathogens: the Complete Genome Sequences of Two Strains of *Mycoplasma hyopneumoniae* and a Strain of *Mycoplasma synoviae*. *J Bacteriol* 187, 5568–5577. doi:10.1128/JB.187.16.5568-5577.2005
209. von Einem, U.I., Gorbalenya, A.E., Schirrmeier, H., Behrens, S.-E., Letzel, T., Mundt, E., 2004. VP1 of infectious bursal disease virus is an RNA-dependent RNA polymerase. *Journal of General Virology* 85, 2221–2229. doi:10.1099/vir.0.19772-0
210. Wang, Y., Wu, X., Li, H., Wu, Y., Shi, L., Zheng, X., Luo, M., Yan, Y., Zhou, J., 2009. Antibody to VP4 protein is an indicator discriminating pathogenic and nonpathogenic IBDV infection. *Molecular Immunology* 46, 1964–1969. doi:10.1016/j.molimm.2009.03.011

211. Weisman, J., Hitchner, S.B., 1978. Virus-Neutralization versus Agar-Gel Precipitin Tests for Detecting Serological Response to Infectious Bursal Disease Virus. *Avian Diseases* 22, 598–603. doi:10.2307/1589634
212. Whithear, K., Soeripto, Harringan, K., Ghiocas, E., 1990. Safety of temperature sensitive mutant *Mycoplasma gallisepticum* vaccine. *Australian Veterinary Journal* 67, 159–165. doi:10.1111/j.1751-0813.1990.tb07745.x
213. Wyrzykowski, B., Albaric, O., Moreau, S., Nguyen, F., Fleurance, R., Belluco, S., Wyers, M., Colle, M.-A., 2013. Retrospective Study of *Mycoplasma gallisepticum* Meningoencephalitis in Six Turkey Flocks in Western France. *Journal of Comparative Pathology*, 125th Anniversary Issue 148, 173–177. doi:10.1016/j.jcpa.2012.06.006
214. Yao, K., Goodwin, M.A., Vakharia, V.N., 1998. Generation of a Mutant Infectious Bursal Disease Virus That Does Not Cause Bursal Lesions. *Journal of Virology* 72, 2647–2654.
215. Yao, K., Vakharia, V.N., 2001. Induction of Apoptosis in Vitro by the 17-kDa Nonstructural Protein of Infectious Bursal Disease Virus: Possible Role in Viral Pathogenesis. *Virology* 285, 50–58. doi:10.1006/viro.2001.0947
216. Ye, C., Jia, L., Sun, Y., Hu, B., Wang, L., Lu, X., Zhou, J., 2014. Inhibition of Antiviral Innate Immunity by Birnavirus VP3 Protein via Blockage of Viral Double-Stranded RNA Binding to the Host Cytoplasmic RNA Detector MDA5. *Journal of Virology* 88, 11154–11165. doi:10.1128/JVI.01115-14
217. Yoder, H.W., Hofstad, M.S., 1964. Characterization of Avian *Mycoplasma*. *Avian Diseases* 8, 481–512. doi:10.2307/1587937
218. Zhai, L., Wang, Y., Yu, J., Hu, S., 2014. Enhanced immune responses of chickens to oral vaccination against infectious bursal disease by ginseng stem-leaf saponins. *Poult Sci* 93, 2473–2481. doi:10.3382/ps.2014-04056
219. Zhang, D., Long, Y., Li, M., Gong, J., Li, X., Lin, J., Meng, J., Gao, K., Zhao, R., Jin, T., 2018. Development and evaluation of novel recombinant adenovirus-based vaccine candidates for infectious bronchitis virus and *Mycoplasma gallisepticum* in chickens. *Avian Pathology* 47, 213–222. doi:10.1080/03079457.2017.1403009
220. Zhao, Y., Aarnink, A.J.A., Cambra-Lopez, M., Fabri, T., 2013. Viral shedding and emission of airborne infectious bursal disease virus from a broiler room. *British Poultry Science* 54, 87–95. doi:10.1080/00071668.2012.762505.



## CHAPTER III: PUBLISHED PAPER

NOTICE: this is post-print (final draft post-refereeing) author's version of a work that was accepted for publication in Poultry Science. Changes resulting from the publishing process, such as editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version is published in: V. Felice, G. Franzo, E. Catelli, A. Di Francesco, M. Bonci, M. Cecchinato, G. Mescolini, D. Giovanardi, P. Pesente and C. Lupini "Genome sequence analysis of a distinctive Italian infectious bursal disease virus". Poultry science 2017, 96:4370–4377. doi: 10.3382/ps/pex278. Epub 10 October 2017.

Full-Length Articles

### **Genome sequence analysis of a distinctive Italian Infectious Bursal Disease virus**

V. Felice<sup>\*</sup>,<sup>1</sup>, G. Franzo<sup>§</sup>, E. Catelli<sup>\*</sup>, A. Di Francesco<sup>\*</sup>, M. Bonci<sup>\*</sup>, M. Cecchinato<sup>§</sup>, G. Mescolini<sup>\*</sup>, D. Giovanardi<sup>#</sup>, P. Pesente<sup>#</sup>, C. Lupini<sup>\*</sup>

<sup>\*</sup>Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia (BO), Italy.

<sup>§</sup>Department of Animal Medicine, Production and Health, University of Padua, Legnaro (PD), Italy.

<sup>#</sup> Tre Valli Laboratory, San Michele Extra (VR), Italy.

<sup>1</sup>Corresponding author: Viviana Felice

Department of Veterinary Medical Sciences, University of Bologna, Via Tolara di Sopra, 50, 40064 Ozzano dell'Emilia (BO), Italy.

Tel.: 0039 0512097459

E-mail: viviana.felice2@unibo.it

## **ABSTRACT**

In a recent study, an emerging Infectious Bursal Disease Virus (**IBDV**) genotype (ITA) was detected in IBDV-live vaccinated broilers without clinical signs of Infectious Bursal Disease (**IBD**). VP2 sequence analysis showed that strains of the ITA genotype clustered separately from vaccine strains and from other IBDV reference strains, either classic or very virulent. In order to obtain a more exhaustive molecular characterisation of the IBDV ITA genotype and speculate on its origin, genome sequencing of the field isolate IBDV/Italy/1829/2011, previously assigned to the ITA genotype, was performed, and the sequences obtained were compared to the currently available corresponding sequences. In addition, phylogenetic and recombination analysis were performed. Interestingly, multiple amino acid (**AA**) sequence alignments revealed that the IBDV/Italy/1829/2011 strain shared several AA residues with very virulent IBDV strains as well as some virulence markers, especially in the VP1 protein. Nevertheless, sequence analysis demonstrated the presence of several residues typical of IBDV strains at a low degree of virulence in the IBDV/Italy/1829/2011 strain. Although homologous recombination and reassortant phenomena may occur naturally among different IBDV strains, no evidence of those events was found in the genome of the IBDV/Italy/1829/2011 strain which was confirmed to be a genetically distinctive IBDV genotype.

Key words: Infectious Bursal Disease Virus; genotype ITA; genome characterisation; phylogenetic analysis; recombination.

## INTRODUCTION

Infectious bursal disease (**IBD**), also known as “Gumboro disease”, is a worldwide, highly contagious poultry disease caused by the IBD virus (**IBDV**) which belongs to the *Avibirnavirus* genus within the *Birnaviridae* family (Van den Berg, 2000). The IBDV destroys the developing B-lymphocytes in the bursa of Fabricius, the major organ for the development of humoral immunity in birds. The destruction of the chicken bursa results in immunosuppression and has a notable economic impact on productions due to increased susceptibility to secondary infections and a suboptimal response to vaccinations (Balamurugan and Kataria, 2006).

The IBDV is a non-enveloped, bisegmented, double-stranded RNA virus. The viral genome consists of two segments, called A (3.4 kb) and B (2.8 kb). Segment A contains two partially overlapping open reading frames (**ORFs**), ORF1 and ORF2. The smaller ORF1 encodes the non-structural viral protein VP5 (17 kDa), dispensable for viral replication *in vitro*, but also involved in the pathogenicity of the virus (Lombardo et al., 2000). The larger ORF2 encodes the precursor polyprotein NH<sub>2</sub>-VP2-VP4-COOH (108 kDa) which is autocatalytically cleaved by the protease VP4 into the viral capsid protein VP2 (40-45 kDa), the ribonucleoprotein VP3 (30-34 kDa) and the viral protease VP4 (28 -30 kDa) (Ture and Saif, 1992; Mundt et al., 1995; Van den Berg, 2000). Several studies have been focused on the VP2 protein as it is the major structural protein, induces neutralising antibodies and is responsible for the antigenic variation due to its hypervariable region, between amino acid (**AA**) residues 206 and 350. The VP3 protein does not contain virus-neutralising epitopes, and is involved in virus replication and RNA packaging. The VP4 protein processes the precursor polyprotein (Nagarajan and Kibenge, 1997). Segment B contains one ORF, encoding the RNA-dependent RNA polymerase VP1 (90 kDa), and is responsible for viral replication and mRNA synthesis (Ture and Saif, 1992; Von Einem et al., 2004). Two distinct serotypes (1 and 2) of IBDV have been differentiated. Serotype 1 strains vary in virulence and are classified as very virulent (**vv**), classic, attenuated or antigenic variant (Van den Berg, 2000). Serotype 2 strains are avirulent and do not induce protection against serotype 1 strains (Etteradossi and Saif, 2013).

The IBDV affects young chickens and is widespread in nearly all commercial poultry-producing countries around the world. In Italy, the first report of IBD dates back to 1965 (Rinaldi et al., 1965); since then the disease became endemic in Italy, and live vaccination of young birds was introduced (Coletti et al., 1983; Asdrubali and Franciosini, 1993). More recently, the genotyping of the Italian IBDV isolates allowed a clearer epidemiological picture. Predominant circulation of the vv strains was confirmed and the presence of atypical classic strains was reported (Moreno et al., 2007; Moreno



et al., 2010) despite the routine use of intermediate and intermediate plus live vaccines, and inactivated booster in breeders.

In a recent study, an emerging IBDV genotype (ITA) was detected in IBD-live vaccinated broilers without clinical signs of IBD and with a history of poor growth performance. VP2 sequence analysis showed that strains of the ITA genotype clustered separately from vaccine strains and from other IBDV reference strains, either classic or very virulent, retrieved from the GenBank or previously reported in Italy (Lupini et al., 2016).

In order to obtain a more exhaustive molecular characterisation of the IBDV ITA genotype and speculate on its origin, genome sequencing of the IBDV/Italy/1829/2011 field isolate, belonging to the ITA genotype on the basis of the VP2 sequence analysis (Lupini et al., 2016), was performed, and the sequences obtained were compared to the currently available homologous sequences.

## **MATERIALS AND METHODS**

### ***Virus***

The IBDV/Italy/1829/2011 field strain had been isolated from the bursa of Fabricius of 3-week-old IBD-live vaccinated broilers, having poor growth performance but without overt clinical signs of IBDV. In the present study, the isolate was propagated once in 12 day-old specific pathogen-free (SPF) eggs via the chorioallantoic membrane route (Senne et al., 2008) in order to perform the molecular analysis. Virus titer was  $10^{2.3}$  mean embryo infective dose/ml.

### ***Genome sequencing***

The total viral RNA was extracted using the QIAamp® Viral RNA Mini kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. Two reverse transcriptions for segment A and one for segment B were carried out, using ImProm-IITM Reverse Transcriptase (Promega, Milan, Italy) in a 10 µl final volume containing 2 µl of 5X reaction buffer, 1.2 µl of MgCl<sub>2</sub> (3 mM), 0.5 µl of dNTP (0.5 mM), 0.5 µl of reverse primers (Table 1), 3.3 µl of nuclease-free water and 2 µl of RNA. The RT mixtures were incubated at 42°C for 60 min and were then maintained at 70°C for 15 min.

Segment A and segment B were amplified in six and three overlapping fragments, respectively. PCRs were carried out using Go Taq® DNA Polymerase (Promega, Milan, Italy) in a final volume of 25 µl

containing 5 µl of 5X Go Taq® Flexi Buffer (Promega, Milan, Italy), 1.75 µl of MgCl<sub>2</sub>, 0.5 µl of dNTP (0.2 mM), 0.5 µl of each primer (Table 1), 12.5 µl of nuclease-free water and 4 µl of cDNA. The PCR cycling parameters consisted of a precycle step at 95°C for two min followed by 35 cycles at 95°C for 1 min, primer-specific parameters and finally at 72°C for 1 min. The last cycle was followed by a final extension step of 72°C for 5 min.

The Wizard® SV Gel and PCR Clean-Up System (Promega, Milan, Italy) was used to purify the reverse transcriptase-polymerase chain reaction products, according to the manufacturer's instructions. Sanger sequencing was performed in both directions using the PCR primers (Bio-Fab Research, Rome, Italy).

### *Sequence analysis*

Nucleotide and predicted amino acids sequences of the A and the B segments of the IBDV/Italy/1829/2011 strain were edited and assembled using Bioedit software, they were aligned and were then compared with 30 published representatives of all the molecular types of the IBDV strains retrieved from the GenBank database (Table 2), using Mega 6 (Tamura et al., 2013).

### *Recombination and phylogentic analysis*

A collection of 46 complete IBDV genome sequences was downloaded from GenBank. Alignments were carried out both for each segment separately and for a concatenation of the two using Multiple Alignment using Fast Fourier Transform (Kato et al., 2013). A NeighborNet network based on the full genome was reconstructed using Splits Tree4v4.12.3 (Huson and Bryant, 2010), and the presence of recombination within the dataset was also tested using the Phi test implemented in the same software (Huson and Bryant, 2010). Recombination analysis was carried out on all datasets using Recombination Detection Program 4 (**RDP**) (Martin et al., 2010). Settings were adjusted according to the RDP manual. Recombination breakpoints were also estimated using Genetic Algorithm Recombination Detection (Kosakovsky et al., 2006). Phylogenetic trees were reconstructed using PhyML, a combination of Nearest neighbor interchange, and subtree pruning and regrafting was selected after removal of the recombinant region/sequences. Branch support was estimated with the fast non-parametric version of the approximate Likelihood-Ratio Test (Shimodaira–Hasegawa [SH]-aLRT) (Anisimova et al., 2011). Ancestral state reconstruction of amino acids was performed on

VP1, VP2-3-4 polyprotein and VP5 using the analysis of phylogenetics and evolution package (Paradis et al., 2004) implemented in R, based on trees reconstructed on an extended collection of sequences.

Finally, a phylogenetic tree was reconstructed using a full collection of 1149 VP2 partial sequences. For computational reasons, the database was reduced by collapsing identical sequences, and the phylogenetic tree was reconstructed using Fasttree (Price et al., 2010).

## RESULTS AND DISCUSSION

Segments A and B of the IBDV/Italy/1829/2011 strain were successfully amplified, obtaining 2937 nucleotides for segment A and 2746 for segment B. The nucleotide sequences were entered into the GenBank database under the accession numbers KY930929 (segment A) and KX520665 (segment B). Segment A showed 96% nucleotide similarity with the representative classic strains and 95-94% with the attenuated and vvIBDV strains considered in the present study, respectively. Segment B showed 96% nucleotide similarity with the representative classic and attenuated strains, and 90% with vvIBDV strains.

All the nucleotide sequences were fully translatable into amino acid sequences. The comparison between the amino acid sequences of IBDV/Italy/1829/2011 and the corresponding sequences of the representative reference IBDV strains is reported (Figures S1-S12) and discussed.

**Segment A.** The ORF1 of the IBDV/Italy/1829/2011 encoded the VP5 which has an important role in the release of viral progeny from infected cells and in the induction of apoptosis *in vitro* (Lombardo et al., 2000). Amino acid sequence analysis of VP5 showed that IBDV/Italy/1829/2011 shared Ile 78 with the non-vvIBDV strains and Trp 137 with the vvIBDV strains (Supplementary Figure 1-4). These residues seem to be involved in virus virulence as demonstrated in a previous report showing that amino acids Phe 78 and Trp 137 of the vvIBDV strains changed into Ile 78 and Arg 137 after attenuation by passages in the chicken embryo fibroblasts (Wang et al, 2007). In addition, Hernández et al. (2010) reported that Trp 137 is a conserved residue of 6 vvIBDV strains considering it a typical AA of vvIBDV.

The ORF2-encoded polyprotein consists, as previously mentioned, of VP2, VP4 and VP3. Overall, the predicted AA sequence of the polyprotein indicated that the IBDV/Italy/1829/2011 strain shared 7 AA residues with the non-vvIBDV strains (Leu 294, Ile 451, Lys 685, Pro 715, His 751, Ala 990, Thr 1005) and 1 with the vvIBDV strains (Ser 299). Interestingly, 12 peculiar AA residues were

found (Cys 45, Glu 53, His 220, Gln 222, Glu 253, Lys 256, Ser 260, Val 321, Thr 708, Phe 750, Ala 778, Ile 875) (Supplementary Figures 5-8).

In particular, Nagarajan and Kibenge (1997) reported that VP2 showed a serine-rich heptapeptide region in position 326-332 (Ser-Trp-Ser-Ala-Ser-Gly-Ser), observed in virulent strains (Supplement Figure 8). The VP3 AA sequence showed Ala 990 as non-vvIBDV (Supplementary Figures 5-7). Wang et al. (2010) demonstrated that mutations at position 990 would be able to reduce viral replication both *in vitro* and *in vivo*.

**Segment B.** The coding region contained 2634 nucleotides which encoded the VP1 protein (878 AAs). The VP1 AA sequence showed that IBDV/Italy/1829/2011 shared 6 AA residues with the non-vvIBDV strains (Ile 4, Val 61, Thr 287, Arg 508, Gly 646, Ser 687) and 2 AA residues with the vvIBDV strains (Thr 145, Ser 511). In addition, 3 peculiar AA residues, Phe 413, His 561 and Arg 756, were found as compared to Tyr 413, Gln 561 and Lys 756 which were detected in both the vv and the non-vvIBDV strains (Supplementary Figures 9-12). It has been reported that specific VP1 amino acids contributed to enhancing viral replication, pathogenicity and virulence (Van den Berg, 2000; Yu et al., 2013; Gao et al. 2014). In particular, the amino acid at position 4 and the 145/146/147 amino acid triplet are located in the N-terminal domain of VP1 which is responsible for the protein priming activity of IBDV, potentially affecting the polymerase activity function (Yu et al., 2013). The VP1 protein of IBDV/Italy/1829/2011 showed Ile 4 as a non-vvIBDV strain and a Thr-Glu-Gly triplet at positions 145/146/147 as vvIBDV strains. Using a reverse-genetics system, it has been reported that the 4 Val > Ile substitution reduces viral replication and pathogenicity in SPF chickens (Yu et al., 2013). Moreover, Gao et al. (2014) demonstrated that the Thr-Glu-Gly triplet was able to enhance viral replication in chickens as compared to Asn-Glu-Gly, the typical triplet of the non-vvIBDV strains.

With respect to the recombinations and phylogentic analysis, the IBDV/Italy/1829/2011 strain displayed a genetic distance between 0.044-0.168, 0.040-0.120 and 0.043-0.124 for segment A, segment B and both segments, respectively. The presence of several reticulations in the phylogenetic network and Phi test results suggested frequent recombination events among IBDV strains. Nevertheless, these did not seem to affect the IBDV/Italy/1829/2011 strain (Figure 1). The RDP and the Genetic Algorithm Recombination Detection analyses provided concordant results which confirmed this evidence. Reassortment and recombination were proven to be frequent. More specifically, reassortment was detected in 25 strains out of 46 while recombination was detected only within segment A where 21 strains out of 46 displayed a recombinant insert, approximately between

positions 1169 and 1456. The only two exceptions were represented by the EU595670 strain (recombination breakpoints 1-1351) within segment A and the KC109816 strain (recombination breakpoints 437-2087) within segment B. Nevertheless, although suggestive, the limited number of complete genome sequences available requires caution in generalising these results and defining actual recombination hot spots. No evidence of recombination was found for the IBDV/Italy/1829/2011 genotype. The phylogenetic tree confirmed the absence of a close relationship between IBDV/Italy/1829/2011 and other representative strains (Figure 2). Analysis of the phylogenetic tree based on segment A, where IBDV serotypes 1 and 2 are most divergent, demonstrated that the current isolate is the one most related to serotype 2 strains and it could therefore represent the descent of a group which originated in the distant past (Figure 2). These results were also confirmed when a broad collection of VP2 partial sequences (date range of the origin of the strains was from 1995 to 2015) was used for phylogenetic inference (Supplementary Figure 13).

In this study, the Authors reported the results of the genome sequencing of the IBDV/Italy/1829/2011 strain, confirming that it was a genetically distinctive IBDV strain. Interestingly, multiple AA sequence alignments revealed that IBDV/Italy/1829/2011 shared several AA residues with vvIBDV strains and some virulence markers, especially in the VP1 protein, were detected. Nevertheless, detailed analysis of the predicted AA sequences pointed out the presence of some residues typical of IBDV strains at a low degree of virulence. The main mechanisms of evolution of RNA viruses is their high substitution rate which might cause the emergence of new IBDV strains able to overcome vaccine immunity (Eterradossi and Saif, 2013), as has been reported for other avian RNA viruses (Catelli et al., 2010; Cecchinato et al., 2010). Moreover, homologous recombination (He et al., 2009; Jackwood, 2012) and reassortant phenomena may naturally occur between different IBDV strains (Wei et al., 2006; Cui et al., 2013; Kasanga et al., 2013). Interestingly, no evidence of recombination or reassortment was found in IBDV/Italy/1829/2011 whereas reassortment and recombination events were detected in 25 and 21 out of 46 IBDV genomes analysed, respectively.

The IBDV/Italy/1829/2011 strain had been isolated from IBD live vaccinated broilers which did not show clinical signs of IBD. Multiple AA sequence alignments revealed that it shared AA residues with both vvIBDV and IBDV strains at low degree of virulence, but homologous recombination and reassortant phenomena were not found in its genome, confirming IBDV/Italy/1829/2011 to be a genetically peculiar IBDV strain. In order to elucidate the relationship between the genetic profile and the virulence of the IBDV/Italy/1829/2011 strain, additional *in vivo* pathogenicity studies are needed.

Table 1. Primers used to amplify and sequence IBDV/Italy/1829/2012 segments A and B.

Primer (5'-3') Reverse Transcriptase	Location of 5' nucleotide	Primer (5'-3') PCR	Location of 5' nucleotide	Amplicon size (bp)
<i>Segment A</i>				
Gum-5R CCCGGATTATGTCTTTGA <sup>1</sup>	1459	GA1F CTCAGGTCAGAGACCTCGAC <sup>4</sup>	223	491
		GA1R GCCTGTCACTGCTGTACACAT <sup>4</sup>	714	
		Gum-2F GCCCAGAGTCTACACCAT <sup>1</sup>	717	742
		Gum-5R CCCGGATTATGTCTTTGA <sup>1</sup>	1459	
Gum-8R AGGGGACCCGCGAACGGATCC <sup>1</sup>	3261	GA4nF GAACCTGGTCACAGAATACG <sup>4</sup>	1254	532
		GA4nR ATAGCGTGGCACCCCTCTCT <sup>4</sup>	1786	
		GA4Fmod CCGTAGTCGACGGGATTCT <sup>4</sup>	1700	497
		GA4Rmod CAGTGGCGAGCTTGGTGC <sup>4</sup>	2197	
		GA5F CYCAAYGCYTRTGGCGAGATT <sup>4</sup>	2140	481
		GA5R GCTGTCCCGTACTTGGCTCTT <sup>4</sup>	2621	
		GA6FmodCTCGCAAACGCACCACAAGC <sup>4</sup>	2564	586
		GA6R CAGGAGCCTCACTCAAGGTC <sup>4</sup>	3150	
<i>Segment B</i>				
2 sense GAGAGCCGCCAATAGCCATG <sup>d</sup>	2755	G772+ CACCCGGTGAGGATGACAAGC <sup>2</sup>	751	1109
		GumF2RmodGATCCCGAGATCTTTGCTGTA <sup>2</sup>	1860	
		B1744forGTCCCCCTTGACACAACCAGGGTAC <sup>4</sup>	1743	1080
		2 sense GAGAGCCGCCAATAGCCATG <sup>4</sup>	2823	
		T7BC1 GGATACGATGGGTCTGACCCT <sup>3</sup>	1	885
		B898rev CATAGGTAGTCCACTTGATGAC <sup>4</sup>	886	

<sup>1</sup> Jackwood et al., 2008

<sup>2</sup> Kong, 2004

<sup>3</sup> Boot J. H., 2000

<sup>4</sup> primers manually designed.

Table 2. IBDV reference strains used in the sequence analysis.

IBDV strains	Accession number	
	Segment A	Segment B
<b>Attenuated</b>		
D78	AF499929.1	EU162090.1
ViBursaCE	EU162089.1	EU162092.1
ViBursaG	EU162088.1	EU162091.1
Cu1	D00867.1	AF362772.1
JD1	AF321055.1	AY103464.1
903 78	JQ411012.1	JQ411013.1
CEF94	AF194428.1	AF194429.1
Gt	DQ403248.1	DQ403249.1
CT	AJ310185.1	AJ310186.1
J1C7	EF646853.1	EF646854.1
W2512	/	AF083092.1
IC-IBDV-Br	KC603936.1	KC603936.1
<b>Classic</b>		
F52 70	HG974565.1	HG974566.1
STC	D00499.1	/
CS-2-35	EF418033.1	EU162093.1
cro-pa-98	/	EU184690.1
Cu-1	/	AF362775.1
GA-1	EF418034.1	EF162094.1
<b>Very virulent</b>		
Gx	AY444873.3	AY705393.1
SH99	LM651365.1	LM651366.1
OKYM	D49706.1	D49707.1
GZ 96	AY598356.1	AY598355.1
UPM94 273	AF527039.1	AF527038.1
UK661	X92760.1	NC_004179.1
Ks	DQ927042.1	DQ927043.1
PO7	AY665672.1	/
CAHFS_K669	JN585293.1	/
Hub-1	AIG93145.1	GQ449693.1
<b>Variant</b>		
Variant E	AF133904.1	AF133905.1
GLS	AY368653.1	AY368654.1




Figure 1. Phylogenetic network based on the NeighborNet method including 47 IBDV genomes (concatenation of segment A and B). The IBDV/Italy/1829/2011 strain is circled.






Figure 2. Midpoint-rooted maximum likelihood (ML) phylogenetic tree reconstructed using the segment A (left) and segment B (right) alignments. Branch support estimated with the Shimodaira–Hasegawa [SH]-aLRT model is reported as black ( $> 0.7$ ) or gray ( $> 0.5$ ) circles near the corresponding node. IBDV/Italy/1829/2011 strain (double asterisk). IBDV serotype 2 (asterisk).

## REFERENCES

1. Anisimova, M., M. Gil, J. Dufayard, C. Dessimoz, and O. Gascuel. 2011. Survey of branch support methods demonstrates accuracy, power, and robustness of fast likelihood-based approximation schemes. *Syst Biol.* 60:685-699.
2. Asdrubali, G., and M.P. Franciosini. 1993. Recenti acquisizioni sulla malattia di Gumboro. *Rivista di avicoltura.* 7:43-46.
3. Balamurugan, V., and J.M. Kataria. 2006. Economically important non-oncogenic immunosuppressive viral diseases of chicken-current status. *Vet. Res. Commun.* 30:541-566.
4. Boot, H. J., ter Huurne A. H., and Peeters B. P. 2000. Generation of full-length cDNA of the two genomic dsRNA segments of Infectious Bursal Disease virus. *J Virol Methods.* 84:49-58.
5. Catelli, E., C. Lupini, M. Cecchinato, E. Ricchizzi, P. Brown, and C.J. Naylor. 2010. Field avian Metapneumovirus evolution avoiding vaccine induced immunity. *Vaccine.* 28:916-921.
6. Cecchinato, M., E. Catelli, C. Lupini, E. Ricchizzi, J. Clubbe, M. Battilani, and C.J. Naylor. 2010. Avian metapneumovirus (AMPV) attachment protein involvement in probable virus evolution concurrent with mass live vaccine introduction. *Vet Microbiol.* 146:24-34.
7. Coletti, M., G. Asdrubali, V. Amico, G. Covarelli, and L. Mechelli. 1983. Ricerche sierologiche ed istologiche in polli vaccinati contro la malattia di Gumboro (bursite infettiva). *Rivista zootecnica e veterinaria.* 11:304-307.
8. Cui, P., S.J. Ma, Y.G. Zhang, X.S. Li, X.Y. Gao, B.A. Cui, and H.Y. Chen. 2013. Genomic sequence analysis of a new reassortant infectious bursal disease virus from commercial broiler flocks in central China. *Arch Virol.* 158:1973–1978.
9. Etteradossi, N., and Y.M. Saif. 2013. Infectious Bursal Disease. Pages 219-246 in *Disease of Poultry.* 13th edn. D.E. Swayne, J.R. Glisson, L.R. McDougald, L.K. Nolan, D.L. Suarez, and N. Venugopal (eds). Ames, Iowa State Press.
10. Gao L, K. Li, X. Qi, H. Gao, Y. Gao, L. Qin, Y. Wang, N. Shen, X. Kong, and X. Wang. 2014. Triplet amino acids located at positions 145/146/147 of the RNA polymerase of very virulent infectious bursal disease virus contribute to viral virulence. *J Gen Virol.* 95:888-97.
11. He, C.Q., L.Y. Ma, D. Wang, G.R. Li, and N.Z. Ding. 2009. Homologous recombination is apparent in infectious bursal disease virus. *Virology.* 384:51–58.
12. Hernández, M, P. Villegas, D. Hernández , A. Banda, L. Maya, V. Romero, G. Tomás, and R. Pérez. 2010. Sequence variability and evolution of the terminal overlapping VP5 gene of the infectious bursal disease virus. *Virus Genes.* 41:59-66.
13. Huson, D.H., and D. Bryant. 2010. User Manual for SplitsTree4 V4.11.3.

14. Jackwood, D.J. 2012. Molecular epidemiologic evidence of homologous recombination in infectious bursal disease viruses. *Avian Dis.* 56:574-577.
15. Jackwood, D.J., B. Sreedevi, L.J. LeFever, and S.E. Sommer-Wagner. 2008. Studies on naturally occurring infectious bursal disease viruses suggest that a single amino acid substitution at position 253 in VP2 increases pathogenicity. *Virology.* 20:110-116.
16. Kasanga, C.J., T. Yamaguchi, H. M. Munang'andu, K. Ohya, and H. Fukushi. 2013. Genomic sequence of an infectious bursal disease virus isolate from Zambia: classical attenuated segment B reassortment in nature with existing very virulent segment A. *Arch Virol.* 158:685–689.
17. Katoh, K., and D.M. Standley. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol.* 30:772-780.
18. Kong, L.L., A. R. Omar, M. Hair-Bejo, I. Aini, and H. F. Seow. 2004. Sequence analysis of both genome segments of two very virulent Infectious bursal disease virus field isolates with distinct pathogenicity. *Arch Virol.* 149:425-434.
19. Kosakovsky Pond, S.L., D. Posada, M.B. Gravenor, C.H. Woelk, and S.D. Frost. 2006. GARD: a genetic algorithm for recombination detection. *Bioinformatics.* 22:3096-3098.
20. Lombardo, E., A. Maraver, I. Espinosa, A. Fernández-Arias, and JF. Rodriguez. 2000. VP5, the nonstructural polypeptide of infectious bursal disease virus, accumulates within the host plasma membrane and induces cell lysis. *Virology.* 277:345-57.
21. Lupini, C., D. Giovanardi, P. Pesente, M. Bonci, V. Felice, G. Rossi, E. Morandini, M. Cecchinato, and E. Catelli. 2016. A molecular epidemiology study based on VP2 gene sequences reveals that a new genotype of infectious bursal disease virus is dominantly prevalent in Italy. *Avian Pathol.* 45:458-464.
22. Martin, D.P., P. Lemey, M. Lott, V. Moulton, D. Posada, and P. Lefevre. 2010. RDP3: a flexible and fast computer program for analyzing recombination. *Bioinformatics.* 26:2462-2463.
23. Moreno, A.M., F. Fallacara, I. Barbieri, G. Tosi, G. Rivallan, N. Etteradossi, R. Ceruti, and P. Cordioli. 2007. Genetic and antigenic characterisation of infectious bursal disease viruses isolated in Italy during the period 2002. *Avian Dis.* 51:863-872.
24. Moreno, A.M., I. Barbieri, R. Ceruti, E. Morandini, and P. Cordioli. 2010. Caratterizzazione genomica di ceppi del virus della malattia di Gumboro isolati in Italia nel periodo 2006–2009. *Atti della Società Italiana di Patologia Aviaria.* 199–203.
25. Mundt, E., J. Beyer and H. Miiller. 1995. Identification of a novel viral protein in infectious bursal disease virus-infected cells. *J Gen Virol.* 76:437-443.
26. Nagarajan, M.M., and F.S. Kibenge. 1997. Infectious bursal disease virus: a review of molecular basis for variations in antigenicity and virulence. *Can J Vet Res.* 61:81-88.

27. Paradis, E., J. Claude, and K. Strimmer. 2004. APE: Analyses of Phylogenetics and Evolution in R language. *Bioinformatics*. 20:289-290.
28. Price, M.N., P.S. Dehal, and A.P. Arkin. 2010. FastTree 2—approximately maximum-likelihood trees for large alignments. *PloS one*. 5:e9490.
29. Rinaldi, A., G. Cervio, and G. Mandelli. 1965. Comparsa di una nuova forma morbosa dei polli negli allevamenti avicoli della Lombardia verosimilmente identificabile con la cosiddetta Malattia di Gumboro. *Selezione Veterinaria*. 6:207-209.
30. Senne, D.A. 2008. Virus propagation in embryonating eggs. Pages 204-208 in *A Laboratory Manual for the Isolation, Identification and Characterisation of Avian Pathogens*. 5th edn. L. Dufour-Zavala, D.E. Swayne, J.R. Glisson, J.E. Pearson, W.M. Reed, M.W. Jackwood, and P.R. Woolcock (Eds.). Madison, WI: American Association of Avian Pathologists.
31. Tamura, K., G. Stecher, D. Peterson, A. Filipski, and S. Kumar. 2013. MEGA6: molecular evolutionary genetics analysis version 6.0. *Mol Biol Evol*. 30:2725-2729.
32. Ture, O., and Y.M. Saif. 1992. Structural Proteins of Classic and Variant Strains of Infectious Bursal Disease Viruses. *Avian Dis*. 36:829-836.
33. Van Den Berg, T.P. 2000. Acute infectious bursal disease in poultry: a review. *Avian Pathol*. 29:175-194.
34. von Einem, U.I., A.E. Gorbalenya, H. Schirrmeier, S.-E. Behrens, T. Letzel and E. Mundt. 2004. VP1 of infectious bursal disease virus is an RNA-dependent RNA polymerase. *J Gen Virol*. 85:2221-2229.
35. Wang, X., H. Zhang, H. Gao, C. Fu, Y. Gao, and Y. Ju. 2007. Changes in VP3 and VP5 genes during the attenuation of the very virulent infectious bursal disease virus strain Gx isolated in China. *Virus Genes*. 34:67-73.
36. Wang, Y., X. Qi, Z. Kang, F. Yu, L. Qin, H. Gao, Y. Gao, and X. Wang. 2010. A single amino acid in the C-terminus of VP3 protein influences the replication of attenuated infectious bursal disease virus in vitro and in vivo. *Antivir Res*. 87:223–229.
37. Wei, YWei, Y., J. Li, J. Zheng, H. Xu, L. Li and L. Yu. 2006. Genetic reassortment of infectious bursal disease virus in nature. *Biochem. bioph. res. co*. 350:277–287.
38. Yu, F., X. Ren, Y. Wang, X. Qi, J. Song, Y. Gao, L. Qin, H. Gao and X. Wang. 2013. A single amino acid V4I substitution in VP1 attenuates virulence of very virulent infectious bursal disease virus (vvIBDV) in SPF chickens and increases replication in CEF cells. *Virology*. 440:204-209.

```

          10      20      30
    IBDV/Italy/1829/2011  ....|.....|.....|.....|.....|
D78  ----MVSRDQTNDRSDDKPARSNPTDCSVH
ViBursaCE  ----MVSRDQTNDRSDDKPARSNPTDCSVH
ViBursaG   ----MVSRDQTNDRSDDKPARSNPTDCSVH
Cu1        ----MVSRDQTNDRSDDKPARSNPTDCSVH
JD1        ----MVSRDQTNDRSDDKPARSNPTDCSVH
903 78    ----MVSRDQTNDRSDDKPARSNPTDCSVH
CEF94     ----MVSRDQTNDRSDDKPARSNPTDCSVH
Gt        ----MVSRDQTNDRSDDKPARSNPTDCSVH
CT        ----MVSRDQTNDRSDDKPARSNPTDCSVH
J1C7     ----MVSRDQTNDRSDDKPARSNPTDCSVH
IC-IBDV-Br ----MVSRDQTNDRSDDKPARSNPTDCSVH

          40      50      60
    IBDV/Italy/1829/2011  ....|.....|.....|.....|.....|
D78  ----TEPSDANNRIGVHSGRHPGEAH.....
ViBursaCE  ----TEPSDANNRIGVHSGRHPGEAH.....
ViBursaG   ----TEPSDANNRIGVHSGRHPGEAH.....
Cu1        ----TEPSDANNRIGVHSGRHPGEAH.....
JD1        ----TEPSDANNRIGVHSGRHPGEAH.....
903 78    ----TEPSDANNRIGVHSGRHPGEAH.....
CEF94     ----TEPSDANNRIGVHSGRHPGEAH.....
Gt        ----TEPSDANNRIGVHSGRHPGEAH.....
CT        ----TEPSDANNRIGVHSGRHPGEAH.....
J1C7     ----TEPSDANNRIGVHSGRHPGEAH.....
IC-IBDV-Br ----TEPSDANNRIGVHSGRHPGEAH.....

          70      80      90
    IBDV/Italy/1829/2011  ....|.....|.....|.....|.....|
D78  ----QFDGGGHRVRAKCLFVWIPWLNCGSLHTA
ViBursaCE  .....R.....
ViBursaG   .....R.....
Cu1        .....
JD1        .....
903 78    .....
CEF94     .....
Gt        .....
CT        .....
J1C7     .....R.....
IC-IBDV-Br .....

          100     110     120
    IBDV/Italy/1829/2011  ....|.....|.....|.....|.....|
D78  ----EQWELQVRS DAPDCPEPTGQLQLQASESE
ViBursaCE  .....
ViBursaG   .....
Cu1        .....
JD1        .....
903 78    .....
CEF94     .....
Gt        G.....
CT        G.....
J1C7     .....
IC-IBDV-Br .....

          130     140
    IBDV/Italy/1829/2011  ....|.....|.....|.....|.....|
D78  ----SHSEVKHIPWVRLCTKWHHKRDLPRKPE
ViBursaCE  .....S.....R.....
ViBursaG   .....K.....R.....
Cu1        .....S.....R.....
JD1        .....S.....R.....
903 78    .....S.....R.....
CEF94     .....S.....R.....
Gt        .....S.....R.....
CT        .....S.....R.....
J1C7     .....S.....R.....
IC-IBDV-Br .....S.....R.....

```

Supplementary Figure 1. Alignment of the VP5 IBDV/Italy/1829/2011-deduced AA sequence with VP5 sequences of the IBDV reference strains representing the attenuated strains.

```

                                10      20      30
IBDV/Italy/1829/2011  ....|....|....|....|....|
F52 70                ----MVG RDQTNDRSDDKPARSNPTDCSVH
STC                    ----MVS RDQTNDRSDDKPARSNPTDCSVH
CS-2-35                ----MVS RDQTNDRSDDKPARSNPTDCSVH

                                40      50      60
IBDV/Italy/1829/2011  ....|....|....|....|....|
F52 70                TEP SDANNRTGVHSGRHPGEAH.....
STC                    TEP SDANNRTGVHSGRHPGEAH.....
CS-2-35                TEP SDANNRTGVHSGRHPGEAH.....

                                70      80      90
IBDV/Italy/1829/2011  ....|....|....|....|....|
F52 70                QFD CGGHRVRANCLF PWI PWLNCGCSLHTA
STC                    .....
CS-2-35                .....

                                100     110     120
IBDV/Italy/1829/2011  ....|....|....|....|....|
F52 70                EQWELQVRS DAPDCPEPTGQLQLLQASESE
STC                    .....T.....
CS-2-35                ...P.....

                                130     140
IBDV/Italy/1829/2011  ....|....|....|....|....|
F52 70                SHSEVKHTPWWRLCTKWHHKRRDLPRKPE
STC                    .....R.....
CS-2-35                .....R.....
                        .....S.....R.....

```

Supplementary Figure 2. Alignment of the VP5 IBDV/Italy/1829/2011-deduced AA sequence with the VP5 sequences of the IBDV reference strains representing the classic strains.

```

          10      20      30
IBDV/Italy/1829/2011  ....|....|....|....|....|
Variant E            -----
GLS                  ----MVSRDQTINDRSDDKPARSNPTDCSVH
                    ----MVSRDRTINDRSDDKPARSNPTDCSVH

          40      50      60
IBDV/Italy/1829/2011  ....|....|....|....|....|
Variant E            -----SQVRDLDL
GLS                  TEPSDANNRTGVHSGRHPGEAH.....
                    TEPSDANNRTGVHSGRHPGEAH.....

          70      80      90
IBDV/Italy/1829/2011  ....|....|....|....|....|
Variant E            QFDCGGHRVRANCLFPWIPWLNCGCSLHTA
GLS                  .....
                    .....

          100     110     120
IBDV/Italy/1829/2011  ....|....|....|....|....|
Variant E            EQWELQVRS DAPDCPEPTGQLQLLQASESE
GLS                  .....
                    .....

          130     140
IBDV/Italy/1829/2011  ....|....|....|....|....|
Variant E            SHSEVKHTPWWRLCTKWHHKRRDLPRKPE
GLS                  ...K.....R.....
                    ...K.....R.....

```

Supplementary Figure 3. Alignment of the VP5 IBDV/Italy/1829/2011-deduced AA sequence with the VP5 sequences of the IBDV reference strains representing the variant strains.

```

                                10      20      30
IBDV/Italy/1829/2011  ....|....|....|....|....|
Gx  ----MVS RDQTNDRS DDEPARSNPTDCSVH
OKYM ----MVS RDQTNDRS DDEPARSNPTDCSVH
GZ 96  MLSIMVSRDQTNDRS DDEPARSNPTDCSVH
UPM94 273  MLSIMVSRDQTNDRS DDKPARSNPTDCSVH
UK661  MLSIMVSRDQTNDRS DDKPARSNPTDCSVH
ks  MLSIMVSRDQTNDRS DDKPARSNPTDCSVH
PO7  -----DDKPARSNPTDCSVY
CAHFS_K669  MLSIMVSRDQTNDRS DDKPARSNPTDCSVH

                                40      50      60
IBDV/Italy/1829/2011  ....|....|....|....|....|
Gx  TEP SDANNRTGVHSGRHPREAH.....
OKYM TEP SDANNRTGVHSGRHPREAH.....
GZ 96  TEP SDANNRTGVHSGRHPREAH.....
UPM94 273  TEP SDANNRTGVHSGRHPREAH.....
UK661  TEP SDANNRTGVHSGRHPREAH.....
ks  TEP SDANNRTGVHSGRHPREAH.....
PO7  TEP SDANNRTGVHSGRHPREAH.....
CAHFS_K669  TEP SDANNRTGVHSGRHPREAH.....

                                70      80      90
IBDV/Italy/1829/2011  QFD CGGHRVRANCLFPWI PWLNGC CSLHTA
Gx  .....F.....
OKYM .....F.....
GZ 96  .....F.....
UPM94 273  .....F.....
UK661  .....L.....
ks  .....F.....
PO7  .....F.....
CAHFS_K669  .....F.G.....


                                100     110     120
IBDV/Italy/1829/2011  EQWELQVRS DAPDCPEPTGQLQLLQASESE
Gx  .....G.....
OKYM .....G.....
GZ 96  .....G.....
UPM94 273  .....G.....
UK661  .....G.....
ks  .....G.....
PO7  .....G.....
CAHFS_K669  .....G.....

                                130     140
IBDV/Italy/1829/2011  SHSEVKHTPWWRLCTKWHHKRRDLPRKPE
Gx  .Y.....
OKYM .....Y.....
GZ 96  .Y.....
UPM94 273  .....Y.....
UK661  .....Y.....
ks  .....Y.....
PO7  .....Y.....
CAHFS_K669  .....Y.....

```

Supplementary Figure 4. Alignment of the VP5 IBDV/Italy/1829/2011-deduced AA sequence with the VP5 sequences of the IBDV reference strains representing the vvIBDV strains.





Supplementary Figure 5. Alignment of the deduced amino acid sequences of VP2 (1-512 amino acids of polyprotein), VP4 (513-755 amino acids of polyprotein) and VP3 (756-1012 amino acids of polyprotein) of the IBDV/Italy/1829/2011 strain with the corresponding sequences of the IBDV reference strains representing the attenuated strains.

```

10 20 30 40 50 60 70 80
IBDV/Italy/1829/2011 .....LRSETSTCNLTVGDTESGLIVFFPGFPGSIVGAHTLQSHGWY
FS2 70 MNLQDQQTQIVFFIRSLMPTTGPASIPDPTLEKHT.....Y.....G.....
STC MNLQDQQTQIVFFIRSLMPTTGPASIPDPTLEKHT.....Y.....G.....L
CS-2-35 MNLQDQQTQIVFFIRSLMPTTGPASIPDPTLEKHT.....Y.....G.....
GA-1 MNLQDQQTQIVFFIRSLMPTTGPASIPDPTLEKHT.....Y.....G.....

90 100 110 120 130 140 150 160
IBDV/Italy/1829/2011 KFDQMLLTAQLPASYNYCRILVRSRLTVRSSTLPGGVYALNGTINAVTFQGSLSLSTVYSVGLMSATANINDKIGNVLV
FS2 70 .....
STC .....
CS-2-35 .....
GA-1 .....

170 180 190 200 210 220 230 240
IBDV/Italy/1829/2011 GEGVTVLSLPTSDYDLYVRLGDIPIAIGLDPKVAATCDSRPRVYITTAADDYQFSHQHGGVYITLFSANIDAITSL
FS2 70 .....Y.F.....
STC .....Y.F.....
CS-2-35 .....Y.F.....
GA-1 .....Y.F.....

250 260 270 280 290 300 310 320
IBDV/Italy/1829/2011 SVGGELVFCQVSEKLDKQINLLEFGSSVITFAVASDRELTAGTDMKMFMLVLPFRETQPIPTSLKELIVTSKSGSQ
FS2 70 .....I.....QG.V.G.T.....TA.....A.....N.....
STC .....QG.V.G.T..F.....T.....A.....N.....V.....
CS-2-35 .....QG.V.G.T.....A.....AN.....T.....N.....
GA-1 .....WS.V.G.T.....T.....AN.....T.....N.....

330 340 350 360 370 380 390 400
IBDV/Italy/1829/2011 VGDQMSWSASGLAVTIHSGMYFGALRFVTLVAVRVARQGVVTVAGVNFELIPNPELAKNLVTVYGFDPGAMNITKL
FS2 70 .....A.....T.....
STC .....A.....T.....
CS-2-35 .....A.....R.....T.....
GA-1 .....A.....R.....T.....

410 420 430 440 450 460 470 480
IBDV/Italy/1829/2011 ILSERDRLGKTVWFTREYTFDEREYFNEVDLNSFLKTAGAFKFDIIRAIRRIAVPVVSLFPAAFLAHAGEVDYL
FS2 70 .....
STC .....
CS-2-35 .....
GA-1 .....

490 500 510 520 530 540 550 560
IBDV/Italy/1829/2011 LGDEQAASQTRAAASGKARASGRILQRLTLADKGYEVVANLFQVFNQVVDGLLASKGLVLAHNLDCVLRGATLFF
FS2 70 .....
STC .....
CS-2-35 .....
GA-1 .....

570 580 590 600 610 620 630 640
IBDV/Italy/1829/2011 VVITTVEDAMTEKALNSKMFVAVIGVREDLQFPPSQGSEIRTLSGHVVGYAPDGLPLETGRDYTVVPIDDVWDSIML
FS2 70 .....I.....
STC .....
CS-2-35 .....
GA-1 .....

650 660 670 680 690 700 710 720
IBDV/Italy/1829/2011 SRDPIEIVGNQNLAIAMVDFKVPFIHVAHTGALNAGSEIEKVFSPKLTATNHLGLKLAGPOTFDVNTGFHWMTF
FS2 70 .....R.....A.....
STC .....F.....A.....
CS-2-35 .....R.....A.....
GA-1 .....R.....A.....

730 740 750 760 770 780 790 800
IBDV/Italy/1829/2011 IKRFPHNFRDMLRPLYLNLPLYPNAGRQFHLAMASSEFKETFELESVRAAMEAANADFLQSAHSVPMLEENGIVTD
FS2 70 .....T.....D.....V.S.....
STC .....Y.....V.....
CS-2-35 .....Y.....V.....
GA-1 .....Y.....V.....

810 820 830 840 850 860 870 880
IBDV/Italy/1829/2011 MANFALSDFNHRNRLANAPQAGSKSQRAKYGTAGYGEARGPTPEEAQREKDTIRISKMETMGIFYFATPEHIALNGH
FS2 70 .....T.....V.....
STC .....A.....V.....
CS-2-35 .....V.....
GA-1 .....V.....

890 900 910 920 930 940 950 960
IBDV/Italy/1829/2011 RQSPGGLYQNTRETFDQNDVLYHNEKSRLASDGLLRRAATSTVGRFQGRFEPQAFIDEVAKVYELNHRGDFWGE
FS2 70 .....A.....E...K.....
STC .....E...K.....
CS-2-35 .....E...K.....
GA-1 .....E...K.....

970 980 990 1000 1010
IBDV/Italy/1829/2011 QMKDLLLTAMDKHRHRRFAPKPKPKFNAPVQRPGRGLGRWIRTVSDEDE
FS2 70 .....
STC .....L.....
CS-2-35 .....L.....
GA-1 .....L.....

```


Supplementary Figure 6. Alignment of the deduced amino acid sequences of VP2 (1-512 amino acids of polyprotein), VP4 (513-755 amino acids of polyprotein) and VP3 (756-1012 amino acids of polyprotein) of the IBDV/Italy/1829/2011 strain with the corresponding sequences of the IBDV reference strains representing the classic strains.

```


      10      20      30      40      50      60      70      80
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      90      100     110     120     130     140     150     160
IBDV/Italy/1829/2011 KFDQMLLTAQNLPASVNYCRLVSRSLTVRSSTLPGGVYALNGTINAVTFQGSLSLELTDVSYNGLMSATANINDKIGNVLV
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      170     180     190     200     210     220     230     240
IBDV/Italy/1829/2011 GEGVTVLSLPTSYDLGVYRGLDPIPAIGLDPKMVAATCDSSDRPRVYTTAADDYQFSSQHQGGVTVITFLSANIDAITSL
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      250     260     270     280     290     300     310     320
IBDV/Italy/1829/2011 SVGGELVFTSVESLKLDAISYLLIGFDGTVITRAVASDNGLTAGTDNLMFNLVIFPTSEITPITSIKLEIVTISKSGGQ
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      330     340     350     360     370     380     390     400
IBDV/Italy/1829/2011 VSDQMSWSASGSLAVTIHGGNYPGALREVLVAVERVAKGSVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKL
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      410     420     430     440     450     460     470     480
IBDV/Italy/1829/2011 ILSERDLGIRKTVWPTREYTFDFREYFMEVADLNSPLKIAAGAFGPKDIIAIRRIAVPVVSTLFPAAAPLAHAIGEGVDYL
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      490     500     510     520     530     540     550     560
IBDV/Italy/1829/2011 LSGDEAQAASGTARAASGKARAASGRIRQLTLAADKGYEVVANLFQVFQNFVVDGLASPGVLRGAHNLDCVLRGATLFP
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      570     580     590     600     610     620     630     640
IBDV/Italy/1829/2011 VVITTVEDAMTPKALNSKMFVIEGVREDLQPPSQRGSFIRTLSGHRVYGYADGVLPLETGRDYTVVPIDDVWDDSI
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      650     660     670     680     690     700     710     720
IBDV/Italy/1829/2011 SKDPIPIVGNISGLAIAYMDVFRPKVFIHVAMTGALNACGEIEKVSFSSFKLTAHRLGLKLAGPGETDVTNGTWNWATF
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      730     740     750     760     770     780     790     800
IBDV/Italy/1829/2011 IKRFPHNPRDWRGLPYLNLPLYLFPNAGRQFHLAMAASEFKETPELESAVRAMEAAANADPLFQSAISVFMLEENGIVTD
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      810     820     830     840     850     860     870     880
IBDV/Italy/1829/2011 MANFALSDPNAHRMRNFLANAPQAGSKSQRAKYGTAGYVGEARGFTPEEAQREKDRISKKMETMGIYFATPEWIALNGH
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      890     900     910     920     930     940     950     960
IBDV/Italy/1829/2011 RGFSPGQLKYWQNTREIPDNEDYLDYVHAEKSRLASDEQLRAATS IYGAPGQAEPPQAFIDEVAKVYIEINHGRGPNQE
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      970     980     990     1000    1010
IBDV/Italy/1829/2011 QMKDLLLTAMEMKHRNPRRAPPKPKPKENAPTQRPGRGLGRWIRTVSDDELE
Variant E .....|.....|.....|.....|.....|.....|.....|.....|
GLS .....|.....|.....|.....|.....|.....|.....|.....|

```

Supplementary Figure 7. Alignment of the deduced amino acid sequences of VP2 (1-512 amino acids of polyprotein), VP4 (513-755 amino acids of polyprotein) and VP3 (756-1012 amino acids of polyprotein) of the IBDV/Italy/1829/2011 strain with the corresponding sequences of the IBDV reference strains representing the variant strains.



Supplementary Figure 8. Alignment of the deduced amino acid sequences of VP2 (1-512 amino acids of polyprotein), VP4 (513-755 amino acids of polyprotein) and VP3 (756-1012 amino acids of polyprotein) of the IBDV/Italy/1829/2011 strain with the corresponding sequences of the IBDV reference strains representing the vvIBDV strains.



Supplementary Figure 9. Alignment of the VP1 IBDV/Italy/1829/2011-deduced AA sequence with the VP1 IBDV reference strains representing the attenuated strains.

```

      10      20      30      40      50      60      70      80
IBDV/Italy/1829/2011 MSDIFNSPQARSTISAAGIKPTAGQDVEELLIPKVVVPEEDPLASPSRLAKFLRENGVKVLRQSPRLPENEYETDQILP
f52 70 .....K.....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      90      100     110     120     130     140     150     160
IBDV/Italy/1829/2011 DLANMRQIDEGAVLAKFTLSLFIGDQEIFPKYPTHRPSEKKNAYFPDIALKQMIYLFQVPEATEGLADEVTLTQMR
f52 70 .....K.....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      170     180     190     200     210     220     230     240
IBDV/Italy/1829/2011 DKAYSGTYMGQATRLVAMKEVATGRNPNKDEPKLGYTFESLAQLDDITLTVGPFGEEDKFWVELTRVPSRMLVLTGVDD
f52 70 .....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      250     260     270     280     290     300     310     320
IBDV/Italy/1829/2011 GFEVEVDLPIKILKSSGLFVYVPTKSEYIGEMLAISNGFLRELSLTKQGMPTKSSKLLSLSYVYLSGLLFP
f52 70 .....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      330     340     350     360     370     380     390     400
IBDV/Italy/1829/2011 KAERYDKSTWLTKTRNIWSAPSPTHLMISMITWPFVMSNSFNVLNIGGCPSLYKFNPFSGGLNRIEVLPAPEEPKALY
f52 70 .....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      410     420     430     440     450     460     470     480
IBDV/Italy/1829/2011 ADNIYIVHNFWEIIDLKGEAKCTQKQKQAMWYLLTRGSDWGGPMQVWTFEMNIAADLVDSCLIMLQIKTY
f52 70 .....Y.....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      490     500     510     520     530     540     550     560
IBDV/Italy/1829/2011 GQSGNAATEINHHLLSTLVLDQWNLMRQSPDSEEFKSIEDKLGINFKERSIDDIRGLRQLVPLAQGYLGGVVEE
f52 70 .....R.....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      570     580     590     600     610     620     630     640
IBDV/Italy/1829/2011 HSPTEVLDLLGWSATYSKDLGIYVPLDKERLFCSAAYKGVENKSLKSKVGEIQAYKVRVEALRLVGGNNVPLMKA
f52 70 .....Q.....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      650     660     670     680     690     700     710     720
IBDV/Italy/1829/2011 CKNNAGAARRHLEAKGFPLDEFLEAWSSELSEFGEAFEGFNKILVTSLSLALNRPVFPKPNVNRPVNTGGLKAVSHL
f52 70 .....K.....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      730     740     750     760     770     780     790     800
IBDV/Italy/1829/2011 KTRGRYRNEAGLSGLVLLATARSRLQDAVKAKAEERLHKSKFDDPDADWFERSETLSDLLEKADIASKVAHSALVETSDA
f52 70 .....K.....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

      810     820     830     840     850     860     870
IBDV/Italy/1829/2011 LEAVQSTSVYTKYIEVKNEQTASNFVVGHLPAKRAVGVQALLGAGTSRFMGMEAPTRSKNAVMAKRRQRQKESR
f52 70 .....
CS-2-35 .....
cro-pa98 .....
Cu-1 .....
GA-1 .....

```


Supplementary Figure 10. Alignment of the VP1 IBDV/Italy/1829/2011-deduced AA sequence with the VP1 IBDV reference strains representing the classic strains.

```

      10      20      30      40      50      60      70      80
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E MSDIFNSPQARSTISAAFGIKPTAGQDVEELLIIPKVVVPPEDPLASPSRLAKFLRENGYKVLQPRSLPENEEYETDQILP
GLS .....K.....|.....|.....|.....|.....|.....|.....|.....|
      90      100     110     120     130     140     150     160
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E DLAWMRQIEGAVLKPTLSLPIGDQEFYFKYYPTHRPSKEKPNAYPPDIALLKQMIYLFLOVPEATEGLKDEVTLLTQNIR
GLS .....R.....|.....|.....|.....|.....|.....|.....|.....|
      170     180     190     200     210     220     230     240
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E DKAYGSGTYMGQATRLVAMKEVATGRNPNKDKPLKGYTFESIAQLLDITLVPVGGEDDKPWWPLTRVPSRMLVLTGDVD
GLS .....I.....|.....|.....|.....|.....|.....|.....|.....|
      250     260     270     280     290     300     310     320
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E GDFEVEDYLPKINLKSSSGLPYVGRTRKGETIGEMIAISNQFLRELS TLKQAGTGSNKKLLSMLS DYWYLS CGLLFP
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      330     340     350     360     370     380     390     400
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E KAERYDKSTWLTKTRNIWSAPSPTLHMISMITWVPMNS ENNVLNIEGCP SLYKFNFPRGGLNRIVEWLLAEEPKALVY
GLS .....|.....|.....|.....|.....|.....|.....|.....|
      410     420     430     440     450     460     470     480
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E ADNIIYVHSNTWFSIDLEKGEANCTRQHMQAAMYIILTRGWS DNGDFMNFQ TWATFAMNIA PALVVDSSCLIMNLQIKTY
GLS .....Y.....|.....|.....|.....|.....|.....|.....|.....|
      490     500     510     520     530     540     550     560
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E GQGSNAATFINNHLLSTLVLDQWNLMRQPS PDSEEFKSIEDKLGINFK IERSIDDIRGKLRQLVPLAQPGYLSGGVEPE
GLS .....M.....|.....|.....|.....|.....|.....|.....|.....|
      570     580     590     600     610     620     630     640
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E HSSPTVELDLLGWSATYSKDLGIYVFLDKERLFC SAAYFKGVENKSLKSKVGIEQAYRVVRYEALRLVGGWNYPLLNKA
GLS .....Q.....|.....|.....|.....|.....|.....|.....|.....|
      650     660     670     680     690     700     710     720
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E CRNNAGAARRHLEAKGFP LDEF LAEWS ELS EFG EAF EGF NIKL TVTSESLAELNRPVPPKPPNVNRPVNTGGLKAVSNAL
GLS .....R..I.....|.....|.....|.....|.....|.....|.....|.....|
      730     740     750     760     770     780     790     800
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E KTGRYRNEAGLSGLVLLATARSRLQDAVKAKAEERLHKS KPD DAD WFERSETLS DLLEKAD IASKVAHSALVETSDA
GLS .....K.....|.....|.....|.....|.....|.....|.....|.....|
      810     820     830     840     850     860     870
IBDV/Italy/1829/2011 .....|.....|.....|.....|.....|.....|.....|.....|
Variant E LEAVQSTSVYTPKYPEVKNPQTASNPVVGHLHPAKRATGVQAAL LGAGTSRPMGMEAPTRSKNAVKMAKRRQKQESR
GLS .....K..R.....|.....|.....|.....|.....|.....|.....|.....|


```

Supplementary Figure 11. Alignment of the VP1 IBDV/Italy/1829/2011-deduced AA sequence with the VP1 IBDV reference strains representing the variant strains.



Supplementary Figure 12. Alignment of the VP1 IBDV/Italy/1829/2011-deduced AA sequence with the VP1 IBDV reference strains representing the vvIBDV strains.





Supplementary Figure 13. Maximum likelihood (ML) phylogenetic tree reconstructed using partial VP2 alignment (399 nucleotides) after removal of the identical sequences. Clusters have been defined (renamed and color-coded) on the basis of a maximum genetic distance (i.e. p-distance among sequences < 0.01) and branch support (i.e. support > 0.8) thresholds. IBDV/Italy/1829/2011 (double asterisk).

# CHAPTER IV

## **Influences of swab types and storage temperatures on isolation and molecular detection of *Mycoplasma gallisepticum* and *Mycoplasma synoviae***

Christopher Ball<sup>a</sup>, Viviana Felice<sup>b</sup>, Anne Forrester<sup>a</sup>, Elena Catelli<sup>b</sup>, Kannan Ganapathy<sup>a</sup>

<sup>a</sup>University of Liverpool, Institute of Infection and Global Health, Leahurst Campus, Neston,

Cheshire, CH64 7TE, UK

<sup>b</sup> Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia (BO),  
Italy

\*Corresponding author Tel.: +44 151 7946019; fax: +44 151 7946005.

E-mail address: gana@liverpool.ac.uk

### **Abstract**

*Mycoplasma gallisepticum* (MG) and *Mycoplasma synoviae* (MS) are important poultry pathogens worldwide, which are responsible for substantial economic losses. Routine diagnosis is performed by collecting oropharyngeal swabs followed by isolation and/or detection by molecular methods. The storage temperature and the type of swabs could be critical factors for a successful isolation or molecular detection. The aim of this study was to compare the influence of different types of cotton tipped swabs stored at different temperatures on detection of MG and MS, by both culture and conventional or quantitative PCR. Performances of wooden and plastic shaft swabs, both without transport medium, were compared. MG PG31 and MS WVU 1853 strains were ten-fold diluted in broth. Swabs were dipped in each dilution, then incubated overnight at room temperature (RT) or at 4 °C before attempting the recovery of mycoplasma by culture or PCRs. Results suggest that swabs with plastic shaft should be preferred for MG and MS detection by both culture and PCR. While a lower storage temperature (4°C) is optimal for culture recovery, it seems that both temperatures investigated here are adequate for molecular detection.

Keywords: wooden swabs; plastic swabs; temperature; *Mycoplasma gallisepticum*; *Mycoplasma synoviae*; detections.

## **Introduction**

*Mycoplasma gallisepticum* (MG) and *Mycoplasma synoviae* (MS) are important poultry pathogens worldwide, responsible for substantial economic losses. Oropharyngeal swabs collected from suspected infected flocks are routinely analyzed to confirm the presence of mycoplasmas by culture and/or molecular methodology. Sample storage temperature and the type of swab could influence successful detection (Christensen et al., 1994; Zain and Bradbury, 1995; Zain and Bradbury, 1996; Daley et al., 2006; Ferguson-Noel *et al.*, 2012), where use of a suitable transport media (such as mycoplasma broth or charcoal) has been advised for transportation of samples.

As favorable transportation of samples for culturing may be the most important factor affecting successful detection of mycoplasmas (Drake *et al.*, 2005), it is important to consider for field samples arriving at the laboratory 1-2 days after sampling. For PCR detection of MG or MS, the results can be influenced by various factors, including amount of DNA recovered which could depend on type of swabs used, as well as the DNA extraction method (Brownlow *et al.*, 2012).

The aim of this study is to compare two types of dry cotton swabs (wooden *versus* plastic shafts) which were stored at two different temperatures. The influences of these factors on detection of MG and MS by isolation, conventional and real-time PCR were assessed.

## **Materials and methods**

### ***Mycoplasma* strains and culture**

Two mycoplasma type strains were used throughout the study: MG PG31 and MS WVU 1853. Both strains were titrated using the viable counts method according to Miles *et al.* (1938) and expressed as colony-forming units (CFU)/ml. Briefly, strains were ten-fold diluted up to  $10^{-7}$  in mycoplasma broth (MB), then 100  $\mu$ l of each strain dilution were inoculated onto mycoplasma agar (MA) plates, using one plate per dilution. Both broth and agar media were prepared as previously reported (Bradbury, 1977; Zain and Bradbury, 1995). The plates were incubated at 37 °C in 5% CO<sub>2</sub> incubator for 7 days before colonies were counted using a dissecting microscope. Titres were determined as  $1.63 \times 10^8$  and  $4.7 \times 10^7$  CFU/ml for MG and MS respectively.

### **Swabs**

The performances of the following types of cotton tip dry swabs without transport medium were compared: wooden shaft and plastic shaft (Alpha Laboratories, Ltd, UK). For each mycoplasma species four sets of each type of swab were used for culture or molecular analysis: two sets were stored at +4°C and the other two sets at room temperature (21-23 °C) overnight. Each set consisted

of 8 swabs. In addition, cotton swabs with plastic shaft in Amies charcoal transport medium (Deltalab, Barcelona, Spain) were used for comparison.

### **Experimental design**

MG and MS stock cultures with known titres were serially diluted (neat to  $10^{-7}$ ). Each series of wooden or plastic swabs, as well as the charcoal media swabs, were dipped into these broth dilutions for 15 seconds. Subsequently, swabs were storage overnight at either room temperature (RT) or at 4 °C. Then MG and MS recovery was attempted by culture and molecular methods (see below). The experiment was repeated in triplicate.

### **Mycoplasma recovery by culture**

Following storage at different temperatures overnight, each of the swabs were plated onto MA and incubated at 37 °C in a 5% CO<sub>2</sub> incubator. After 7 days of incubation, colonies were quantified using a score from 0 to 4 as previously described (Ley *et al.*, 2003).

### **Molecular detection of mycoplasmas**

Swabs intended for mycoplasma molecular detection were dipped into 600 µl of working solution D (4M guanidinium thiocyanate, 25mM sodium citrate, pH 7; 0.5% sarcosyl, 0.1M 2-mercaptoethanol) (Chomczynski and Sacchi, 2006) and stored at -20 °C for a minimum of three hours. DNA was then extracted using the DNA Mini kit (Qiagen, UK) according to manufacturer's instructions and stored at -20 °C until use. The extracted DNAs were tested using a duplex PCR targeting the MG *mgc2* gene and the MS *vlhA* gene (Moscoso *et al.*, 2004). DNAs were also tested in duplicate using a commercial quantitative PCR (qPCR) kit for both MG and MS detection (BioChek, Netherlands) on the Rotor-gene Q platform (Qiagen, UK). Obtained Ct values were compared against a previously established standard curve (data not shown) of known concentrations, where relative log REU values were obtained.

### **Statistical analysis**

Detection limits obtained from both culture or conventional PCR were analyzed to identify statistically significant differences using Student *t*-test. A P-value <0.05 was considered statistically significant.

## Results

### Mycoplasma recovery by culture

*M. gallisepticum*: Culture of MG from swabs stored at RT showed that recovery was significantly more efficient for plastic ( $7.62 \times 10^2$  CFU/ml) than wooden ( $3.49 \times 10^5$  CFU/ml) swabs ( $p=0.005$ ) (Figure 1A). Plastic swabs also had the greatest detection ability for MG culture from swabs stored at 4 °C ( $3.49 \times 10^2$  CFU/ml) compared to RT ( $7.62 \times 10^2$  CFU/ml) (Figure 1A) though there were no significant differences.

*M. synoviae*: We were able to isolate MS to a minimum of  $4.7 \times 10^3$  CFU/ml from plastic and wooden swabs stored at 4°C and plastic swabs stored at RT. No MS were isolated from wooden swabs stored at RT (Figure 1B).

### Molecular detection of mycoplasmas

*M. gallisepticum*: PCR detection limit was on average significantly lower for plastic ( $3.49 \times 10^3$  CFU/ml) compared to wooden ( $7.62 \times 10^4$  CFU/ml) swabs when stored at RT ( $p=0.013$ ) (Figure 1C), whereas both swab types stored at 4 °C showed no difference in detection limits (Figure 1C). The MG qPCR assay had greater detection capability when applied to plastic swabs stored at RT ( $1.63 \times 10^4$  CFU/ml) compared to wooden swabs ( $1.63 \times 10^5$  CFU/ml), however similar to PCR data, both swab types showed the same sensitivity at 4 °C (Figure 1E).

*M. synoviae*: By PCR, plastic swabs showed an average positive result up to a lower concentration compared to wooden swabs when stored at 4 °C ( $4.7 \times 10^5$  CFU/ml and  $1 \times 10^6$  CFU/ml) and a significantly lower result when stored at RT ( $1 \times 10^5$  CFU/ml and  $2.2 \times 10^6$  CFU/ml respectively) (Figure 1D). In contrast, the MS qPCR showed the same detection sensitivity for both type of swabs at RT ( $1 \times 10^4$  CFU/ml), but a greater efficiency when applied to plastic swabs at 4°C (plastic =  $2.2 \times 10^3$  CFU/ml; wooden =  $4.7 \times 10^3$  CFU/ml) (Figure 1F).

## Discussion

Typically, when potentially infected poultry or game birds are sampled for mycoplasma detection, cotton tipped swabs are transported to the laboratory by the following day. While it is advised that transportation should also include ice or a cold pack to preserve sample integrity, it may not always be possible. For this reason, we investigated the influences of overnight storage at two temperatures (4°C and room temperature) on recovery of MG and MS using molecular and traditional culture methodologies.

Findings from this study showed dry plastic and charcoal swabs (both having plastic shaft) to have similar ability for detecting either MG or MS via culture when stored at RT. In contrast, when stored

at 4 °C, the dry swabs were significantly more effective for culturing MG compared to those with charcoal, whereas charcoal swabs had a significantly greater sensitivity for culturing MS compared to the dry swabs. The charcoal swabs also had a significantly greater ability for culturing both MG and MS compared to wooden dry swabs when stored at RT and 4°C. Interestingly there was no difference in ability between the charcoal and wooden swabs when culturing MG at 4 °C. There was also no difference between plastic and wooden dry swabs when stored at 4°C, suggesting that transporting swab samples back to the laboratory on ice to be important for successful detection. In the current study, plastic swabs showed a greater ability of recovery of MG by culturing when stored at 4°C than at RT, similar to data previously reported by Zain and Bradbury (1996).

In this study, the charcoal swabs showed a similar level of detection, irrespective of the storage temperature, perhaps due to the preserving properties of charcoal medium negating the effects of temperature fluctuations. The type of transport media and swab type used for sample preservation has shown to vary in ability to culture both aerobic and anaerobic bacteria (Tan *et al.*, 2014), with a possible reduction in recovery ability after 24 hours (Roelofsen *et al.*, 1999). In the current study, samples were processed within 24 hours of storage, which could perhaps be extended over a longer duration to assess the ability of charcoal medium in supporting the survivability of MG or MS.

On culture of mycoplasmas, it appears that for both MG and MS, samples collected using wooden swabs and stored at RT could be detrimental for detection of these organisms, either by isolation or PCR, in particular for MS. In this study, although reduced number of colonies were recovered for MG, there were absolutely no colonies recovered for MS in wooden swabs that were stored at RT. Similarly, reduced levels of MG or MS detection were found in wooden swabs stored at RT when detection was attempted by PCR. The worse performance of the wooden swabs could be explained taking into account that the wood could offer a greater surface area due to its porosity and desiccation properties (Ismail *et al.*, 2013), therefore the wooden shaft may have absorbed more amount of Mycoplasma inoculated broth than plastic shaft.

Moreover, the growth rate and viability of MG and MS can be also affected by the pH of the broth (Lin *et al.*, 1983; Ferguson-Noel *et al.*, 2013) and it was previously hypothesized that greater humidity and lower temperature protected against the effect of low pH (Zain and Bradbury, 1996). This could be particularly true for MS, which may no longer be viable under a low pH (Ferguson-Noel *et al.*, 2013). In the present study, the broth pH was not measured during incubation, an alteration in pH alongside the difference in physical features of the wooden compared to the plastic shaft (Ismail *et al.*, 2013) may have contributed to the absence of recovery of MS colonies from wooden swabs, when stored at RT.


The greatest sensitivity was detected using molecular methods for detecting MG from plastic swabs at RT. This could be related to permissive mycoplasma growth temperatures, which ranged from 20

to 45°C (Brown *et al.*, 2011). Previous work has reported that MG grown in mycoplasma broth and incubated at room temperature initially shows an increased titre up to 8 hours post inoculation, followed by a rapid decline in viability (Christensen *et al.*, 1994). Additionally, Zain and Bradbury (1996) demonstrated that the viability of MG on wet swabs reduces following 4 h of incubation at 24-26 °C. In the present study, molecular data showed that while the total genomic presence (viable and non-viable) increased, the actual viability decreased when swabs were stored at RT.

In conclusion, results from the current study suggest that swabs with plastic shaft should be preferred for MG and MS detection by both culture and PCR. While a lower storage temperature (4°C) is better for culture recovery, it seems that both temperatures investigated here are adequate for molecular detection.

### **Acknowledgement**

The authors would like to thank BioChek for the qPCR kits that were used for this study.



**Figure 1.** Comparison of each swab type following storage at different temperatures. (A) Culture efficiency for MG; (B) Culture efficiency for MS; (C) PCR detection of MG; (D) PCR detection of MS; (E) qPCR detection of MG; (F) qPCR detection of MS. Data shown as mean of the highest dilution producing a positive culture result. Groups with the notation differ significantly ( $p < 0.05$ ) either within the same temperature (a) or between different temperatures (x)



## REFERENCES

1. Bradbury J.M., 1977. Rapid Biochemical Tests for Characterization of the Mycoplasmatales. *J. of Clin. Microbiol.* 5, 531-534.
2. Brown D.R., May M., Bradbury J.M., Balish M.F., Calcutt M.J., Glass J.I., Tasker S., Messick J.B., Johansson K-E, Neimark H. 2011. Genus I. *Mycoplasma*. In: Krieg N.R., Staley J.T., Brown D.R., Hedlund B.P., Paster B.J., Ward N.L, Ludwig W. and Whitman W.B. (Eds.), *Bergey's Manual of Systematic Bacteriology*, Springer New York Dordrecht Heidelberg London, pp. 575-611.
3. Brownlow R.J., Dagnall K., Ames C.E., 2012. A comparison of DNA collection and retrieval from two swab types (cotton and nylon flocked swab) when processed using three Qiagen extraction methods. *J forensic sci.* 57, 713-717.
4. Chomczynski P, Sacchi N. 2006. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. *Nat Protoc.*; 1(2): 581-5.
5. Christensen N.H., Christine A.Y., McBain A.J., Bradbury J.M., 1994. Investigations into the survival of *Mycoplasma gallisepticum*, *Mycoplasma synoviae* and *Mycoplasma iowae* on materials found in the poultry house environment. *Avian Pathol.* 23, 127-143.
6. Daley P, Castriciano S, Chernesky M, Smieja M., 2006. Comparison of flocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients. *J Clin Microbiol.* Jun; 44(6):2265-7.
7. Drake C., Barenfanger J., Lawhorn J., Verhulst S., 2005. Comparison of easy-flow Copan liquid Stuart's and Starplex swab transport system for recovery of fastidious aerobic bacteria. *J. of Clin. Microbiol.* 43, 1301-1303.
8. Ferguson-Noel N. and Noormohammadi A. H., 2013. *Mycoplasma synoviae* infection. In: Swayne D.E., Glisson J.R., McDougald L.R., Nolan L.K., Suarez D.L., Venugopal N. (Eds.), *Disease of Poultry - Wiley-Blackwell by John Wiley & Sons, Inc., AAAP, Ames, Iowa.* pp.900-906.

9. Ferguson-Noel N., Laibinis V.A., Farrar M., 2012. Influence of swab material on the detection of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* by Real-Time PCR. *Avian Dis.* 56, 310–314.
10. Ismaïl R., Aviat F., Michel V., Le Bayon I., Gay-Perret P., Kutnik M., Fédérighi M. 2013. Methods for recovering microorganisms from solid surfaces used in the food industry: A review of the literature. *Int. J. Environ. Res. Public Health.* 10, 6169-6183.
11. Ley D.H. and Yoder H. W., 2003. *Mycoplasma gallisepticum* infection. In: B. W. Calneck ed. Mosby-Wolfe (Eds.), *Diseases of Poultry*. Ames. pp 194-207.
12. Lin M. Y., Kleven S. H., 1983. Improving the *Mycoplasma gallisepticum* and *M. synoviae* antigen yield by readjusting the pH of the growth medium to the original alkaline state. *Avian Dis.* 28, 266-272.
13. Miles A. A., Misra S. S., Irwin J. O., 1938. The estimation of the bactericidal power of the blood. *J. Hyg. (Lond.)* 38(6), 732-49.
14. Moscoso H., Thayer S. G., Hofacre C. L., Kleven S. H., 2004. Inactivation, storage, and PCR detection of *Mycoplasma* on FTA® Filter Paper. *Avian Dis.* 48, 841-850.
15. Roelofsen, E., van Leeuwen, M., Meijer-Severs, G.J., Wilkinson, M.H., Degener, J.E., 1999. Evaluation of the effects of storage in two different swab fabrics and under three different transport conditions on recovery of aerobic and anaerobic bacteria. *Journal of clinical microbiology* 37, 3041-3043.
16. Tan, T.Y., Yong Ng, L.S., Fang Sim, D.M., Cheng, Y., Hui Min, M.O., 2014. Evaluation of bacterial recovery and viability from three different swab transport systems. *Pathology* 46, 230-233.
17. Zain Z.M., Bradbury J.M., 1995. The influence of type of swab and laboratory method on the recovery of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* in broth medium. *Avian Pathol.* 24, 707-716.
18. Zain Z.M., Bradbury J.M., 1996. Optimising the conditions for isolation of *Mycoplasma gallisepticum* collected on applicator swabs. *Vet. Microbiol.* 49, 45-57.

# CHAPTER V

## **Gene targeted sequencing analysis of *Mycoplasma gallisepticum* strains in commercial poultry flocks from Middle East and South Asia**

Viviana Felice<sup>\*1</sup>, Christopher Ball<sup>§</sup>, Kannan Ganapathy<sup>§</sup>, Elena Catelli<sup>\*</sup>, Antonietta Di Francesco<sup>\*</sup>

<sup>\*</sup>Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia (BO), Italy

<sup>§</sup>Institute of Infection and Global Health, University of Liverpool, Leahurst Campus, Neston, Cheshire CH64 7TE, UK.

<sup>1</sup>Corresponding author: Viviana Felice

Department of Veterinary Medical Sciences, University of Bologna, Via Tolara di Sopra, 50, 40064 Ozzano dell'Emilia (BO), Italy.

Full telephone: 0039 0512097559

E-mail address: [viviana.felice@gmail.com](mailto:viviana.felice@gmail.com)

## ABSTRACT

The aim of this study was to attempt the molecular characterization of *Mycoplasma gallisepticum* (MG) strains detected in chicken flocks from Middle East and South Asia, by gene-targeted sequencing (GTS) analysis of MG surface-protein genes. Between 2012 and 2015, samples from one layer flock from the United Arab Emirates (UAE), three breeder flocks from Saudi Arabia (SAU) and one broiler flock from Sri Lanka (SL) were submitted for MG molecular testing. All samples were first screened using a PCR targeting a partial sequence of the *mgc2* gene; the positive samples were characterized by GTS analysis amplifying MGA\_0319, *mgc2*, *gapA* and *pvpA* gene fragments. BLAST comparisons, followed by phylogenetic analysis, was carried out to compare against published vaccine and field strain sequences. Strains detected in ts-11 vaccinated breeders from SAU showed 100% sequence identity with the applied vaccine, based on GTS analysis. Strains detected in layers in UAE, despite birds also being vaccinated were found to be field strains, clustering together with Israeli MG strains, using concatenated GTS sequences. Strains from Sri Lanka broilers clustered separately from USA, Israeli, Australian, vaccine and reference strains. To our knowledge, this study reports the first molecular characterization of MG strains by GTS analysis from commercial poultry in SAU, UAE and SL.

Keywords: *Mycoplasma gallisepticum*; Gene targeted sequencing; Middle East; South Asia

## INTRODUCTION

*Mycoplasma gallisepticum* (MG) is the most important and economically significant mycoplasma in the poultry industry worldwide. It causes chronic respiratory disease in chickens and infectious sinusitis in turkeys. Common approaches to prevent MG infections consist of either maintaining infection-free breeder flocks through the use of strict biosecurity measures, continuous monitoring and vaccination in areas where complete eradication is difficult to attain (Raviv and Ley, 2013). Early detection of MG is essential to implement the correct management measures needed to manage and prevent the spread of infection. In this regard, molecular methods are largely used instead of culture, taking into account the slow growth of mycoplasmas and the frequent overgrowth of other mycoplasma species such as *Mycoplasma gallinarum* and *Mycoplasma gallinaceum* (Kleven, 2008). Since the development and application of live MG vaccines, several molecular techniques for MG strain differentiation have been reported, including restriction fragment length polymorphism (Kiss et al., 1997), random amplified polymorphic DNA (RAPD) (Fan et al., 1995), amplified fragment length polymorphism (Hong et al., 2005), sequencing of the 16S and 23S rRNA intergenic spacer region (IGSR) (Raviv et al., 2007), gene-targeted sequencing (GTS) analysis (Ferguson-Noel et al., 2005) and recently *vlhA* and *pvpA* gene-based real time PCRs (Ghorashi et al., 2010; Ghorashi et al., 2013) or a combination of PCRs targeting *vlhA3.05*, *mg0359* and *vlhA3.04a* genes (Ricketts et al., 2017). A GTS assay targeting portions of putative cytoadhesin genes (*pvpA*, *gapA* and *mgc2*) and an uncharacterized hypothetical surface lipoprotein-encoding gene, designated coding DNA sequence (CDS) MGA\_0319, has been reported as an accurate and reproducible method of typing MG strains (Ferguson-Noel et al., 2005). A major benefit of this approach is that the GTS method allows the development of a reference database and standardized global comparisons between laboratories (Ferguson-Noel et al., 2005; Armour et al., 2013). The aim of this study was to characterize circulating MG strains using the GTS method for samples derived from different farms in different countries, and to cross-compare it against available sequences in the Gen-Bank.

## MATERIAL AND METHODS

### *Samples*

Between 2012 and 2015, samples from a number of countries, including UAE (layer - flock A), SAU (breeder - flocks B, C and D) and Sri Lanka (broiler - flock E) were submitted to the University of Liverpool for MG molecular testing. Birds from flocks A, B and C were sampled at two separate time points. Samples consisted of tracheal swabs (flocks B, C and D) or tissue samples (trachea, lung,

turbinates and kidneys) embedded onto Flinders Technology Association (FTA) cards (Flock A and E) (Table 1). Clinical signs attributable to MG infection were reported in flock A and E prior to sampling. The breeder and layer flocks were reported to have received the live ts-11 MG vaccine.

### ***DNA extraction***

Swabs or individual circles from FTA card were placed into 600 µl or 1.5 ml of working solution D (4M guanidinium thiocyanate, 25mM sodium citrate, pH 7; 0.5% sarcosyl, 0.1M 2-mercaptoethanol) (Chomczynski and Sacchi, 2006) respectively, then stored at –20 °C for a minimum of three hours. DNA was extracted using the DNA Mini kit (Qiagen, Germany) according to manufacturer's instructions and stored at –20 °C until use.

### ***Molecular detection and differentiation of MG***

The extracted DNAs were first analyzed using a PCR assay targeting a 237-303 bp fragment of the proline-rich domain of the *mgc2* adhesin-encoding gene (**pr-*mgc2***) of MG (Moscoso et al. 2004). Pr-*mgc2* positive DNA samples were further characterized by GTS analysis (Ferguson-Noel et al. 2005), targeting the following genes: MGA\_0319 (590 bp), *mgc2* (824 bp), *gapA* (332 bp) and *pvpA* (702 bp). A single sample was selected for each sample point (Table 1) for molecular characterization. A modified forward *pvpA*3F (5'-GGYAGTCCTAAGTTATTWGGTC-3') (Liu et al. 2001) primer was used in substitution for *pvpA* amplification (497pb), to improve the success of detection.

### ***DNA sequencing and phylogenetic analysis***

Pr-*mgc2* and all targeted gene (MGA\_0319, *mgc2*, *gapA* and *pvpA*) amplicons were submitted for commercial bi-directional sequencing (Macrogen, Spain). Each sequence was edited and assembled using Bioedit, then BLAST comparisons were made with corresponding MG sequences available in GenBank (NCBI). Multigene sequences (*mgc2/pvpA/MGA\_0319/gapA*) were aligned using Clustal V, concatenated and a Neighbor-Joining dendrogram was constructed in MEGA6 (Tamura et al., 2013) including field and vaccines MG strains retrieved from GenBank (Table 2). Bootstrap values, obtained with 1000 replicates, were considered significant when >70.

## RESULTS AND DISCUSSION

From 55 submitted samples, 50 were MG positive by *pr-mgc2* PCR (Table 1). *Pr-mgc2* sequences showed samples from the same country of origin to form distinct clusters (SAU, UAE and SL) (data not shown).

The GTS analysis was performed on a representative strain from each sampled flock, confirming the clustering of sequences according to the country of origin. Strains included in the analysis were UAE/10/CK/12/44wks and UAE/10/CK/12/64wks (flock A), SAU/19/CK/15/19wks and SAU/19/CK/15/32wks (flock B), SAU/25/CK/15/16wks and SAU/25/CK/24wks (flock C), SAU/28/CK/15/32wks (flock D) and SL/1/CK/15 (flock E).

MGA\_0319, *mgc2*, *gapA* and *pvpA* gene sequences were obtained from all strains with the exception of UAE/10/CK/12/44wks and UAE/10/CK/12/64wks for which the sequencing of the *pvpA* gene was unsuccessful. Based on nucleotide identity, one representative sequence for Country was submitted to GenBank (Table 3).

The five SAU strains, all from ts-11 vaccinated breeders, clustered with the ts-11 vaccine strain (figure 1), demonstrating 100% sequence identity in all analyzed genes to each other and the ts-11 vaccine. Both an increase in vaccine virulence, and vertical transmission of ts-11 vaccine has been previously reported (El Gazzar et al., 2011; Armour and Ferguson, 2015). However, the absence of typical MG clinical signs suggests that our detections are not likely to be revertants. To further determine the relationship between our vaccine-like detections to the vaccine applied, extensive genome sequencing of the detected strains would be required (Armour et al., 2013; Ricketts et al., 2017).

Despite the sampled layer flocks from the UAE being vaccinated with ts-11, the detected strains are potentially field strains, due to their lower nucleotide identity when compared with the vaccine strains (97.1% in MGA\_0319, 96.5% in *mgc2* and 97.8% in *gapA*) and forming a distinct cluster with Israeli MG field strains (OR-2, BRT-14) (figure 1). In addition, the strains UAE/10/CK/12/44wks and UAE/10/CK/12/64wks were detected from kidneys of layer birds affected by clinical signs. Even if MG field strains can be isolated from the respiratory tracts of protected chickens (Abdelwhab et al., 2011; Khalifa et al., 2014), as the vaccine prevents invasion of other tissues, detection from visceral tissue is considered highly indicative of clinical disease (Bíró et al., 2005). Moreover it should be noted that the birds were sampled at 44 and 64 wks of age (Table 1) and these time points fall close or outside of the ts-11 vaccine protection window (up to 40 wks post-vaccination as reported from manufacturer's instructions).

The SL/1/CK/15 MG strain, originating from Sri Lanka broilers, affected by respiratory disease is considered as a potential field strain, as it clusters separately from USA, Israeli, Australian, vaccine and reference strains (Figure 1). Although MG circulation is reported in both Sri Lanka breeder and broiler chickens (Weerasooriya et al., 2017), to our knowledge no sequence data is currently available.

One potential route of MG field infection to the flocks in this study could potentially be through the movement of birds, either directly (flock to flock transmission) or indirectly (through wild bird transmission) (Raviv and Ley, 2013). Moreover, based on the phylogenetic analysis, UAE strains had close genetic relationship with Israeli MG strains, suggesting the epidemio-geographical relationship between these strains. To our knowledge, this study reports the first molecular characterization by GTS analysis of MG strains from commercial poultry in SAU, UAE and SL.



Table 1. Vaccination history, sampling time and PCR results of investigated flocks

<b>Year of sampling</b>	<b>Country</b>	<b>Flock</b>	<b>MG vaccination programme (5 week)</b>	<b>Age at sampling (week)</b>	<b>PCR for <i>pr-mgc2</i> (No. pos/No. tested)</b>
2012	United Arab Emirates	A (layer)	ts-11	44	tissues (4/4)
				64	tissues (4/4)
2015	Saudi Arabia	B (breeder)	ts-11	19	tracheal swabs (4/6)
				32	tracheal swabs (1/1)
2015	Saudi Arabia	C (breeder)	ts-11	16	tracheal swabs (7/10)
				24	tracheal swabs (11/11)
2015	Saudi Arabia	D (breeder)	ts-11	32	tracheal swabs (12/12)
2015	Sri Lanka	E (broiler)	Not vaccinated	Not known	tissues (7/7)


Table 2. Published MG sequences used in the GTS analysis

Field strain	Country	GenBank accession number			
		<i>mgc2</i>	<i>gapA</i>	MGA_0319	<i>pvpA</i>
S6	USA	KY421064.1	JQ770168.1	AY556073.1	EU847585.1
R	USA	AY556228.1	AY556150.1	AY556072.1	AY556306.1
OR-2	Israel	AY556296.1	AY556219.1	AY556140.1	AY556373.1
BRT14	Israel	AY556291.1	AY556214.1	AY556136.1	AY556368.1
AU96022CK96	Australia	AY556301.1	AY556224.1	AY556145.1	AY556378.1
K503	USA	AY556234.1	AY556156.1	AY556078.1	AY556310.1
A5969-CK55	USA	AY556227.1	AY556149.1	AY556071.1	AY556305.1
<b>Vaccine strain</b>					
TS-11		AY556232.1	AY556154.1	AY556076.1	AY556382.1
F		AY556230.1	AY556152.1	AY556074.1	JN001169.1
6/85		KP318741.1	JQ770170.1	/	KP881243.1

Table 3. GenBank accession numbers of MG strains characterized in the current study

<b>MG strain</b>	<b>GenBank accession numbers</b>			
	<i>mgc2</i>	<i>gapA</i>	MGA_0319	<i>pvpA</i>
UAE/10/CK/12/44wk	MK217482	MK217478	MK114557	n.a. <sup>1</sup>
SAU/28/CK/15/32wk	MK217480	MK217477	MK217479	MK217481
SL/1/CK/15	MK036426	MK036427	MK036428	MK036429

<sup>1</sup>n.a.: not available



**Figure 1.** *GapA/MGA\_0319/mgc2/pvpA* dendrogram.

Dendrogram based on the alignment of nucleotide sequences of *MGA\_0319*, *mgc2*, *gapA* and *pvpA* genes of MG strains detected in the study and USA, Israeli, Australian, vaccine and reference strains. Only bootstrap values >70 are reported. The MG sequences were labelled with a square (UAE), a circle (SAU) or a triangle (SL), according to the Country of origin.

UAE/10/ck/12/44wk and UAE/10/ck/12/64wk sequences are lacking of the *pvpA* gene.

## REFERENCES

1. Abdelwhab, E.M., Abdelmagid, M.A., El-Sheibeny, L.M., El-Nagar, H.A., Arafa, A., Selim, A., Nasef, S.A., Aly, M.M., Hafez, H.M., 2011. Detection and molecular characterization of *Mycoplasma gallisepticum* field infection in TS-11-vaccinated broiler breeders. *J Appl Poult Res* 20, 390–396. doi:10.3382/japr.2009-00130
2. Armour, N.K., Ferguson-Noel, N., 2015. Evaluation of the egg transmission and pathogenicity of *Mycoplasma gallisepticum* isolates genotyped as ts-11. *Avian Pathol.* 44, 296–304. doi:10.1080/03079457.2015.1044890
3. Armour, N.K., Laibinis, V.A., Collett, S.R., Ferguson-Noel, N., 2013. The development and application of a *Mycoplasma gallisepticum* sequence database. *Avian Pathol.* 42, 408–415. doi:10.1080/03079457.2013.819486
4. Bíró, J., Povaszán, J., Korösi, L., Glávits, R., Hufnagel, L., Stipkovits, L., 2005. Safety and efficacy of *Mycoplasma gallisepticum* TS-11 vaccine for the protection of layer pullets against challenge with virulent *M. gallisepticum* R-strain. *Avian Pathol.* 34, 341–347. doi:10.1080/03079450500179913
5. Chomczynski, P., Sacchi, N., 2006. The single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years on. *Nature Protocols* 1, 581–585. doi:10.1038/nprot.2006.83
6. El Gazzar, M., Laibinis, V.A., Ferguson-Noel, N., 2011. Characterization of a ts-11–like *Mycoplasma gallisepticum* Isolate from Commercial Broiler Chickens. *Avian Dis.* 55, 569–574. doi:10.1637/9689-021711-Reg.1
7. Fan, H.H., Kleven, S.H., Jackwood, M.W., 1995. Application of polymerase chain reaction with arbitrary primers to strain identification of *Mycoplasma gallisepticum*. *Avian Dis.* 39, 729–735.
8. Ferguson, N.M., Hepp, D., Sun, S., Ikuta, N., Levisohn, S., Kleven, S.H., García, M., 2005. Use of molecular diversity of *Mycoplasma gallisepticum* by gene-targeted sequencing (GTS) and random amplified polymorphic DNA (RAPD) analysis for epidemiological studies. *Microbiology* 151, 1883–1893. doi:10.1099/mic.0.27642-0
9. Ghorashi, S.A., Bradbury, J.M., Ferguson-Noel, N.M., Noormohammadi, A.H., 2013. Comparison of multiple genes and 16S–23S rRNA intergenic space region for their capacity in

- high resolution melt curve analysis to differentiate *Mycoplasma gallisepticum* vaccine strain ts-11 from field strains. *Vet Microbiol.* 167, 440–447. doi:10.1016/j.vetmic.2013.09.032
10. Ghorashi, S.A., Noormohammadi, A.H., Markham, P.F., 2010. Differentiation of *Mycoplasma gallisepticum* strains using PCR and high-resolution melting curve analysis. *Microbiology* 156, 1019–1029. doi:10.1099/mic.0.031351-0
  11. Khalifa, R., Eissa, S., El-Hariri, M., Refai, M., 2014. Sequencing Analysis of *Mycoplasma gallisepticum* Wild Strains in Vaccinated Chicken Breeder Flocks. *MMB* 24, 98–104. doi:10.1159/000357733
  12. Kiss, I., Matiz, K., Kaszanyitzky, É., Chávez, Y., Johansson, K.-E., 1997. Detection and identification of avian mycoplasmas by polymerase chain reaction and restriction fragment length polymorphism assay. *Vet Microbiol.* 58, 23–30. doi:10.1016/S0378-1135(97)81568-4
  13. Kleven, S.H., 2008. Control of Avian *Mycoplasma* Infections in Commercial Poultry. *Avian Dis.* 52, 367–374. doi:10.1637/8323-041808-Review.1
  14. Liu, T., García, M., Levisohn, S., Yogev, D., Kleven, S.H., 2001. Molecular Variability of the Adhesin-Encoding Gene *pvpA* among *Mycoplasma gallisepticum* Strains and Its Application in Diagnosis. *J Clin Microbiol* 39, 1882–1888. doi:10.1128/JCM.39.5.1882-1888.2001
  15. Moscoso, H., Thayer, S.G., Hofacre, C.L., Kleven, S.H., 2004. Inactivation, Storage, and PCR Detection of *Mycoplasma* on FTA® Filter Paper. *Avian Dis.* 48, 841–850. doi:10.1637/7215-060104
  16. Raviv, Z., Callison, S., Ferguson-Noel, N., Laibinis, V., Wooten, R., Kleven, S.H., 2007. The *Mycoplasma gallisepticum* 16S–23S rRNA Intergenic Spacer Region Sequence as a Novel Tool for Epizootiological Studies. *Avian Dis.* 51, 555–560. doi:10.1637/0005-2086(2007)51[555:TMGSRI]2.0.CO;2
  17. Ricketts, C., Pickler, L., Maurer, J., Ayyampalayam, S., García, M., Ferguson-Noel, N.M., 2017. Identification of Strain-Specific Sequences That Distinguish a *Mycoplasma gallisepticum* Vaccine Strain from Field Isolates. *J Clin Microbiol* 55, 244–252. doi:10.1128/JCM.00833-16
  18. Tamura, K., Stecher, G., Peterson, D., Filipski, A., Kumar, S., 2013. MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0. *Mol Biol Evol* 30, 2725–2729. doi:10.1093/molbev/mst197

19. Hong, Y., García, M., Levisohn, S., Savelkoul, P., Leiting, V., Lysnyansky, I., Ley, D.H., Kleven, S.H., 2005. Differentiation of *Mycoplasma gallisepticum* Strains Using Amplified Fragment Length Polymorphism and Other DNA-Based Typing Methods. *Avian Dis.* 49, 43–49. doi:10.1637/7254-080504R
20. Elbehiry, A., Al-Dubaib, M., Marzouk. E., 2016. Serological, Rapid Molecular Characterization and Antibiotic Resistance for Field Isolates of *Mycoplasma Gallisepticum* in Chicken in Saudi Arabia. *Alexandria Journal of Veterinary Sciences* 49:70–79. doi: 10.5455/ajvs.224786.
21. Weerasooriya, G., Fernando, P.S., Liyanagunawardena, N., Wijemuni, M., 2017. Identification of *Mycoplasma gallisepticum* from Chronic Respiratory Disease (CRD) suspected poultry flocks. Book of Abstract of 69<sup>th</sup> Annual Scientific Sessions of the Sri Lanka Veterinary Association, p. 11.
22. Raviv, Z., Ley, D.H., 2013. *Mycoplasma gallisepticum* infection. In: Swayne, D.E., Glisson, J.R., McDougald, L.R., Nolan, L.K., Suarez, D.L., Venugopal, N. (Eds.), *Disease of Poultry*, Ames, Iowa State Press, pp. 877–893.

# CHAPTER VI

## MYCOPLASMA SPECIES IN BACKYARD POULTRY IN ITALY

### **Molecular detection and characterization of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* strains in backyard poultry in Italy**

Viviana Felice<sup>\*,1</sup>, Antonietta Di Francesco\*, Giulia Mescolini\*, Flavio Silveira\*, Alessandro Guerrini\*, Elena Catelli\*, Caterina Lupini\*

\*Department of Veterinary Medical Sciences, University of Bologna, via Tolara di Sopra 50, 40064 Ozzano dell'Emilia, Bologna, Italy.

<sup>1</sup>Corresponding author: Viviana Felice

Department of Veterinary Medical Sciences, University of Bologna, Via Tolara di Sopra, 50, 40064 Ozzano dell'Emilia (BO), Italy.

Full telephone: 0039 0512097559

E-mail address: viviana.felice@gmail.com

The nucleotide sequences data reported in this paper have been submitted to GenBank nucleotide sequence database and have been assigned the following accession numbers: MH727587, from MH807700 to MH807703, from MH807704 to MH807715, from MH814580 to MH814597.

Scientific section: Molecular and cellular biology



## **ABSTRACT**

*Mycoplasma gallisepticum* (**MG**) and *Mycoplasma synoviae* (**MS**) represent the most important avian *Mycoplasma* species in the poultry industry, causing considerable economic losses. Several studies have reported the circulation of MG or MS in commercial poultry farms in Italy.

The aim of the present study was to attempt the detection and molecular characterization of MG and MS strains in eleven backyard poultry flocks located in different Italian regions. Tracheal swabs were collected and DNA was extracted. For MS, a PCR targeting a *vlhA* gene fragment was performed, and typing and subtyping was attempted. The presence of MG was investigated by a screening PCR, then MG typing by gene-targeted sequencing (**GTS**). All the amplicons were sequenced, then MG and MS dendrograms were constructed. All the flocks examined resulted *Mycoplasma* positive: 5 out of 11 (45.45%) were MG and MS positive, 3 (27.27%) were MG positive, and the remaining 3 (27.27%) were MS positive.

The MS detections were assigned to types C, D and F. All strains of type D belonged to subtype D1 and two unknown subtypes were identified. A MS sequence showed peculiar characteristics, which did not allow assignment to a known MS type or subtype.

MG GTS analysis identified six MG strains belonging to five subclusters circulating in Italian backyards chicken flocks.

The results of this study provide evidence of a risk for commercial poultry farms, especially in areas where backyard and commercial farms are close, suggesting the implementation of biosecurity measures.

**Keywords:** Backyard poultry, Italy, *Mycoplasma gallisepticum*, *Mycoplasma synoviae*

## INTRODUCTION

*Mycoplasma gallisepticum* (MG) and *Mycoplasma synoviae* (MS) represent the most important avian *Mycoplasma* species worldwide in the poultry industry, causing considerable economic losses (Raviv and Ley, 2013). MG causes chronic respiratory disease in chickens and sinusitis in turkeys (Kleven, 1998). MG disease is characterized by respiratory rales, coughing, nasal discharge and conjunctivitis, and infraorbital sinusitis in turkeys. Increased carcass and downgrading condemnation caused by aereosacculitis, decreased growth and egg production and increased medication costs, make MG one of costliest infection diseases (Raviv and Ley, 2013).

MS is mostly considered to occur as a subclinical upper respiratory infection, which can progress to respiratory disease with air sac lesions, when combined with Newcastle disease or infectious bronchitis, and to infectious synovitis when it becomes systemic (Lockaby et al., 1999). In the last decade, the importance of MS seems to be increasing. The emergence of MS strains that affect egg shell quality with typical eggshell apex abnormalities and decreased egg production (Feberwee et al., 2009; Catania et al., 2010a; Catania et al., 2016a) as well as arthropathic and amyloid-inducing strains (Kleven et al., 1975; Landman and Feberwee, 2001) have been reported. Control of *Mycoplasma* has generally been based on eradication of the organisms from breeder flocks and the maintenance of a *Mycoplasma*-free status in the breeders and their progeny by implementation of biosecurity.

In Italy, several studies have investigated MG or MS detection and characterization in commercial poultry farms. The presence of MG or MS was detected in turkeys, broiler breeders, layers, pullets and some minor poultry species (Catania et al., 2010a,b, 2012, 2016a, 2017; Massi et al., 2014; Moronato et al., 2014; Taddei et al., 2012). A case of MS infection in the lesser flamingo (*Phoeniconaias minor*) in a zoo of Northern Italy was also reported (Catania et al., 2016b).

The aim of this study was to attempt the detection and molecular characterization of MG and MS strains in backyard poultry flocks in different regions of Italy.

## MATERIALS AND METHODS

### *Samples*

Between January 2016 and December 2017, eleven backyard poultry flocks (1–11) located in different areas of Italy (Northern, Central and Southern Italy) were investigated for MG and MS presence (Table 1). The main breeds were Sussex, Robusta Lionata and Cocincine Millefiori, reared for ornamental purposes or consumption of meat. Anamnesis reported a low or moderate morbidity of respiratory signs (sneezing, nasal discharge, foam in the eye or rattle breathing) in adult birds, but

this was severe in chicks with mortality up to 100%. None of these flocks were vaccinated against MG or MS, except flock 10, where a killed MG vaccine was used.

In total, 100 birds were sampled (8–10 per flock). Tracheal swabs were collected from only the symptomatic birds and then stored at –20°C until processing as a pool for each flock.

### ***DNA extraction***

Pools of tracheal swabs were eluted in 2 mL of sterile PBS. Total DNA was extracted from elutions using the DNA Mini kit (Qiagen, Germany) according to the manufacturer's instructions, then tested using PCR for MS and MG.

### ***Detection and typing of *Mycoplasma synoviae****

With respect to MS, a PCR targeting a 430 bp fragment of the *vlhA* gene coding for an abundant immunodominant surface protein was performed. The target region included tandem repeats that encode proline-rich repeats (**PRR**) and the highly polymorphic RIII region, allowing the typing and subtyping of MS strains (Benčina et al., 2001). The forward primer *vlhA*-F (5'-GATGCGTAAAATAAAAAGGAT-3') (Moscoso et al., 2004) and the reverse primer *vlhAR2* (5'-AGTAACCGATCCGCTTAATGC-3') (Hammond et al., 2009) were used. A previously characterized MS sample was included as positive control in all PCRs.

### ***Detection and typing of *Mycoplasma gallisepticum****

The presence of MG was investigated using a PCR targeting a 237–303 bp fragment of the proline-rich domain of the *mgc2* (**pr-mgc2**) adhesin-encoding gene (Moscoso et al., 2004). In order to type DNA samples, the gene-targeted sequencing (**GTS**) assay targeting portions of putative cytoadhesin genes (*pvpA*, *gapA* and *mgc2*) and an uncharacterized hypothetical surface lipoprotein-encoding gene (designated coding DNA sequence (**CDS**) MGA\_0319) (Ferguson-Noel et al., 2005) was performed.

In particular, 590, 824 and 332 bp fragments of the MGA\_0319, *mgc2* and *gapA* genes were amplified according to Ferguson-Noel et al (2005). With regard to the *pvpA* gene, forward *pvpA3F* (5'-GCCAMTCCAACCTCAACAAGCTGA-3') and reverse *pvpA4R* primers (5'-GGACGTSBTCCTGGCTGGTTAGC-3') (Ferguson-Noel et al., 2005) or modified forward *pvpA3F*

(5'-GGYAGTCCTAAGTTATTWGGTC-3') (Liu et al. 2001) and pypA4R (Ferguson-Noel et al., 2005) primers, amplifying a 497 or 702 bp fragment, respectively, were used. Ts-11 vaccine strain was included as positive control in all PCRs.

### ***Sequencing and phylogenetic analysis***

The *vlhA* MS and the GTS MG amplicons were sequenced in both directions by a commercial sequencing service (Macrogen Europe). The obtained sequences were edited and assembled using Bioedit software. Nucleotide identity of the *vlhA* sequences was determined using the nucleotide BLAST algorithm with GenBank database (<http://www.ncbi.nlm.nih.gov>) (Johnson et al., 2008).

Dendrograms were generated by the neighbor-joining method using Molecular Evolutionary Genetics Analysis (MEGA 6) (Tamura et al., 2013). Bootstrap values were calculated based on 1000 replicates and considered significant when >70. In addition to the sequences obtained in this study, published corresponding sequences of 34 MS reference strains and previously published Italian strains were included in the phylogenetic analysis (Supplementary Table 1). For MG sequences, the dendrogram was constructed with only MG samples for which all four genes have been successfully sequenced. The MG sequences in GTS analysis were compared with published strains including reference and vaccine strains (Supplementary Table 2).

## **RESULTS AND DISCUSSION**

All flocks examined were *Mycoplasma* positive when detected using PCR. Of 11 flocks, 5 (45.45%) were MG and MS positive, 3 (27.27%) were MG positive, and the remaining 3 (27.27%) were MS positive (Table 1).

With respect to MS sequence analysis, the *vlhA* amplicons were successfully sequenced except those from flocks 6, 7 and 11. The MS strains analyzed were named as follows: IT/MS675/ck/16 (flock 1), IT/MS705/ck/16 (flock 4), IT/MS801/ck/17 (flock 5), IT/MS804/ck/17 (flock 8), IT/MS879/ck/17 (flock 9). The nucleotide sequences were submitted to the GenBank database (Table 2). The comparison of the sequences with GenBank showed a percentage of similarity ranging from 92% to 100%. According to the length of the PRR region (Bençina et al., 2001), three known MS types, C (96 nt), D (69 nt), and F (108 nt), were detected in flocks 1 (F), 4 (D), 5 (D), and 8 (C) (Fig. 1). Interestingly, the *vlhA* sequence of the IT/MS879/ck/17 strain (flock 9) showed mutations in the PRR

region, which meant this flock could not be assigned to a known MS type or subtype (Fig. 1). With regards to the RIII region, the known subtype D1 was detected in flocks 4 and 5, and two unknown subtypes, termed C7 and F2, were identified in flocks 8 and 1 (Fig. 1). Based on the dendrogram, *vlha* sequences of MS strains detected in the study clustered with Spanish, Japanese (IT/MS675/ck/16) and Italian MS strains (IT/MS705/ck/16 and IT/MS801/ck/17) except for the *vlha* IT/MS879/ck/17 sequence, which formed a completely separate branch from other Italian and reference strains (Fig. 2).

With respect to the MG sequence analysis, of the 11 samples examined, 8 were *pr-mgc2* positive. All the corresponding GTS amplicons were successfully sequenced, except the MGA\_0319 gene from flocks 9 and flock 10 samples. The MG strains analyzed with GTS were named as follows: IT/MG675/ck/16 (flock 1), IT/MG690/ck/16 (flock 2), IT/MG704/ck/16 (flock 3), IT/MG705/ck/16 (flock 4), IT/MG801/ck/17 (flock 5), IT/MG802/ck/17 (flock 6), IT/MG879/ck/17 (flock 9) and IT/MG880/ck/17 (flock 10). Nucleotide sequences were submitted to the GenBank database (Table 3). Since IT/MG879/ck/17 and IT/MG880/ck/17 sequences were not included in the dendrogram, they were analysed using the nucleotide BLAST algorithm with the GenBank database. Sample IT/MG879/ck/17 showed a percentage of nucleotide similarity of 99% with ts-11 vaccine in *gapA*, 100% with ts-11 vaccine and Australian (K2966) strain in *mgc2* and 92% with German 2591/13CK strain in *pvpA*. Sample IT/MG880/ck/17 showed a percentage of nucleotide similarity of 99% with ts-11 vaccine, Australian (K2966), South Africa, Brazilian (2011/UFGM2) MG strains in *mgc2*, 99% with ts-11 vaccine, Australian (K2966), South Africa, USA, North America MG strains and Brazilian (2011/UFGM2) MG strains in *gapA* and 95.3% with German 2591/13CK strain in *pvpA*.

The dendrogram obtained from sequences of the MGA\_0319, *mgc2*, *gapA* and *pvpA* genes showed that MG strains belong to five different subclusters (Fig. 4). IT/MG704/ck/16 (flock 3) and IT/MG690/ck/16 (flock 2) clustered with ts-11 and 6/85 vaccine strains, respectively. Similarities observed between IT/MG704/ck/16 and ts-11 was of 92,3% and between IT/MG690/ck/16 and 6/85 was of 94.8%. These low degree of similarities suggest that these strains are not vaccine-like strains supporting that the transmissibility of ts-11 or 6/85 vaccine strains to birds with indirect contact was not possible (Ley et al., 1997).

IT/MG705/ck/16 (flock 4) and IT/MG801/ck/17 (flock 5), formed a cluster separately from all other analyzed strains, showing a high degree of similarity (99.6%) one with each other. However, the flocks 4 and 5 were geographically distant and no epidemiological link was reported between them.

The circulation of MS or MG strains in Italy have been reported in previous work, especially focused on commercial poultry farms (Catania et al., 2010b; Taddei et al., 2012; Catania et al., 2016a;), despite continued efforts to keep the poultry industry *Mycoplasma*-free.

Our study focused on backyard poultry farms, highlighting MS and MG occurrence in flocks distributed in various Italian regions. MG and MS DNA was detected in birds of different ages and breeds in association with respiratory signs, suggesting a potential clinical role, although other causes of respiratory disease cannot be excluded.

Based on the description of the *vlhA* fragment, A, C, D, E, F, G and H types have been detected in Italy (Moronato et al., 2014). In this study, the detection of MS sequences with peculiar molecular characteristics (IT/MS879/ck/17) or new subtypes (C7, F2) evidenced the potential role of backyard chickens as source of new *Mycoplasma* strains.

Phylogenetic analysis of MS *vlhA* sequences showed high nucleotide similarity with corresponding sequences of MS strains from Italy and European or extra-European countries, except IT/MS879/ck/17 sequence, which showed only 92% similarity with MS strains from several countries, including Italy. The dendrogram confirmed the peculiarity of IT/MS879/ck/17 being phylogenetically distant from other known MS strains.

With respect to MG sequences, GTS analysis allowed observation of six MG strains. in a restricted geographical area such as Italy, indicating the ability of this method to differentiate among Italian MG strains.

The presence of the MS and MG sequences showing high nucleotide similarity with corresponding sequences from Italian or foreign *Mycoplasma* strains is not surprising considering the features of the farms tested, which commonly introduce animals from Italian farms and from European or extra-European countries, and participate in Italian or foreign exhibitions.

Haesendonck et al. (2014) and Derksen et al. (2018) reported that the backyard poultry flocks could act as reservoir or amplifier for poultry respiratory diseases serving as a continuous source of infection for industrial chickens. The present study detected the circulation of MS and MG in backyard poultry farms, confirming the potential role of this type of breeding to spread pathogens to commercial poultry production, especially in densely poultry-populated areas where backyard and commercial farms are close. Whereas the principles and practices of on-farm biosecurity may be familiar to commercial farmers, hobbyists and backyard farmers may not be aware of the steps required to keep infectious diseases out of their flock and prevent their spread to close farms.

The results of this study suggest that backyard chickens should be checked periodically to investigate the status of *Mycoplasma* infection. Moreover, the implementation of biosecurity measures in backyard poultry farms are needed. More exhaustive studies including attempts at isolation, *in vivo* pathogenicity studies and molecular analysis may be useful to better investigate the molecular profile and the potential epidemiological role of *Mycoplasma* strains circulating in backyard poultry farms.

Table 1. Examined flocks with MG and MS PCR results.

<b>Year</b>	<b>Flock</b>	<b>Region</b>	<b>MS (type-subtype)</b>	<b>MG</b>
2016	1	Lombardy	+(F2)	+
2016	2	Lombardy	-	+
2016	3	Emilia Romagna	-	+
2016	4	Tuscany	+(D1)	+
2017	5	Sicily	+(D1)	+
2017	6	Campania	+(n.a.)	+
2017	7	Emilia Romagna	+(n.a.)	-
2017	8	Friuli Venezia Giulia	+(C7)	-
2017	9	Lazio	+(n.k.)	+
2017	10	Umbria	-	+
2017	11	Lazio	+(n.a.)	-

n.a.: not available

n.k.: not known

Table 2. Accession numbers of MS strains submitted to GeneBank database

<b>Strain</b>	<b>Accession number</b>
IT/MS675/ck/16	MH727587
IT/MS705/ck/16	MH807700
IT/MS801/ck/17	MH807701
IT/MS804/ck/17	MH807702
IT/MS879/ck/17	MH807703

Table 3. Accession numbers of MG strains submitted to GeneBank database

<b>Strain</b>	<b>Accession numbers</b>			
	<i>gapA</i>	<b>MGA_0319</b>	<i>Mgc2</i>	<i>pvpA</i>
IT/MG675/ck/16	MH807704	MH807705	MH807706	MH807707
IT/MG690/ck/16	MH807708	MH807709	MH807710	MH814582
IT/MG704/ck/16	MH807711	MH807712	MH807713	MH807714
IT/MG705/ck/16	MH807715	MH814597	MH814590	MH814585
IT/MG801/ck/17	MH814594	MH814596	MH814589	MH814584
IT/MG802/ck/17	MH814593	MH814595	MH814588	MH814583
IT/MG879/ck/17	MH814591	/	MH814586	MH814580
IT/MG880/ck/17	MH814592	/	MH814587	MH814581






Figure 1. Deduced amino acid sequences of the PRR region of *vIhA* gene of MS strains detected in the study and reference strain WVU1853. Only residues that differ from the sequence of WVU1853 are shown.

```

      10      20      30      40      50      60
WVU1853  A T T G C T C C T G C T G T T A T A G C A A T T T C A T G T G G T G A T C A A A C T C C A G C A C C T G A A - - - -
IT/MS879/ck/17  . . . . . T . . . . .

      70      80      90      100     110     120
WVU1853  - - - - C C A A C A C C T G G A A A C C C A A A T A C T G A T A A T C C T C A A A A C C C A - - - - A A T
IT/MS879/ck/17  G G T A C T G A T . A T . . . C A . . . . G G . . . . . G G T A C T G A T . . .

      130     140     150     160     170     180
WVU1853  C C A G G A A A T C C A G G T A C T - - - - C C A G G A A A T C C A G G T A C T G A T A A T C C T C A A A A C C C A
IT/MS879/ck/17  . . T C A . . . C . . . . . G A T A A T . T C A . . . C . . . . .

      190     200     210     220     230     240
WVU1853  A A T C C A G G A A A C C C A G G A G G T G G T A C A G T T G A C C C T G T A G A G G C T G C T A A A A C A G A A G C T
IT/MS879/ck/17  . . . . . G . T . . . . . T . . . . . A . . . . .

      250     260     270     280     290     300
WVU1853  A A A A C C G C T A T T G A T G C T T C A G C A G A A T T A T C A G A T T C A G T T A A A G A A G C A T T A A A A A G A
IT/MS879/ck/17  . . G . T . . . . . T . . . . .

      310     320     330     340     350     360
WVU1853  C A A G T T G A A G C A A C T A C A A C A G A A G C T G A A G C C A G A G A T T T A A A A A C T A A A G C A G A C G C T
IT/MS879/ck/17  . . . . . A . . . . . C . . . . . T . . . . . T . . . . .

      370     380     390
WVU1853  C T T G T T T C A G C T G T A A A A G C A T T A A G C G G A T C G G T T A C T
IT/MS879/ck/17  . . . . .

```

Figure 2. Deduced amino acid sequences of the PRR region of *vlhA* gene of IT/MS879/ck/17 strains detected in the study and reference strain WVU1853. Only residues that differ from the sequence of WVU1853 are shown.




Figure 3. Phylogenetic tree based on the alignment of nucleotide sequences of *vlhA* genes of MS strains detected in the study (circle) and reference strains. Only bootstrap values >70 are reported.




Figure 4. Phylogenetic tree based on the alignment of nucleotide sequences of *gapA*, *MGA\_0319*, *mgc2* and *pvpA* genes of MG strains detected in the study (triangle) and reference strains. Only bootstrap values >70 are reported.

## REFERENCES

- Benčina, D., M. Drobnič-Valič, S. Horvat, M. Narat, S. H. Kleven, and P. Dovč. Molecular basis of the length variation in the N-terminal part of *Mycoplasma synoviae* hemagglutinin. *FEMS Microbiology Letters* 203:115–123.
- Catania, S., D. Bilato, F. Gobbo, A. Granato, C. Terregino, L. Iob, and R. A. J. Nicholas. 2010a. Treatment of Eggshell Abnormalities and Reduced Egg Production Caused by *Mycoplasma synoviae* Infection. *Avian Diseases* 54:961–964.
- Catania, S., F. Gobbo, A. S. Ramirez, D. Guadagnini, E. Baldasso, M. L. Moronato, and R. A. J. Nicholas. 2016b. Laboratory investigations into the origin of *Mycoplasma synoviae* isolated from a lesser flamingo (*Phoeniconaias minor*). *BMC Vet Res* 12 Available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788927/> (verified 23 February 2018).
- Catania, S., F. Gobbo, D. Bilato, L. Gagliazzo, M. L. Moronato, C. Terregino, J. M. Bradbury, and A. S. Ramírez. 2016a. Two strains of *Mycoplasma synoviae* from chicken flocks on the same layer farm differ in their ability to produce eggshell apex abnormality. *Veterinary Microbiology* 193:60–66.
- Catania, S., G. Battanoli, E. Baldasso, A. Fincato, S. Rodio, L. Iob, 2012. Analisi dei ceppi circolanti di *Mycoplasma synoviae* mediante l'utilizzo di metodiche biomolecolari. *Atti Della Società Italiana di Patologia Aviaria*. 234–236.
- Catania, S., M. Mainenti, C. Zanardello, M. Picchi, A. Matucci, F. Gobbo, 2017. *Mycoplasma synoviae*: un ottimo esempio di patogeno adattabile alle condizioni dell'ospite. Caso clinico. *Atti Della Società Italiana di Patologia Aviaria*. 199–203.
- Catania, S., R. Ceruti, M. Mingardo, G. Ortali, C. Terregino, L. Iob, 2010b. Indagine preliminare sulla presenza di *Mycoplasma gallisepticum* e *Mycoplasma synoviae* in allevamenti avicoli

- italiani. *Atti Della Società Italiana di Patologia Aviaria*. 117–120.
- Derksen, T., R. Lampron, R. Hauck, M. Pitesky, and R. A. Gallardo. 2017. Biosecurity Assessment and Seroprevalence of Respiratory Diseases in Backyard Poultry Flocks Located Close to and Far from Commercial Premises. *Avian Diseases* 62:1–5.
- Feberwee, A., J. J. de Wit, and W. J. M. Landman. 2009. Induction of eggshell apex abnormalities by *Mycoplasma synoviae*: field and experimental studies. *Avian Pathology* 38:77–85.
- Ferguson, N. M., D. Hepp, S. Sun, N. Ikuta, S. Levisohn, S. H. Kleven, and M. García. 2005. Use of molecular diversity of *Mycoplasma gallisepticum* by gene-targeted sequencing (GTS) and random amplified polymorphic DNA (RAPD) analysis for epidemiological studies. *Microbiology* 151:1883–1893.
- Haesendonck, R., M. Verlinden, G. Devos, T. Michiels, P. Butaye, F. Haesebrouck, F. Pasmans, and A. Martel. 2014. High Seroprevalence of Respiratory Pathogens in Hobby Poultry. *Avian Diseases* 58:623–627.
- Hammond, P. P., A. S. Ramírez, C. J. Morrow, and J. M. Bradbury. 2009. Development and evaluation of an improved diagnostic PCR for *Mycoplasma synoviae* using primers located in the haemagglutinin encoding gene *vlhA* and its value for strain typing. *Veterinary Microbiology* 136:61–68.
- Johnson, M., I. Zaretskaya, Y. Raytselis, Y. Merezhuk, S. McGinnis, and T. L. Madden. 2008. NCBI BLAST: a better web interface. *Nucleic Acids Res* 36:W5–W9.
- Kleven, S. H., H.-H. Fan, and K. S. Turner. 1998. Pen Trial Studies on the Use of Live Vaccines to Displace Virulent *Mycoplasma gallisepticum* in Chickens. *Avian Diseases* 42:300–306.
- Kleven, S. H., O. J. Fletcher, and R. B. Davis. 1975. Influence of strain of *Mycoplasma synoviae* and

- route of infection on development of synovitis or airsacculitis in broilers. *Avian Dis.* 19:126–135.
- Landman, W. J. M., and A. Feberwee. 2001. Field studies on the association between amyloid arthropathy and *Mycoplasma synoviae* infection, and experimental reproduction of the condition in brown layers. *Avian Pathology* 30:629–639.
- Ley, D. H., J. E. Berkhoff, and S. Levisohn. 1997. Molecular epidemiologic investigations of *Mycoplasma gallisepticum* conjunctivitis in songbirds by random amplified polymorphic DNA analyses. *Emerg Infect Dis* 3:375–380.
- Liu, T., M. García, S. Levisohn, D. Yogev, and S. H. Kleven. 2001. Molecular Variability of the Adhesin-Encoding Gene *pvpA* among *Mycoplasma gallisepticum* Strains and Its Application in Diagnosis. *J Clin Microbiol* 39:1882–1888.
- Lockaby, S. B., F. J. Hoerr, L. H. Lauerman, B. F. Smith, A. M. Samoylov, M. A. Toivio-Kinnucan, and S. H. Kleven. 1999. Factors associated with virulence of *Mycoplasma synoviae*. *Avian Dis.* 43:251–261.
- Massi, P., L. Fiorentini, I. Barbieri, L. Giovannetti, M. Casadio, G. Tosi, 2014. Monitoraggio della colonizzazione e persistenza del vaccino vivo attenuato per *Mycoplasma synoviae* in riproduttori pesanti. *Atti Della Società Italiana di Patologia Aviaria.* 168–169.
- Moronato, M.L., E. Baldasso, A. Fincato, K. Quattieri, B. Flaminio, S. Catania, 2014. Circolazione di differenti genotipi di *Mycoplasma synoviae* nel settore avicolo industriale. *Atti Della Società Italiana di Patologia Aviaria.* 184–186.
- Moscoso, H., S. G. Thayer, C. L. Hofacre, and S. H. Kleven. 2004. Inactivation, Storage, and PCR Detection of *Mycoplasma* on FTA® Filter Paper. *Avian Diseases* 48:841–850.

Raviv, Z., and D.H. Ley. 2013. *Mycoplasma gallisepticum* infection. Pages 877–893 in Disease of Poultry. 13<sup>th</sup> edn. D.E. Swayne, J.R. Glisson, L.R. McDougald, L.K. Nolan, D.L. Suarez, N. Venugopal (eds.). Ames, Iowa State Press.

Taddei, R., G. Tosi, I. Barbieri, M. Casadio, L. Fiorentini, P. Massi, 2012. Tipizzazione molecolare di ceppi di *Mycoplasma gallisepticum* circolanti in Italia tra il 2010 ed il 2012. Atti Della Società Italiana di Patologia Aviaria. 342–349.

Tamura, K., G. Stecher, D. Peterson, A. Filipksi, and S. Kumar. 2013. MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0. Mol Biol Evol 30:2725–2729.



**Supplementary table 1.** Accession numbers of MS sequences retrieved from GenBank used in the analysis.

<b>Strain</b>	<b>Country</b>	<b>Accession number</b>
<b>WVU1853</b>	USA	AM998371.1
<b>MS-H</b>	Australia	KP704286.1
<b>FB-8</b>	Israel	KC832812.1
<b>EB-11</b>	Israel	KC832809.1
<b>MSG508</b>	India	JX855831.1
<b>ULB07/P5</b>	Slovenia	KP055183.1
<b>IZSVE/5889/10</b>	Spain	KJ722788.1
<b>IZSVE/2264/2</b>	Spain	KJ722787.1
<b>IZSVE/1184/2</b>	Spain	KC832821.1
<b>B76-02</b>	Italy	FN666087.1
<b>IZSVE/2014/374-12</b>	Italy	KY991393.1
<b>IZSVE/4383/11</b>	Italy	KC832815.1
<b>IZSVE/2010/5711</b>	Italy	HG421742.1
<b>IZSVE/4564</b>	Italy	KC832814.1
<b>IZSVE/4504</b>	Italy	KC832822.1
<b>IZSVE/2013/371-1</b>	Italy	KY991387.1
<b>IZSVE/428/1</b>	Italy	KC832819.1
<b>IZSVE/2013/2098-30</b>	Italy	KY991384.1
<b>IZSVE/2013/5404-6</b>	Italy	KY991385.1
<b>IZSVE-2014-368-6</b>	Italy	KY991390.1
<b>IZSVE-2014-368-2</b>	Italy	KY991389.1
<b>TRACH</b>	Italy	LT615236.1
<b>PASC8</b>	Italy	LT615237.2
<b>WT-5</b>	Japan	AB501282.1
<b>MSR-MSH</b>	Iran	JX960401.2
<b>IRG8/C/08</b>	Iran	KP659463.1
<b>K1968</b>	USA	KJ606929.1
<b>B95/04/K4412</b>	Germany	FM164342.1
<b>B3-98</b>	Holland	FM164354.1
<b>B47/06</b>	Slovakia	FM164373.1
<b>B103/07</b>	UK	FM164371.1
<b>B133-99-5</b>	Hungary	AJ580983.1
<b>B142/02</b>	Hungary	AJ580989.1
<b>B133/96</b>	/	AJ580986.1

**Supplementary table 2.** Accession numbers of MG sequences retrieved from GenBank used in the analysis.

<b>MG strain</b>	<b>Country</b>	<b>Accession number</b>			
		<i>mgc2</i>	<i>gapA</i>	<b>MGA_0319</b>	<i>pvpA</i>
<b>ts-11</b>	Australia	AY556232.1	AY556154.1	AY556076.1	AY556382.1
<b>F</b>	USA	AY556230.1	AY556152.1	AY556074.1	JN001169.1
<b>6/85</b>	USA	KP318741.1	JQ770170.1	/	KP881243.1
<b>S6</b>	USA	KY421064.1	JQ770168.1	AY556073.1	EU847585.1
<b>R</b>	USA	AY556228.1	AY556150.1	AY556072.1	AY556306.1
<b>AU96022-CK96</b>	Australia	AY556301.1	AY556224.1	AY556145.1	AY556378.1
<b>K503</b>	USA	AY556234.1	AY556156.1	AY556078.1	AY556310.1
<b>A5969-CK55</b>	USA	AY556227.1	AY556149.1	AY556071.1	AY556305.1